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ABSTRACT 
Alveolar Rhabdomyosarcoma IS characterised by a t(2;13)(q35;qI4) chromosome 
trartslocation, which leads to the fusion of the P AX3 artd the FKHR genes. The resulting 
fusion gene encodes a chimeric protein which has aberrant transcriptional activity. The 
data here describes the molecular definition of the genomic breakpoints on both 
derivative chromosomes in one case and the derivative chromosome 13 breakpoints in 
two other cases. The DNA sequences adjacent to the breakpoints on the derivative 
chromosome 13 are remarkable for their resemblartce to recognition sequences for the 
protein trartslin. Electrophoretic mobility shift studies (EMSA) confirm that these 
sequences bind translin. These findings suggest that translin may not only be important 
in the genesis of chromosomal trartslocations in lymphoid malignancy, but also in 
trartslocations found in solid tumours. 
Mutation analysis of tumour samples and cell lines from patients with embryonal and 
alveolar rhabdomyosarcoma suggests that there are no subtle disease associated 
mutations within the P AX3 gene that could contribute towards the neoplastic state. 
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CHAPTER ONE INTRODUCTION 
1.1 CANCER GENETICS 
"Each cancer is the result of an independent evolutionary process at the somatic cell level, involving the 
mechanisms of mutation and selection but without the intervention of a sexual process. The accumulation of 
the successive mutations that result in a cancer must take place stepwise, with each mutation having a selective 
advantage leading to an expanded cellular population within which the next mutation, giving rise to a further 
selective advantage andfurther expansion, takes place. Thus, it is the selection rather than the mechanism of 
mutation which is important in the genesis of cancer. Once a cellular population has escaped from the 
constraints of normal growth control, malignancy is established. The stepwise nature of this model for cancer 
indicates that it is a time-dependent process, and so the incidence of cancer increases with age. The clue to 
understanding cancer is to define the set of individual genetic steps that constitute the somatic evolutionary 
process and. through understanding their functions, to define the nature of the selective advantages associated 
with each step" (Bodmer et aI, 1994). 
There are two classes of genes whose mutation may result in cancer; 
The first class are the Oncogenes which are defined as genes which, when acting alone or in 
combination with other genes, can induce the transformation of cells in tissue culture. The 
first oncogenes to be discovered were those found to be homologous to the genes of viruses 
which are capable of inducing tumourigenesis in normal animal and human cells (Bishop 
1981, 1987). Oncogenes code for proteins such as growth factors, growth factor receptors, 
protein kinases or transcription factors. The discovery of proto-oncogenes has been followed 
by the discovery of a number of mechanisms which result in their aberrant activation. These 
include gene amplification and DNA rearrangements such as chromosome translocation (see 
below). 
The second class of genes are termed the tumour suppressor genes. Both alleles of a tumour 
suppressor gene have to be inactivated to allow tumourigenesis. The study of inherited 
predisposition to particular tumours has led to an understanding of what role tumour 
suppressor genes play in cancer. For example, retinoblastoma is a childhood malignancy 
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which occurs in both sporadic and familial fonns. It was postulated by Knudsen (Knudsen, 
1973) that in either case development of a tumour depends on two mutation events; in the 
familial fonn one mutation occurs in the gennline and the other is a somatic mutation, 
whereas in the sporadic fonn both are somatic mutations. Studies on the tumour suppressor 
gene Rb in patients with retinoblastoma have shown that this hypothesis is correct (Friend et 
aI, 1986). Loss of function of tumour suppressor genes are caused by point mutations, 
deletions, insertions or loss of whole chromosomes. 
1.2 CHROMOSOME INSTABILITY. 
The relationship between 'chromosome instability' and cancer has been apparent since the 
development of chromosome banding techniques in the sixties (Cassperson et aI, 1968). It 
became clear that the majority of cancer cells had aberrant chromosome numbers and/or 
( structural chromosome abnonnalities and also that there was an association between specific 
abnonnalities and particular types of cancer. The main observable cytogenetic changes are 
deletions and translocations/inversions. Many translocations have been cloned and some 
general principles have emerged from the study of the associated genes. Deletions often 
result in loss of a tumour suppressor gene. 
There are two consequences of translocations; 
Firstly, if a gene for a T-cell receptor or an immunoglobulin is juxtaposed to a proto-
oncogene, the latter becomes activated. The c-MYC gene translocation in Burkitt's 
lymphoma is a good example of the activation of a proto-oncogene by proximity to aT-cell 
receptor or immunoglobulin gene. T-cell receptor or immunoglobulin genes are frequently 
involved in chromosome aberrations because they are naturally rearranged to generate active 
antigen-receptor genes. This process occasionally, in error, leads to an interchromosomal 
translocation or intrachromosomal inversion, as in Burkitt's lymphoma. c-MYC can 
dimerize with another protein, MAX, to become transcriptionally active. MAX can also 
dimerize with other proteins so that an equilibrium in the amount of each of these proteins is 
found in the nonnal cell. After chromosome translocation, this equilibrium is disrupted by 
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overexpression of c-MYC and results in transcription of down stream target genes, leading to 
oncogenesis (Blackwood and Eisenman, 1991; Prendergast et aI, 1991; Amati et aI, 1993). 
Secondly, if the breaks occur within a gene on each chromosome involved, a fusion gene is 
created encoding a chimeric protein. The genes involved often encode transcription factors, 
indicating that altered transcription plays a major part in tumourigenesis. The first constant 
rearrangement to be identified was the Philadelphia chromosome in chronic myeloid 
leukaemia (CML), subsequently characterised as a reciprocal translocation between the long 
arms of chromosomes 9 and 22, t(9:22)(q33:q21) (Nowell and Hungerford, 1960; Rowley, 
1973). The fusion of the BCR and c-ABL genes on the Philadelphia chromosome typifies 
the situation in which breakage on each chromosome occurs within the introns of genes, 
producing fusion genes and subsequently leading to expression of a fusion protein. 
Sequences from both genes are essential for the oncogenic activity of the fusion protein and 
results in enhanced tyrosine kinase activity (Sawyers et al, 1991). The BCR-ABL fusion 
protein is thought to exist in a complex with a protein, GRB-2. The BCR-ABL-GRB-2 
complex is thought to be required for the activation of the Ras signalling pathway, a highly 
conserved pathway which transmits signals from extracellular growth factors to the nucleus 
and which is often aberrantly activated in neoplasia (Prendergast et al, 1991). 
1.3 RHABDOMYOSARCOMA 
Rhabdomyosarcoma (RMS) is the commonest form of soft-tissue sarcoma in childhood and 
represents between 5% and 8% of all cases of childhood cancer. The histological 
classification of RMS is based on their resemblance to normal fetal skeletal muscle (Horn and 
Enterline, 1958). The two main histological variants of RMS can be discerned, the 
embryonal type (ERMS), so called because of its resemblance to fetal striated muscle, and 
the alveolar type (ARMS), so called because of the presence of open spaces within the 
tumour which resemble the alveolar spaces of the lung (Raney, 1989). Typically, ERMS, 
which accounts for approximately 60% of cases, arises in younger children in central sites 
which include the head and neck region, genito-urinary tract and orbit. Histologically, the 
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tumour is characterised by variable numbers of malignant spindle and primitive round cells 
that may contain cross-striations typical of skeletal muscle. The alveolar subtype arises in 
older children or adolescents and primarily affects peripheral sites such as the limbs. This 
histological variant is characterised by the presence of fibrovascular septa that form alveolar-
like spaces filled with primitive, poorly cohesive, monomorphous, malignant cells. Patients 
with tumours of alveolar histology are generally considered to have a worse clinical 
prognosis compared to those with embryonal rhabdomyosarcoma (Crist et aI, 1990). 
In addition to their resemblance to fetal skeletal muscle, rhabdomyosarcomas have been 
consistently shown to express transcripts for the MyoD family of muscle-specific regulatory 
factors (Davis et aI, 1987; Olson, 1990; Weintraub et aI, 1991; Li and Olson, 1992; Olson and 
Klein, 1994). Members of this family of transcription factors such as MyoD, myogenin and 
myf5 direct the co-ordinated expression of the skeletal myogenic programme which leads to 
terminal differentiation (Tapscott and Weintraub, 1991). It is, therefore, surprising that 
expression of these factors occurs in undifferentiated rhabdomyosarcomas. However, cell 
fusion studies suggest that endogenous rhabdomyosarcoma MyoD protein is not able to 
function as a transcription activator due to a deficiency in the tumour cells of an unknown co-
operating co-factor (Tapscott et al, 1993). Although no correlation between tumour 
histology and the expression pattern of these transcription factors has been reported, the 
restriction of their expression to cells of myogenic lineage has proven a useful diagnostic tool 
to differentiate between rhabdomyosarcomas and other paediatric neoplasm's (Dias et aI, 
1990). 
1.4 CYTOGENETIC ABNORMALITIES IN RHABDOMYOSARCOMA 
Another important technique for the characterisation of childhood tumours has been 
cytogenetic analysis. Although random chromosomal aberrations are common to all 
neoplastic cells, it has been possible to identify non-random chromosomal rearrangements, 
particularly translocations, which are specific to certain tumour types. Cytogenetics not 
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only provides a reliable way of grouping seemingly dissimilar forms of the same disease, but 
has created a starting point for the positional cloning of important genes located at the sites of 
the rearrangements. 
Cytogenetic analysis of rhabdomyosarcoma has demonstrated chromosomal abnormalities in 
both embryonal and alveolar histologies. The translocation t(2;13)(q35;qI4) was first 
described by Seidal in 1982 and was noted to occur specifically in cases of alveolar 
rhabdomyosarcoma (see figure 1.1; Seidal et aI, 1982; Douglass et aI, 1987). Subsequent 
reports have confirmed this association in over 70% of successfully karyotyped alveolar 
rhabdomyosarcomas and it is now considered specific for tumours of this histology (Whang-
Peng et aI, 1992). Additionally, a less frequent variant translocation t(1;13)(p36;qI4) has 
been reported, which occurs in 10-15% of tumours of alveolar histology (Beigel et ai, 1991; 
Douglass et al, 1991; Whang-Peng et al, 1992). Both trans locations appear to involve the 
same region on chromosome 13qI4. Evidence has been found to suggest that patients with 
the t(1;13) have different clinical and pathological features from those with the common 
t(2;13) translocation (personal communication, Dr. Rick Womer). 
In addition to structural abnormalities, flow cytometry studies have indicated that 
approximately two thirds of alveolar tumours have a near tetraploid DNA content, whereas 
this finding is rarely observed in embryonal rhabdomyosarcoma (Shapiro et aI, 1991; Pappo 
et aI, 1993; Wijnaendts et aI, 1993; Niggli et al, 1994). 
A number of differing chromosomal abnormalities have been reported for embryonal 
rhabdomyosarcoma such as deletion of chromosome 1 p with hyperdiploidy and ring 
chromosome 13 (Potluri and Gilbert, 1985; Voullaire et al 1991; Olegard et al, 1992; Whang-
peng et aI, 1992). Perhaps the only consistently observed abnormality is trisomy of 
chromosome 2 (Biegel et al, 1995). Approximately two-thirds of embryonal 
rhabdomyosarcomas have hyperdiploid DNA content; the remaining embryonal 
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Figure 1.1 Ideograms of the normal chromosomes 2 and 13, and of the derivative 
chromosomes der2 and der13 specifically found in alveolar rhabdomyosarcoma. The 
P AX3 gene locus is indicated on chromosome 2 at position q35 and the FK.HR gene 
locus is indicated on chromosome 13 at position q14. Chromosome translocation 
between the normal chromosomes 2 and 13 at these loci generate the derivative 
chromosomes and result in the fusion of the P AX3 and FKHR genes. 
rhabdomyosarcomas are diploid and appear to respond less well to chemotherapy (Shapiro et 
aI, 1991; Pappo et aI, 1993; Wijnaendts et aI, 1993; Niggli et al, 1994). 
Unlike alveolar rhabdomyosarcoma, no consistent translocations or inversions have been 
reported for embryonal rhabdomyosarcoma which could contribute to tumourigenesis (Potluri 
and Gilbert, 1985; Olegard et aI, 1992). However, restriction fragment length 
polymorphism analysis of embryonal rhabdomyosarcoma has shown consistent loss of 
heterozygosity (LOH) through mitotic recombination for loci on chromosome lip, thus 
implying the location of a tumour suppressor gene. This loss has not been observed for 
alveolar rhabdomyosarcoma (Scrable et aI, 1987, 1989). The smallest region affected in 
these cases encompasses llpI5.5-pter and includes the loci for the haemoglobin ~ gene 
cluster (HBBC), tyrosine hydroxylase (TH), H19, insulin (INS), insulin-like growth factor 
2(1GF2) and the Harvey RAS sarcoma virus oncogene (HRAS) (Scrable et al, 1990; 
Newsham et aI, 1991). This region has also been implicated in the development of other 
embryonal tumours, including Wilm's tumour, adrenal carcinoma and hepatoblastoma, as 
well as tumours of the lung, bladder, ovary and breast (Koufos et al, 1985). Furthermore, 
the Beckwith-Wiedemann syndrome, an autosomal dominant syndrome consisting of 
generalized somatic hyperplasia and a predisposition for the development of embryonal 
tumours (including Wilm's tumour and rhabdomyosarcoma), has been mapped to the same 
region ofLOH as that found in embryonal rhabdomyosarcoma (Henry et al, 1991,1993). 
Evidence that a tumour suppressor gene is expressed in this region has been provided by the 
transfer of an intact chromosome 11, using microcell hybridisation, into an embryonal 
rhabdomyosarcoma having LOH for this region (Loh Jr et al, 1992). By selective retention 
of either the short or long arms of chromosome 11 in the microcell hybrids, loss of 
proliferative capacity was observed. Thus, in addition to the known suppressor locus at 
IlpI5.5, these results indicate the existence of another tumour suppressor on llq (Weissman 
et al, 1987). 
18 
The location of the llp15.5 suppressor locus has been refined by microcell fusion with 
subchromosomal fragments containing small segments of chromosome 11 p (Koi et aI, 1993). 
These studies have localised the suppressor locus to a 4.5Mb region between the anonymous 
markers DllS719 and DllS724. 
Studies investigating the parental origin of alleles in this genomic region in familial and 
sporadic cases of embryonal rhabdomyosarcoma have shown that isodisomic chromosome 
11 p alleles are consistently of paternal origin (Scrable et al, 1989). Thus, genomic 
imprinting of the paternal allele in embryonal rhabdomyosarcoma may be an alternative first 
step to inactivation by mutation at the llp15.5 suppressor locus. Similar preferential 
inheritance of parental alleles have been reported for a variety of other tumours including 
retinoblastoma, Wilm's tumour, and osteosarcoma (Sakai et al, 1991; Rainier et al, 1993; 
Tycko, 1994) 
1.5 IDENTIFICATION OF GENETIC LOCI DISRUPTED BY THE t(2;13) 
Standard positional cloning techniques were used initially to attempt to identify loci disrupted 
by the t(2; 13) chromosome translocation in alveolar rhabdomyosarcoma. Studies sought 
initially to refine the location of the chromosome 2 and 13 breakpoints on physical maps of 
these chromosomes. The breakpoint in Rhabdomyosarcoma cell lines was positioned 
proximally on chromosome 13 to the markers D13SlO, esterase D (ESD) and RBI, and 
distally to the markers D13S6 and D13S1 by in situ hybridisation to metaphase chromosomes 
(Valentine et al, 1989). Further refinement was possible by mapping studies using somatic 
cell hybrids retaining either the derivative chromosome 2 or derivative chromosome 13 1, 
I. Derivative chromosomes are created by the chromosome translocation. In this case the derivative 
chromosome 2 is composed of the p-arm, centromere and proximal q-arm of chromosome 2 and the distal q-
arm of chromosome 13. The derivative chromosome 13 is composed of the p-arm, centromere and proximal 
q-arm of chromosome 13 and the distal q-arm of chromosome 2. 
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and by the analysis of long-range physical maps of these regions by pulsed-field gel 
electrophoresis (Barr et aI, 1991a, b,1992; Mitchell et aI, 1991; Shapiro et ai, 1992). No 
rearrangements in 14 candidate genes which mapped to this region could be detected, but 
mapping of the breakpoint region could be refined to a two megabase interval between 
markers D13S29 and TUBBP2 (Barr et aI, 1991b; Shapiro et aI, 1992). On chromosome 2 
the breakpoint region was found to be flanked proximally by inhibin-alpha (INHA) and 
distally by intestinal alkaline phosphatase (ALP1), a genetic distance of at least 5cM (Barr et 
aI, 1992). 
The physical map of the breakpoint region on chromosome 2 was less detailed than that of 
the breakpoint region on chromosome 13. However, the murine pax3 gene (see below), was 
mapped by linkage analysis to the region between the inhibin-alpha and intestinal alkaline 
phosphatase loci on proximal mouse chromosome 1, a segment which is syntenically 
conserved with the distal human 2q region (Schurr, 1990). 
The human homologue of the murine pax3 gene was therefore a candidate for involvement in 
the rearrangement caused by the t(2;13) translocation. Using a chromosome 2 somatic cell 
hybrid mapping panel, human P AX3 was positioned within the same interval on 
chromosome 2q as the alveolar rhabdomyosarcoma-specific t(2;13) breakpoint and was 
shown to be rearranged in tumour DNA from cell lines containing this translocation (Barr et 
aI, 1993). Fine-mapping showed that all rearrangements occur, albeit in differing positions, 
within the same 20kb intron located between the last two exons of the P AX3 gene. In all 
cases these rearrangements result in the translocation of the 5' region of P AX3 to the 
derivative chromosome 13, and the 3' region of P AX3 to the derivative chromosome 2. 
Isolation and characterisation of fusion cDNA clones has shown that the P AX3 
rearrangement results in the creation, on the derivative chromosome 13, of a novel chimeric 
gene composed of 5' PAX3 sequences juxtaposed to 3' sequences derived from a gene 
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designated FKHR (ForKHead in Rhabdomyosarcoma) which is a member of the forkhead 
family of transcription factors, and which is located on chromosome 13q14 (see figure 1.2). 
On the reciprocal derivative chromosome 2, 5' FKHR sequences are juxtaposed to 3' PAX3 
sequences. Analysis of several independently derived RMS cell lines by RT-PCR indicates 
that the t(2;13) translocation results in chimeric transcripts which are uniform in structure, 
consistent with the occurrence of translocation breakpoints within specific P AX3 and FKHR 
introns (Galili et aI, 1993; Shapiro et aI, 1993). 
Although the t(2;13)(q35;qI4) translocation has been found in the majority of cases of 
alveolar rhabdomyosarcoma, several cases with the variant (1; 13)(P36;q 14) translocation 
have been reported (Beigel et aI, 1991;Douglass et al, 1991; Whang-Peng et aI, 1992). The 
(1;13) has been shown to rearrange the PAX7 gene on chromosome 1 and fuse it to identical 
FKHR sequences on chromosome 13 (Davis et al, 1994). The PAX3 and PAX7 genes have 
very similar expression patterns and functional elements (see below) so the respective P AX3-
FKHR and P AX7-FKHR fusion proteins are likely to play similar roles in 
rhabdomyosarcoma tumourigenesis. 
With the characterisation of the loci affected by the t(2; 13) translocation in alveolar 
rhabdomyosarcoma complete, studies could be directed towards an understanding of how the 
PAX3, FKHR and novel chimeric PAX3-FKHR genes could contribute to the aetiology of 
alveolar rhabdomyosarcoma. 
1.6 THE PAX GENE FAMILY 
To date nine PAX genes have been characterised which constitute a family of developmental 
control genes which encode transcription factors containing the characteristic DNA binding 
domain termed the paired-box (Gruss and Walther, 1992). The nine mouse (pax1 to pax9) 
and nine human (PAXI to PAX9) genes have had their chromosomal locations mapped 
(Walther et aI, 1991; Wallin et al, 1993; Stapleton et al, 1993). The paired box was first 
found in five Drosophila genes paired, gooseberry and gooseberry neuro which are 
expressed in early development, and pox meso and pox neuro which have a tissue restricted 
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Figure 1.2 Schematic diagram depicting the consequences of the t(2;13)(q35;q14) 
chromosome translocation in alveolar rhabdomyosarcoma. The P AX3 gene contains 
two DNA-binding motifs, the paired box and the paired type homeodomain, an 
octapeptide motif of unknown function and a C-terminal transactivation domain. The 
FKHR gene contains the 'winged' helix-loop-helix forkhead DNA-binding domain and 
a C-terrninal transactivation domain. The chimeric P AX3/FKHR gene on the 
derivative chromosome 13 contains the two P AX3 DNA-binding motifs and a truncated 
forkhead DNA-binding domain from the FKHR gene. The other chimeric gene on the 
derivative chromosome 2 does not contain an intact DNA-binding domain so is unlikely 
to have any activity. The important difference between the P AX3 gene and the 
P AX3/FKHR chimeric gene on the derivative chromosome 13 maybe the transactivation 
domains . The chimeric protein may bind to the same DNA sequences as P AX3 but 
could transactivate different transcriptional machinery. 
expression pattern in development. Homologues were subsequently detected in the genomes 
of mouse, human, nematode, zebrafish and chick (Bopp et aI, 1986; Burri et al, 1989; 
Noll,1993). There is a very high level of sequence conservation in pax genes between 
species. For example, the human PAX6 protein is 422 amino acids long but shows only one 
amino acid difference from the mouse pax6 protein and has 96% identity with the product of 
the zebrafish homologue. The paired box domain, which spans 128 amino acids, is 
composed of two structurally independent subdomains, each of which contains a helix-tum-
helix motif (Xu et aI, 1995). The amino- and carboxy- terminal subdomains of the pax5 
paired domain bind to adjacent major grooves of the DNA (Czerny et ai, 1993), while the 
drosophila paired protein binds to one major groove through its amino-terminal paired 
subdomain (Xu et aI, 1995). The amino-terminal subdomain also contains a ~ tum motif and 
carboxy-terminal tail, which makes contact in the minor groove and along the phosphate 
backbone of the DNA. Alignment of the Pax binding sites indicates that the arnino- terminal 
subdomain contacts a conserved recognition sequence whereas the more divergent carboxy-
terminal subdomain appears to playa role in site-specific DNA recognition (Czerny et al, 
1993). 
A number of PAX genes also contain a homeobox. This 'paired-type' homeodomain is 
similar to classic homeodomains featuring a helix-tum-helix motif. In addition, most of the 
genes contain a third highly conserved sequence, the octapeptide, which is located between 
the two DNA-binding domains. The function of the octapeptide motif has yet to be 
established. 
The nine paired box genes in mouse and man are dispersed around the genome, unlike the 
clustering of the HOX genes. The genes can be classed into four subgroups based on their 
structural similarities and expression patterns (see figure 1.3). 
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Figure 1.3 The PAX gene family. The nine known members of the PAX gene family 
can be divided into four subcategories depending on their structural motifs. The PAXl 
and P AX9 genes have the paired domain DNA-binding motif and the octapeptide but 
lack the homeodomain. The P AX2, P AX5 and P AX8 genes contain the paired domain 
DNA-binding motif, the octapeptide and a truncated homeodomain. The P AX3 and 
P AX7 genes contain the full complement of motifs and the P AX4 and P AX6 genes 
contain the two DNA-binding motifs but no octapeptide. 
1.6.1 PAXI ANDPAX9 
The PAX1 and PAX9 genes and the equivalent mouse homologues have a similar expression 
pattern to the distantly related pox meso in drosophila and are distinguished by a complete 
lack of the paired type homeodomain. PAX 1 is expressed in the sclerotomal parts of the 
somites and contributes to skeletal development, as demonstrated by its loss of function 
mutation in the undulated mouse which displays distinctive abnormalities of the vertebrae 
(Chalepakis et aI, 1991). 
~ 1.6.2 P AX2, P AX5 AND P AX8 
The second subgroup P AX2, P AX5 and P AX8 and their murine homologues possess a paired 
domain, an octapeptide and a truncated homeodomain encoding the first alpha-helix. Their 
expression in the developing mouse begins at embryonic day 9.5-10.0 post coitum (pc) and 
occurs along the full length of the anterior-posterior axis. Later pax2 and pax8 show similar 
expression patterns in the developing nervous and excretory systems, and pax2 and pax5 are 
distinguished by their expression in the adult testis. Also, pax2 is expressed in the 
developing ear and eye, pax5 in B lymphocytes in both embryo and adult and pax8 in the 
developing and adult thyroid. 
Of these genes P AX5 is the best studied. It is expressed in the developing central nervous 
system, in B-cells and in testis (Adams et al, 1992; Asano and Gruss, 1992). PAX5 (also 
known as BSAP) is an important regulator of B-cell development and some P AX5 target 
genes have been identified (Kozmik et al, 1992; Rothman et aI, 1991; Singh and Birshtein, 
1993; Waters et al, 1989). Transgenic mice homozygous for pax5 have disturbed midbrain 
morphogenesis, abnormal spleen and lymphoid architecture and arrested B-cell development 
(Urbanek et al, 1994). 
P AX5 expression has been demonstrated in certain human tumours including 
medulloblastoma and highly malignant astrocytomas (glioblastoma) where expression 
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appears to correlate with progression of malignancy (Kozmik et al, 1995; Stuart et aI, 1995). 
Expression of P AXS in astrocytomas coincided with the expression of recognised oncogenes 
(myc, fos, jun) but in glioblastomas expression inversely correlated with the tumour 
suppressor gene p53. Following these observations a direct role for PAX5 in the regulation 
of pS3 transcription has been identified. PAX genes bind to a sequence within the S' 
regulatory region of the human pS3 gene and are capable of repressing pS3 promoter activity 
in cell culture. The site to which P AXS binds appears to be crucial for basal transcriptional 
activity and it is likely that PAX proteins interact or compete with a component of the basal 
transcriptional machinery for access to this site, thus controlling pS3 transcription (Stuart et 
aI, 1995). 
A recurring translocation, t(9;14)(P13;q32), has been identified in approximately 2% of 
non-Hodgkin lymphomas (lymphoplasmacytoid immunocytomas) which involves the PAX5 
gene. In a cell line bearing this translocation the intact P AX5 gene has been juxtaposed to an 
immunoglobulin heavy chain gene promoter resulting in deregulation of its expression 
(Busslinger et aI, 1996). 
Transgenic mice which overexpress pax2 have severe kidney abnormalities, suggesting that 
repression of pax2 is required for normal kidney development (Dressler et al, 1993). 
Subsequently, loss-of-function mutations in the human PAX2 gene have been found in 
patients with kidney and retinal defects (Sanyanusin et al, 1995) 
1.6.3 P AX4 and P AX6 
A third subgroup of pax genes, P AX4 and P AX6, are distinguished by a lack of the 
octapeptide motif. However, it has not been possible to demonstrate expression of P AX4 in 
humans or its homologue in the mouse, suggesting that it may be a pseudogene. Murine 
pax6 transcripts are detectable at embryonic day 8-8.S pc and are found particularly in the 
developing central nervous system, in the nose and the developing eye. Expression in the 
adult is confined to the cerebellum. Mutations in pax6 have been found in the mouse mutant 
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smalleye (sey). The variable phenotype in differing sey mutant alleles provides an indication 
of the importance of PAX gene dosage in normal development. In sey a point mutation in 
the coding region of pax6 leads to a truncation of the protein product upstream of the 
homeodomain. Heterozygotes have eye malformations whereas homozygotes are neonatal 
lethal with a complete absence of eyes, nose and olfactory bulb. Mutations in the human 
homologue, P AX6, have been identified in several patients with aniridia, a condition which 
is characterised by the complete or partial absence of the iris, and also in patients with Peters 
anomaly who have defects in the cornea (Glaser et aI, 1992; Jordan et al, 1992; Davis and 
Cowell, 1994; Hanson et aI, 1993; Hanson et aI, 1994). Overexpression of PAX6 in 
transgenic mice also appears to result in severe eye abnormalities (Schedl et al, 1996). 
The apparent semidominance of PAX gene mutations suggests that these gene products are 
required in distinct concentrations. The transcriptional activity from a single allele is 
apparently below a critical threshold, leading to phenotypic alterations (Gruss and Walther, 
1992). 
1.6.4 P AX3 and P AX7 
The fourth and final subgroup of the PAX gene family includes the P AX3 and the P AX7 
genes. Both genes encode the full complement of conserved sequence motifs, the paired 
domain, the octapeptide and the complete paired type homeodomain. Expression of murine 
pax3 transcripts can be detected in 8-8.5 pc embryos and occurs in the dorsal ventricular zone 
of the neural tube including roof plate and neural crest cells, as well as in dermomyotome, 
limb buds and some cranio-facial structures. Expression of pax7 has a similar but not 
identical spatial and temporal pattern to that of pax3. Expression of both genes cannot 
normally be detected in adult tissue. 
The pax3 protein can bind in vitro to the e5 sequence from the promoter of the drosophila 
even-skipped gene. The pax3 recognition site contains two DNA sequence blocks 
encompassing 18bp. An A ITA motif, recognised by homeodomain proteins in general, 
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forms part of the pax3 homeodomain recognition sequence, and the second element includes 
GTTCC which was originally identified as the core motif for DNA binding by the paxl 
protein (Chalepakis et al, 1991; Chalepakis et aI, 1994). Both recognition elements are 
required for high affinity pax3 binding (Goulding et al, 1991). Although the wild-type pax3 
protein apparently does not form homodimers, truncated pax3 proteins can dimerize, and the 
region essential for dimerization has been mapped to the interval between the paired domain 
and the homeodomain (Chalepakis et ai, 1994) 
A number of mutations in the pax3 gene have been identified in splotch mice which have 
neural crest deficiencies, neural tube defects and limb defects. As with pax6, splotch is 
semidominant. The phenotype is called splotch because heterozygotes have white spotting on 
their coats. Homozygotes die by day 13-14 of gestation with neural tube defects, deficiency 
of melanocytes, schwann cells, dorsal root ganglia, thyroid, thymus, parathyroid and limb 
muscle deficiencies. In heterozygotes with the splotch retarded allele there is retarded 
growth in addition to the other abnormalities (Goulding et al, 1993; Epstein et ai, 1993; 
Vogan et ai, 1993). 
Mutations in the PAX3 human homologue have been identified in patients with Waardenburg 
syndrome, a pleiotropic, dominantly inherited condition involving sensorineural hearing loss 
and pigmentary anomalies of the iris, hair and skin. Waardenburg syndrome has been 
subclassified into three types on the basis of the presence or absence of the clinical feature 
dystopia canthorum, an outward displacement of the inner comers of the eyes. Types 1 and 
3 have dystopia and show linkage to PAX3, whereas none of the type 2 patients show linkage 
to P AX3. Type 2 patients have been linked to mutations in the microphthalmia gene 
(Tassabehji et ai, 1994; Steingrimsson et al, 1994). To date, more than forty mutations in 
the P AX3 gene have been reported which involve changes in the paired and homeo domains 
of the gene (Epstein et ai, 1991; Tassabehji et ai, 1992; Baldwin et al, 1992; Morell et ai, 
1992; Tsukamoto et ai, 1992; Hoth et al, 1993; Pasteris et al, 1993; Butt et al, 1994; 
Tassabehji et aI, 1994). Mutational heterogeneity does not account for the substantial 
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phenotypic variation that exists between and within families carrying the same mutation. 
However, the phenotypic concordance reported in a case of monozygotic twins with 
Waardenburg syndrome suggests that variation in the expression of the syndrome is 
genetically mediated by the polygenic background or by interactions with specific genetic 
modifiers (Pandya et aI, 1996). 
Several lines of evidence suggest that mutations in pax3, as well as mutations in other pax 
genes, cause loss-of-function of the mutant allele, thus causing haplo-insufficiency. First, 
missense mutations and small in-frame deletions in an allele which allow expression of the 
protein product have a similar phenotype to those resulting in whole gene deletion or a frame 
shift early in the reading frame. This finding suggests that expression of the mutant allele in 
heterozygotes does not interfere with the function of the wildtype allele, giving a dominant 
negative effect. Second, splotch heterozygotes bearing one wildtype allele, have a less 
severe phenotype than homozygotes bearing only mutant alleles. Cases homozygous for 
Aniridia and Waardenburg syndrome support this observation (Hodgson and Saunders, 1980; 
Zlotogora et aI, 1995). Finally, in vitro DNA-binding studies with mutantpax3 and PAX3 
alleles support a loss-of-function model (Chalepakis et al, 1994). 
Studies involving the overexpression of several of the murine pax genes in tissue culture cells 
and nude mice demonstrate that they can promote oncogenesis and should thus be classified 
as a novel group of proto-oncogenes. The induction of tumour formation in mice is dependent 
on a functional paired domain but does not require the presence of a homeodomain 
(Maulbecker and Gruss, 1993) 
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1.7 THE FORKHEAD GENE FAMILY 
The first forkhead gene (fkh) was isolated from drosophila, a home otic protein that is 
essential for gut differentiation. Mutations within the fkh gene result in the duplication of 
head structures at the posterior portion of the gut (Weigel et aI, 1989). Subsequently, 
hepatocyte nuclear factor 3 (HNF-3), which mediates liver-specific transcription of the 
transthyretin (TTR) gene, was isolated from rat liver (Costa et aI, 1990). The gene coding 
for this product was cloned and found to have significant homology to the jkh gene of 
drosophila. HNF-3 is involved in regulating the expression of several liver-specific genes, 
such as alpha-I-antitrypsin, albumin, phosphoenolpyruvate carboxykinase (PEPCK), 
tyrosine aminotransferase and apolipoprotein B (Ang et aI, 1993). Truncated polypeptides 
produced by deletion of HNF-3 cDNA templates have been used in DNA-binding studies to 
define the DNA-binding domain (Lai et al, 1990). This 300 nucleotide region, in the middle 
of the gene, has the highest homology with the drosophila fkh gene, providing evidence that 
these two genes were the prototypes of a new family of transcription factors. 
HNF-3 has been renamed HNF-3a following the cloning of two related liver factors, HNF-3~ 
and HNF-3y, from liver eDNA libraries which were probed with the conserved forkhead 
DNA-binding domain (Lai et al, 1991). X-ray crystallography studies of the HNF-3y protein 
bound to DNA indicate that family members bind as a monomer inducing a 13 degree bend in 
the DNA molecule. The DNA binding element has a 'winged helix' motif consisting of a 
helix-tum-helix and DNA interactive loops (Clark et~, 1993). 
In addition to the conserved DNA-binding domain, the HNF-3 family of proteins possess 
homology in two C-terminal regions consisting of 19 and 14 amino acids and two larger N-
terminal regions (Lai et al, 1991). Analysis of a series of HNF-3~ deletion mutants in 
transfection assays define these regions as transcription activation domains. The C-terminal 
domain requires the retention of the two conserved regions for activity, whereas the N-
terminal domain requires the presence of the C-terminal domain, suggesting a physical 
interaction between these motifs (Pani et al, 1992). There is less homology between HNF-3 
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genes in these domains than in the forkhead domain, suggesting that they may interact with 
distinct targets of the transcriptional machinery. 
Murine homologues of the HNF-3a and HNF-3~ genes are expressed initially at embryonic 
day 6.5 pc during gastrulation and at day 8.5 pc in the node, notochord and floorplate of the 
neurotube. Later in development HNF-3a and HNF-3~ are expressed in the gut, pancreas, 
liver and lung primordium, with HNF-31 expression restricted to gut, pancreas and liver 
(Sasaki and Hogan, 1993; Monaghan et aI, 1993). Between days 9.5-15 pc HNF-3 gene 
expression occurs in the developing adrenal gland, thyroid gland and oral cavity, in bone 
tissue of the vertebrae, limbs, ribs, jaws and skull (Monaghan et al, 1993). Forkhead genes 
in the adult tends to show a tissue specific expression pattern 
To date there are more than 40 members of the forkhead family of transcription factors based 
on the presence of the forkhead DNA-binding domain in species ranging from yeast to man. 
The winged-helix DNA-binding domain sequence is highly variable between family 
members, with amino acid identity to the HNF-3a sequence as little as 31%. This 
heterogeneity may provide each protein with distinct DNA-binding properties and account for 
the wide range of tissue specific functions of forkhead genes in development and in the adult 
(Hromas and Costa, 1995). 
As stated above, the novel FKHR gene sequences fused to P AX3 gene sequences in the 
t(2;13) translocation in alveolar rhabdomyosarcoma showed significant homology to the 
forkhead family of transcription factors. Northern analysis with FKHR sequences detect a 
6.5kb wildtype sequence which is ubiquitously expressed in adult tissues (Galili et al, 1993). 
The forkhead DNA-binding domain of FKHR lacks an N-terminal KPPY amino acid 
sequence common to most forkhead genes and contains a novel five amino acid insert in the 
middle of the forkhead domain. Additionally, FKHR shows no region of homology with 
other forkhead genes at the C- and N-terminus. Other potential motifs based on sequence 
analysis include a 10 amino acid proline rich domain, which is similar to an SH3 binding site 
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(Ren et aI, 1993). An alanine rich sequence, which has been associated with transcriptional 
repression, and proline rich and acidic regions, which may function as transcriptional 
regulatory domains (Han and Manley, 1993; Mitchell and Tijan, 1989). Expression studies 
with the chimeric P AX3IFKHR product indicate that there are transcriptional activation 
domains in the 3' region of the FKHR gene (see below). 
Two other examples of a role for forkhead genes in neoplasia have been reported. Firstly, 
identification of the avian retroviral oncogene qin as a member of the forkhead family gave 
the first indication that the mammalian forkhead genes may have oncogenic potential (Li and 
Vogt, 1993). Secondly, a t(X; 11) chromosome translocation in a cell line established from 
an infant with acute lymphoblastic leukaemia has been cloned and sequenced (Parry et al, 
1994). The gene on the X-chromosome, AFX1, is a novel member of the forkhead gene 
family and has most homology to the FKHR gene. The fusion point in AFX 1 is at exactly 
the same position in the forkhead domain as in the FKHR gene in the t(2;13) translocation. 
Following the characterisation of the t(2;13) translocation, the structure of the wild-type 
FKHR gene on chromosome 13 was analysed (Davis et al, 1995). The FKHR gene consists of 
three exons spanning 140kb, the first of which is within a CpG island. All t(2;13) 
translocation breakpoints must occur within the large 130kb intron 1 of FKHR, which 
provides a large target for DNA rearrangement. 
1.8 P UJ-FKHR AND P AX7-FKHR IN ALVEOLAR RHABDOMYOSARCOMA 
The t(2;13)(q35;q14) translocation in alveolar rhabdomyosarcoma causes the fusion of the 
PAX3 and the FKHR genes (Barr et aI, 1993). The variant (1;13)(P36;qI4) translocation 
causes the fusion of the P AX7 gene on chromosome 1 to identical FKHR sequences on 
chromosome 13 (Davis et alI994). Functional studies which might lead to an understanding 
of the role of the chimeric fusion products in alveolar rhabdomyosarcoma have been directed 
at the common PAX3-FKHR fusion. However, since the spatial and temporal expression 
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patterns and the structure of both P AX3 and P AX7 are so similar, it would be reasonable to 
infer that the PAX7-FKHR fusion has a similar role in tumourigenesis as the PAX3-FKHR 
fusion. 
Initially, to establish that a mature chimeric protein product is present in t(2;13) bearing 
cells, polyclonal antisera specific for the normal P AX3 and FKHR proteins have been 
prepared (Fredericks et aI, 1995). In the RD cell line, which does not contain the t(2; 13) 
translocation, the P AX3 antiserum could detect a 56kD protein and the FKHR antiserum 
could detect a 72kD protein. These sizes are consistent with the predicted open reading 
frames of the wildtype genes. Immunoprecipitation of proteins from t(2;13) bearing cell 
lines showed that both antisera detected a 97kD protein which could not be detected in the 
RD cell line. The molecular mass of 97kD agrees with the predicted 837 amino acid fusion 
protein. Low levels of the 56kD wildtype P AX3 protein could also be detected but despite the 
presence of wildtype FKHR mRNA the 72kD FKHR protein was not detectable. 
To confirm that both antisera are reacting with the same chimeric protein sequential 
immunoprecipitation experiments were performed. These demonstrated that the 97kD 
protein could be precipitated with one antiserum, dissociated from the complex, and 
reprecipitated with the other antiserum (Fredericks et al, 1995). 
Several observations indicate that it is the derivative chromosome l3, 97kD fusion protein, 
which is important to the aetiology of alveolar rhabdomyosarcoma. Firstly, the reciprocal 
derivative chromosome 2 product would lack both the P AX3 paired domain and 
homeodomains. Secondly, based on functional and structural studies demonstrating the 
essential nature of the amino terminal of the forkhead domain for DNA binding, it is unlikely 
that the disrupted carboxyl FKHR forkhead domain present in the fusion protein contributes 
to sequence-specific DNA interactions (Clark et al, 1993: Clevidence et aI, 1993). Thirdly, 
the derivative chromosome 2 transcript has only been detected by RT -PCR analysis in some 
of the t(2; 13) bearing cell lines, whereas the derivative chromosome 13 product has always 
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been detected (Galili et aI, 1993; Shapiro et al, 1993). These observations are consistent with 
northern analysis of tumour cell RNA which has indicated that, in those tumours expressing 
both chimeric transcripts, the derivative chromosome 13 transcript is significantly more 
abundant. Finally, only the 97kD fusion protein from the derivative chromosome l3 has 
been detected by immunoprecipitation (Fredericks et aI, 1995). 
Since many transcription factors bind DNA in a sequence specific manner, studies have been 
performed to determine whether the PAX3-FKHR fusion protein will bind to similar target 
sequences as wildtype P AX3 protein. P AX3 is able to bind in vitro to a DNA sequence 
• derived from the drosophila even-skipped gene promoter, e5, which contains distinct 
domains that are specifically recognised by the paired box and the homeodomain (Goulding 
et aI, 1991; Chalepakis et aI, 1994). The PAX3-FKHR protein has been shown to bind to a 
radiolabelled e5 probe in an electrophoretic mobility shift assay, but not as effectively as 
wildtype P AX3 protein, despite the two proteins having identical PAX DNA-binding 
domains (Fredericks et al, 1995). In similar studies using the synthetic PRS-9 DNA target 
sequence, which is based on the e5 sequence, two different point mutations in the paired 
domain or deletion of the homeodomain in P AX3-FKHR abolish this binding (Sublett et al, 
1995). These observations are consistent with studies originally performed on binding of the 
pax-] protein to the PRS-9 probe (Chalepakis et aI, 1991). 
Retention of the intact P AX3 paired box and homeodomain in the fusion protein and its 
ability to bind P AX3 target sequences suggest that it may bind to normal P AX3 genomic 
targets but aberrantly regulate transcription by either excessive activation or repression 
through novel FKHR 3' regulatory sequences. This hypothesis is supported by experiments 
which demonstrate that the fusion protein is capable of binding to and transcriptionally 
activating model P AX3 binding sites. Transient cotransfection assays using e5-CAT reporter 
plasmids indicate that the PAX3-FKHR fusion protein is a more potent transcription activator 
than PAX3 (Fredericks et al,1995; Sublett et al, 1995). The principal difference between 
PAX3 and PAX3-FKHR is the substitution of the carboxyl terminal domain ofPAX3 for the 
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putative transcriptional activation domain of FKHR. Experiments have been perfonned to 
demonstrate that it is this substitution that alters the transcriptional activation potential of the 
fusion protein. GAL4 fusion constructs were designed to express various carboxyl tenninal 
portions of FKHR and were used in transient transfection assays to demonstrate that the 
carboxyl tenninal 60 amino acid of FKHR are sufficient for activation of a reporter gene 
(Bennicelli et aI, 1995; Sublett et aI, 1995). In similar experiments, evidence suggests that 
there are elements in the N-tenninal region of P AX3 which can inhibit transactivation of 
P AX3 but not P AX3-FKHR (Bennicelli et aI, 1996). 
Finally, data from studies involving the detection of the (2;13) and (1;13) translocations by 
fluorescence in situ hybridisation suggest that in 20% of cases, multiple copies of the fusion 
gene are detectable (Barr et al, 1996). This finding indicates that translocation and fusion 
gene amplification can occur to potentiate tumourigenicity by complementary mechanisms. 
Although the genes involved in both alveolar rhabdomyosarcoma translocations have been 
identified, progress in understanding their specific mechanisms of transfonnation will 
depend on finding their individual or shared downstream targets. In this regard, specific 
target genes for both PAX3 and PAX7 are unknown. However, a precedent may have been 
set through studies of the molecular genetics of Ewings sarcoma. EWS-FLI is a fusion gene 
that is fonned by an 11 ;22 chromosomal translocation characteristically found in Ewings 
sarcoma (Delattre et al, 1992). The fusion gene encodes a chimeric protein that consists of 
the amino tenninus of EWS, a putative RNA-binding protein, fused to the carboxyl tenninus 
of FLI -1, a member of the ETS family of transcription factors. As with the PAX -FKHR 
fusion protein, EWS-FLI can bind DNA in a site specific manner and the amino tenninus of 
EWS can function as a strong transcriptional activator (Bailly et al, 1994; Lessnick et al, 
1995; Mao et al, 1994; May et al, 1993; Ohno et aI, 1993; Ohno et al, 1994). 
Representational difference analysis (RDA), a PeR-based technique, has been used to 
demonstrate that at least in part, EWS-FLI and FLI-l modulate distinct target genes (Braun 
et aI, 1995). This suggests that not only DNA-binding domains, but also transactivation 
33 
domains of transcription factors are important in determining which target genes are activated 
or repressed. It remains to be seen whether the PAX3-FKHR and PAX7-FKHR fusion 
proteins modulate different target genes to P AX3 and P AX7. 
1.9 MECHANISMS WHICH CAUSE CHROMOSOME TRANSLOCATIONS 
Following the cloning and characterisation of a number of genes associated with several 
different chromosome trans locations it has become possible to consider the molecular 
characteristics of nucleotide sequences adjacent to chromosome breakpoints, and to begin to 
understand the mechanisms by which translocation occurs. 
Malignancies of the B-Iymphocyte lineage often exhibit chromosomal rearrangements that 
involve the cytogenetic locations of the immunoglobulin loci. For example, some cases of 
chronic lymphocytic leukaemia (CLL) of the B-cell type carry a t(11;14) translocation 
involving the immunoglobulin heavy chain locus (IgH) at band 14q32. Probes from the 
joining segment of the heavy chain locus (J.J have been used to isolate molecular clones 
containing the site of joining between chromosomes 11 and 14 (Tsujimoto et al, 1984a). 
Analysis of these clones demonstrates that the breakpoint on chromosome 14 is found 
precisely within the JH segment itself. At the nucleotide level breakpoints are clustered at the 
5' end of J-segments and are also clustered on chromosome 11 within a gene designated 
BCL-I (B-cell leukaemia/lymphoma-I). Around the breakpoints are nucleotides which, 
when compared with normal sequences from chromosome 11 or 14, derive from neither. 
Also, on chromosome 11, sequences are observed that have marked homology to the 
heptamer-nonamer sequences found near immunoglobulin variable (V), diversity (D) or 
joining (J) segments (Tsujimoto et al,1985; Tonegawa, 1983). 
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These features have direct bearing on the likely mechanism of translocation when taken in the 
context of the physiological recombination which takes place at the immunoglobulin loci 
during normal B-Iymphocyte development. The variable region of the immunoglobulin 
heavy chain molecule is encoded by separate gene segments, the V H, D and JH segments on 
chromosome 14. During the somatic development of the B-cell, the segments are brought 
together so that, in an immunoglobulin producing B-Iymphocyte, a contiguous V wD-JH 
exon is formed. 
The enzyme involved in this series of rearrangements is called recombinase (Tonegawa, 
1984). Recombinase recognises the heptamer-nonamer sequences found 3' of each VH, on 
both sides of each D, and 5' of each JH segment. The heptamer-nonamer comprises seven 
conserved nucleotides, then a non-conserved spacer of 12 or 23 nucleotides followed by a 
nine nucleotide conserved segment. During rejoining of the segments to each other 
nucleotides may also be deleted, substituted or added. Additional nucleotides are called N 
regions and are present through the action of terminal deoxynucleotide transferase (Desiderio 
et al, 1984). 
At the molecular level, the t( 11 ; 14) breakpoints are thus very reminiscent of a 
physiologically recombining immunoglobulin gene segment. The breakpoints on 
chromosome 14 are clustered 5' of the JH segments, as would be expected if breakage is 
mediated by the recombinase enzyme. The regions on chromosome 11 have heptamer-
nonamer like signal sequences and N regions suggesting that translocations have occurred 
through the mistaken operation of the immunoglobulin recombinase. 
Similar sequence motifs have been found at the breakpoints of cases of follicular lymphoma 
which carry a t( 14; 18) (Tsujimoto et aI, 1984b; Tsujimoto et al, 1985), acute lymphoblastic 
leukaemia carrying a t(8;14) and Burkitt's lymphoma also carrying a t(8;14) (Cleary and 
Sklar, 1985; Bakhshi et al, 1985; Kleinfield et al, 1986). In approximately 50% of cases 
involving immunoglobulin or T-cell receptor loci, however, no signal motif sequences have 
35 
been found at the break in the other participating chromosome, arguing against a role for V-
D-J recombinase in the rearrangement of the corresponding chromosome. In addition, many 
of these abnormalities have only heptamer signals, with no accompanying nonamer 
sequence, at the site of the break (Baer et al, 1988; Rabbitts et al, 1988). 
A transcriptional accessibility model has been proposed in which rearrangement is thought 
only to occur between two regions at which there is transcriptional activity thus allowing 
recombinase to infiltrate the chromatin of the two chromosomes and carry out the 
interchromosomal event (Yancopoulos and Alt, 1985). In some cases where the recombinase 
recognises signal sequences on both chromosomes, it has been demonstrated that 
rearrangement occurs between two regions at which there is transcriptional activity (Baer et 
ai, 1985, 1987; Denny et ai, 1986). There are, however, tumour-specific chromosomal 
abnormalities where transcriptional activity on both chromosomes has not been observed. 
Instead, stretches of alternating purine-pyrimidine residues are found within a short distance 
of the breakpoint region. Alternating nucleotide segments can form left-handed or Z-DNA 
structures which may disrupt chromatin, in a similar way to transcription, to allow 
recombinase mediated chromosome translocations to be brought about (Boehm et al, 1989; 
Lu et ai, 1991). 
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1.10 AIMS OF THIS PROJECT 
Despite the progress made in understanding the mechanisms which cause chromosome 
translocations which involve the juxtaposition of proto-oncogenes next to genes of the 
immune system, little is known about whether similar mechanisms cause other chromosome 
translocations involving gene fusion. The genes involved in gene fusion translocations have 
been characterised relatively recently. Because they are in various locations around the 
genome, the translocation breakpoints have been more difficult to clone. Of the fifty-six 
different translocations or inversions described in a review (Rabbitts. 1994), twenty-six 
could be caused by mechanisms involving immunoglobulin or T-cell receptor gene 
rearrangement. The mechanisms by which the other thirty arise remain unknown. 
The first aim of this project was to clone chromosome translocation breakpoints from alveolar 
rhabdomyosarcoma cell lines which bear the t(2;13) translocation in an attempt to elucidate 
the mechanism by which they occur. 
The activity of the P AX3 proto-oncogene appears to be very important in the aetiology of 
alveolar rhabdomyosarcoma. It would not be surprising, therefore, if it also plays a role in 
the development of embryonal rhabdomyosarcoma. The second aim of the project was to 
screen embryonal rhabdomyosarcoma cell lines and tumour samples for intragenic mutations 
in the eight P AX3 exons which might contribute to the genesis of embryonal 
rhabdomyosarcoma. 
, 
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CHAPTER TWO MATERIALS AND METHODS 
MATERIALS; 
2.1 Chemical reagents 
Chemicals were obtained from Sigma Chemical company except for the 
following; 
Applied Biosystems: 
BRL Life technologies: 
Stratagene: 
2.2 Enzymes 
Boehringer Mannheim: 
Amersham: 
Perkin-Elmer Cetus: 
Oligonucleotide synthesis reagents 
Ultrapure Agarose 
Perfectmatch 
All Restriction endonucleases (10U/).1I) 
T4 DNA Ligase (lOU/J.lI) 
Klenow Polymerase (5U/J.ll) 
Sequenase V2.0 T7 DNA polymerase(l3U/J.d) 
Amplitaq Polymerase (5U/).11) 
2.3 Nucleotides and Oligonucleotides 
Amersham: [a._35S] dATP aqueous solution 
(370MBq/ml, tOmCilml) 
[a.}2p] dCTP redivue solution 
(370MBq/ml, lOmCi/ml) 
[y_32p] dCTP redivue solution 
(370MBq/ml, lOmCilml) 
2',3' -dideoxynucleoside 5' -triphosphate 
(ddATP, ddCTP, ddGTP, ddTTP) 
Megaprime random oligomers 
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Pharmacia: 
2.4 DNA size markers 
2' -deoxynucleoside 5' -triphosphate 
Poly (dI.dC)( dI.dC) 
1 kb ladder from BRL Life technologies was used for all DNA size estimation. 
2.5 Hybridisation membranes 
Amersham Hybond-N+ was used for southern blotting and library screening. 
2.6 X-ray film 
Kodak Biomax or Fuji XR-100 medical X-ray film 
2.7 Bacterial hosts 
E.coli strain XLI-blue MR (Stratagene) genotype; ~(mcrA)183, ~(mcrCB-hsdSMR­
mrr)173, endAI, supE44, thi-l, recAI, gyrA96, relAI, lac. 
Ecoli strain INVaF' (Invitrogen) genotype; F', endA1 ,recA1, hsdR17(rk-, mk+), 
supE44, thi-1, gyrA96 , relA1, ~80lacZ~15, ~(lacZYA-argF)U169, deoR, 'A.-. 
2.8 CeUlines 
RD; Cell line derived from a malignant embryonal rhabdomyosarcoma from a 7 
year-old Caucasian female. European collection of animal cell cultures (ECACC) 
#85111502. 
culture medium; Eagles minimum essential medium with Earles balanced salt solution, 
2% non-essential amino acids, 2% Vitamins, 10% Foetal bovine serum. 
sub-culture procedure; confluent cultures split 1:3 to 1 :6 using 0.25% trypsinlEDTA. 
RH30; Human alveolar rhabdomyosarcoma cell line. Gift from Dr Aidan 
McManus, Royal Marsden Hospital, Sutton, Surrey. 
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culture medium; Dulbecco's minimum essential medium! Ham's F12 mix, 4% foetal 
bovine serum, glutamax(GibcoIBRL). 
sub-culturing procedure; confluent cultures split 1:3 to 1:6 using 0.25% trypsinlEDTA. 
A673; Human sarcoma line derived from a 15 year old female patient. From 
ECACC #85111504. 
culture medium; Dulbecco's minimum essential medium, 10% foetal bovine serum. 
sub-culturing procedure; confluent cultures split 1:3 to 1: lOusing 0.25% trypsinlEDT A. 
KS62; Human Caucasian Chronic Myelogenous Leukemia. From ECACC 
#89121407. 
culture medium; RPM! 1640 medium, 10% foetal bovine serum. 
sub-culturing procedure; non-adherent cells maintained at between 105_106 cells/ml 
A431; Human squamous carcinoma. ECACC #85090402. 
culture medium; Eagles minimum essential medium with Earles balanced salt solution, 
bovine insulin (0.8mg/ml Bovine insulin in 100mM Oxaloacetate/SOmM Sodium 
Pyruvate), 10% foetal bovine serum. 
sub-culturing procedure; split 1:3 to 1:6 using trypsinlEDT A. 
RPMI 8226; Human myeloma. ECACC #87012702 
culture medium; RPMI 1640, 10% foetal bovine serum. 
sub-culturing procedure; non-adherent cells maintained at between 3-9x10s cells/ml. 
Hela; Human cervix carcinoma. ECACC #85060701 
culture medium; Eagles minimum essential medium, 1 % non-essential amino acids, 
10% foetal bovine serum. 
sub-culturing procedure; split 1:3 to 1: lOusing trypsinlEDT A. 
HL60; Human promyelocytic leukemia. ECACC #85011431 
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culture medium; RPMI 1640, 10% foetal bovine serum. 
sub-culturing procedure; non-adherent cells maintained at 1-5x10s cells/ml. 
GM03576; Fibroblast cell line. From the Coriell institute for medical research, 
USA. 
culture medium; MEM Eagles medium-Earle Balanced salt solution, 10% foetal bovine 
serum. 
sub-culturing procedure; Split 1:3 at confluency using trypsinlEDT A. 
Karyotype;48,XY, + 2, + 21 
GMI0401; Fibroblast cell line. Coriell Institute for Medical Research, USA. 
culture medium; MEM Eagles medium-Earles balanced salt solution, 10% Foetal 
bovine serum. 
Karyotype;4 7 ,XX, +2 
2.9 Cosmid libraries 
A. Human genomic cosmid library from the placenta of a newborn caucasian male. 
Average insert size 35-41kb in vector pWEI5 in XLI-blue MR host (Stratagene, 
#951202). 
B. RHF 14 genomic cosmid library from the RHF 14 somatic cell hybrid cell line. 
Average insert size 35kb in vector lawrist4 in ED 8767 host (Mitchell and Cowell, 
1989). 
2.10 Media 
LB (LB-agar): 1 % w/v bactotryptone 
0.5% w/v bactoyeast extract 
1% w/v NaCI 
(1.5% agar) 
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soc: 
2.11 Solutions 
TAE: 
TBE: 
TE: 
SSC: 
SSPE: 
Denaturing solution: 
Neutralising solution: 
2% w/v bactotryptone 
0.5% bactoyeast extract 
10mMNaCl 
2.SmMKCl 
10mMMgC12 
10mMMgS04 
20mM Glucose 
40mM Tris-acetate 
ImM EDTA (pH8.0) 
89mM Tris-borate 
ImM EDTA (pH8.0) 
10mM Tris-HCI (PH 8.0) 
O.lmM EDTA (pH8.0) 
150mM NaCl 
lSmM Sodium Citrate 
150mMNaCl 
10mM NaH2P04 
ImM EDTA (pH7.7) 
O.5MNaOH 
1.5MNaCl 
O.SM Tris-HCl 
O.3M Sodium Citrate 
3M NaCI 
42 
pH adjusted to S.S 
Denhardts solution (lOOx): 2% Ficoll 
Hybridisation buffer: 
Oligo labelling buffer: 
PCR buffer: 
2% Polyvinylpyrrolidone 
2% Bovine serum albumin (fraction V) 
lOx Denhardts solution 
Sx SSPE 
O.S% w/v Sodium lauryl sulphate 
100J.lg/ml denatured, sonicated salmon sperm DNA 
SOmM Tris-HCl (pH7.S) 
SmMMgCl2 
O.lmM dATP, dGTP, dTTP 
1 OmM ~-mercaptoethanol 
O.lmg/ml pd(N)9 
67mM Tris-HCI (pHS.8) 
16.6mM (NH4hS04 
6.7mMMgC12 
1 OmM ~-mercaptoethanol 
170J.lg/ml Bovine serum albumin 
Restriction enzyme buffers: Buffers recommended by Boehringer Mannheim 
Ligation buffer: 
were used in all reactions 
6mM Tris-HCI pH7.5 
6mMMgC12 
SmMNaCl 
100J.lglml bovine serum albumin 
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SSCP gel loading buffer: 
Sequenase buffer: 
7mM ~-mercaptoethanol 
O.1mMATP 
2mM dithiothreitol 
ImM spermidine 
95% Formamide 
lOmMNaOH 
0.25% Xylene cyanol 
0.25% Bromophenol blue 
40mM Tris-HCI pH7.5 
20mMMgCl2 
50mMNaCI 
Sequenase labelling mix(5x): 7.5~M dGTP 
Sequenase termination mixes: 
7.5~MdCTP 
7.5~MdTTP 
ddGmix 
ddAmix 
ddT mix 
ddC mix 
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80~M dGTP, dATP, dCTP, dTTP 
8~MddGTP 
50mMNaCI 
80~M dGTP, dA TP, dCTP, dTTP 
8~MddATP 
50mMNaCI 
80~M dGTP, dATP, dCTP, dTTP 
8~MddTTP 
50mMNaCl 
80~M dGTP, dATP, dCTP, dTTP 
Sequenase stop solution: 
Plasmid prep resuspension buffer: 
Plasmid prep lysis solution: 
Plasmid prep neutralisation buffer: 
Plasmid wash solution: 
Genomic DNA prep reagent A: 
Genomic DNA prep reagent B: 
8f..LMddCTP 
50mMNaCI 
95% Formamide 
20mMEDTA 
0.05% Bromophenol blue 
0.05% Xylene cyanol FF 
50mM Tris-HCI pH7.5 
100glml RNase A 
10mMEDTA 
200mMNaOH 
1 % w/v Sodium lauryl sulphate 
1.32M Potassium acetate pH4.8 
50% Ethanol 
100mMNaCI 
10mM Tris-HCI pH7.5 
2.SmMEDTA 
10mM Tris-HCI (pH8.0) 
320mM Sucrose 
SmMMgC12 
I % Triton X-I 00 
400mM Tris-HCl (pH8.0) 
60mMEDTA 
150mMNaCI 
l%SDS 
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METHODS; 
2.12 Restriction endonuclease digestion of DNA; 
2.12.1 Plasmid and Cosmid DNA 
1. O. S-1 J,lg of plasmid or 2-3 J,lg of cosmid DNA was digested for agarose gel analysis. 
2. Incubations were; 
xJ,l1 DNA 
S J,ll lOx buffer 
0.5J,l1 restriction enzyme (10U/J,lI) 
to SOJ,l1 with ddH20. 
3. Digestions were incubated for 4-24 hours at 37°C (except TaqI at 6SoC and ApaI at 
30°C). 
4. Digests were analysed by electrophoresis through 0.5-2% Agarose gels containing 
glml of Ethidium bromide in TAE buffer at SO-150V. 
2.12.2 Preparation of genomic DNA 
la. From 5xl06 cultured cells, cells were scrapped into tubes and washed in cold PBS. 
I h. From a 2mm block of solid soft tissue, tissue stored at -80°C was chopped as finely 
as possible. 
2. Tissue was resuspended in 2ml of genomic DNA prep reagent B. 
3. 500J,l1 of SM Sodium Perchlorate was added and the tissue left at room temperature 
on a rotary mixer for IS minutes, followed by incubation at 65°C for 25 minutes with 
occasional mixing. 
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4. 2ml of Chloroform which had been stored at -20°C was added and the lysed, 
deproteinised tissue was left at room temperature for a further 10 minutes on a rotary 
mixer and then centrifuged at 800g for 1 minute. 
S. 300JlI of Silica suspension (Nucleon) was added and the two phase mixture 
centrifuged at 1400g for 3 minutes. 
6. The upper aqueous phase containing Genomic DNA was removed into another tube 
and briefly centrifuged to pellet residual Silica. 
7. Two volumes of 4°C Ethanol was added and gently mixed to precipitate the DNA. 
8. Following centrifugation pelleted DNA was washed in cold 70% Ethanol and air 
dried for S minutes. 
9. SOOJlI ofTE buffer was added and the DNA left at 4°C overnight to allow dissolution. 
2.13 Preparation of DNA from agarose gel slices 
1. If DNA was to be isolated from an agarose gel care was taken to prevent 
contamination with DNA from other sections of the gel. 
2. The gel slice weighing approximately 100mg was put in an eppendorf tube and 
incubated with 300JlI of QX 1 buffer and 10JlI of Qiaex II silica (Qiagen, 20021) at SOoC 
for 10 minutes. 
3. Following centrifugation the supernatant was removed and the silica-DNA pellet 
resuspended in 500JlI of QXl buffer. 
4. By serial centrifugation and resuspension the silica-DNA was washed twice in 500JlI 
of PE buffer (Qiagen). 
5. After a final centrifugation the pellet was air dried for ten minutes. 
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6. The DNA was eluted from the silica by resuspending in 1O-20J.lI of ddH20, 
incubating at room temperature for 5 minutes and centrifugation to pellet the silica. 
7. DNA was stored at 4°C or -20°C. 
2.14 Polymerase chain reaction (peR) methodology; 
2.14.1 Oligonucleotide synthesis 
I. Oligonucleotide primers for PCR were designed using the following guidelines; 
a. 18-25bp in length, 
b. the 3' end being a G or C nucleotide, 
c. preferably no more than a three base stretch of a single nucleotide, 
d. no palindromic sequences within the primer, 
e. no complimentary sequences between primer pairs, particularly at the 3' end. 
2. Primers were synthesised on an Applied Biosystems 392 DNNRNA oligonucleotide 
synthesizer, using phosphoramidite chemistry. 
3. Primers were deprotected overnight at 55°C in 1ml of30% Ammonium Hydroxide. 
4. Primer in solution was dried in a vacuum centrifuge and resuspended in 300J.lI of 
dH20. 
5. 4J.lI of primer was diluted in 96J.lI of H20 and measured for optical density (OD260). 
Primer concentration (J.lg/ml)was calculated as OD260 multiplied by 500 (assuming I 
absorbance unit at OD260 contains 20J.lg/ml of oligonucleotide). 
2.14.2 Basic peR protocol 
1. Reactions were carried out in a final volume of 50J.lI including; 
5J.lllOX PCR buffer (Perkin-Elmer) 
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IJ.11 dNTPs (O.2mM of each) 
5J.11 primer A (100ng/J.11) 
5J.11 primer B (100ng/J.11) 
0.2J.11 Taq DNA polymerase (SU/J.1L)(Perkin-Elmer) 
1 J.11 DNA template (200ng genomic DNA or lOng vector/insert DNA) 
32.8J.11 ddH20. 
Reactions were overlaid with a drop of mineral oil to prevent evaporation during PCR 
cycling. 
2. PCR cycling was carried out in a Perkin-Elmer 480 Thermal cycler under the 
following conditions; 
1 cycle 94°C for 5 minutes 
30 cycles 94°C for 1 minute 
55-60°C for 1 minute 
72°C for 1-3 minutes 
1 cycle 72°C for 10 minutes. 
TAQ DNA polymerase was added to the reaction mix during the first cycle of PCR to 
'hot start' the reaction. 
3. PCR products were analysed by electrophoresis on 0.5-2% agarose gels containing 
Xg/ml Ethidium bromide in T AE buffer at SO-IS0V. 
2.14.3 Cloning of peR products 
1. PCR products to be cloned were prepared from agarose gel slices or, if a clear single 
PCR product was present, taken directly from the PCR reaction tube. 
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2. The cloning strategy relies on the presence of overhanging adenosine nucleotide 
residues normally found at the ends of PCR products. PCR products are ligated into a 
plasmid vector which has complimentary overhanging thymidine nucleotide residues. 
This method prevents vector self ligation and insertion of multiple PCR product copies. 
3. Incubation constituents are as follows; 
1111 Fresh PCR product (50-100ng) 
1111 lOx ligation buffer 
1111 vector (2Sng) (pCRII Invitrogen) 
7111 ddH20 
1111 T4 DNA ligase (4U/lll). 
Ligation reactions were incubated at 14°C overnight. 
Cloned products were then used to transform bacterial hosts as follows; 
4. A thin walled tube containing 50111 of competent E.coli INVaF' bacterial host cells, 
stored at -80°C, were allowed to thaw on ice. 
5. 2111 of O.SM J3-Mercaptoethanol and 2111 of the ligation reaction were mixed very 
gently with the competent cells and incubated on ice for 30 minutes. 
6. The cells were then 'heat shocked' at 42°C for 30 seconds and then returned to ice for 
a further 2 minutes. 
7.450111 of SOC medium was added and the tubes left in a shaking 37°C incubator. 
8. 50-200111 aliquots of cells were then plated onto LB agar plates containing antibiotic 
and X-gal. Plates were left inverted overnight at 37°C. 
9. Individual white colonies were picked into 5ml of LB medium containing antibiotic 
and grown overnight in a shaking 37°C incubator. 
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10. By addition of sterile glycerol to a final concentration of 20% stocks of bacteria 
containing cloned PCR products were stored at -20°C. 
2.14.4 SSCP-PCR 
SSCP-PCR incubations were the same as basic PCR with the following alterations; 
1. Incubations were carried out in a final volume of 25~1 so the volume of each 
constituent of the reaction was adjusted accordingly. 
2. The dNTP mix was low in dCTP (O.OSmM) to increase incorporation of radiolabelled 
[(l32p] dCTP. 
3. 0.1 ~l of [(l32p] dCTP was included in the reaction. 
4. Following cycling 251 of SSCP loading buffer was added and reactions were stored at 
-20°C until loading onto an SSCP gel. 
5. Before gel loading samples were heated at 95°C for ten minutes and immediately 
cooled on ice. 
6. Samples were loaded onto a 6% polyacrylamide gel containing 5% glycerol in TBE 
buffer and run for 16 to 22 hours at 7-9 Watts at 4°C. 
7. The gel was fixed with 10% acetic acid/lO% methanol for 15 minutes, dried and 
autoradiographed overnight. 
2.15 Radiolabelling probes 
1. 20ng of DNA probe in 31 ~l of ddH20 was mixed with 5~1 of random nonamer 
(Amersham) and denatured in a boiling water bath for 5 minutes. 
2. On cooling to room temperature 1 O~l of labelling buffer, 2~1 of e2p] dCTP and 
finally 2J.l.l of Klenow ploymerase were added and incubated at 37°C for 10 minutes. 
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3. The reaction was stopped by addition of 5 fll of 0.2M EDT A. 
4. Labelled DNA probe was separated from unincorporated nucleotide in a final volume 
of 400fll by filtration through a Nick column (Pharmacia, 17-0855). The level of 
incorporation was estimated by comparing the geiger count of the column 
(unincorporated nuc1eotides) with the eluate. A greater than 50% incorporation was 
deemed acceptable. 
5. Before use in hybridisation labelled DNA probe was denatured by boiling for 5 
minutes, then chilled on ice. 
2.16 Cosmid library plating and filter lifts 
1. The titre of cosmid libraries was determined using serial dilutions down to 10-9. 
lOOp] of each dilution was plated on L-agar containing antibiotic and incubated 
overnight at 37°C. The plate with at least 100 colonies was counted. The titre was 
calculated using the following; 
colony number x dilution volume 
volume plated x dilution 
2. Five L-agar + antibiotic 25x25cm plates were prepared containing 100,000 colonies 
on each. Colonies were allowed to grow overnight to approximately lmm diameter. 
The plates were then cooled at 4°C for 30 minutes. 
3. 22x22cm Hybond-N filters were carefully laid over the cold plates, 'keyed' using a 
hot sterile needle and left for 10 minutes to maximise the number of colonies adhering 
to the filter. 
4. Filters were carefully removed from the plates and carefully laid, colony side 
uppermost, onto denaturing solution soaked 3MM Whatman paper for 2x5 minutes. 
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5. Filters were transfered to 3MM Whatman paper presoaked with neutral ising solution 
for a further 2x5 minutes. 
6. Finally filters were briefly washed in 2xSSC and then allowed to air dry for 1 hour. 
7. Filters were wrapped in SaranWrap and placed DNA-side down on a UV-
transilluminator for 2 minutes (312nm wavelength) to fix the DNA to the nylon support. 
2.17 Southern blotting 
Following electrophoresis, DNA in agarose gels was treated in the following way prior 
to transfer to a Hybond-N nylon membrane; 
1. DNA was nicked by treatment with O.25M HCI for 15 minutes. 
2. The gel was rinsed briefly and then denatured in Denaturing solution for 2x30 
minutes followed by neutralisation for 2x30 minutes in Neutralising solution. 
3. Blotting was carried out overnight in 20xSSC. 
4. The filter was briefly rinsed in 2xSSC, air dried and the DNA fixed to the filter by 
crosslinking using a 31 Onm UV -light source for 2-3 minutes 
2.18 Screening of DNA-bound filters by hybridisation 
1. Filters were rolled together with mesh into Hybaid bottles and presoaked with 30ml 
of 20mM Sodium Phosphate. 
2. Sodium phosphate solution was removed and replaced with 13rn1 of preheated 
prehybridisation solution. Bottles were placed in a 65°C rotisserie to prehybridise for 3 
hours. 
3. Prehybridisation solution was replaced with hybridisation solution containing labelled 
denatured probe. Bottles were left overnight. 
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4. Following hybridisation filters were washed twice for 10 minutes in 2 x sse, O.l% 
(w/v) SDS at room temperature. 
5. Filters were further washed at varying stringency. Stringency was varied using salt 
concentration (SSe, 2x to O.lx) and/or temperature (6Soe to room temperature). 
6. Washed filters were wrapped in SaranWrap and autoradiographed using markers 
(Stratagene) for alignment of filters and plates to developed film. 
7. The area on the plate corresponding to a positive signal on the film was scraped into 
LB medium containing antibiotic and retitred. 
8. Secondary screening of 100-300 colonies on lS0mm diameter LB-agar plates was 
carried out as above. 
2.19 Isolation of plasmid DNA 
1. Cells from 3ml overnight cultures grown in LB+antibiotic were pelleted by 
centrifugation and resuspended in 180111 of plasmid prep resuspension solution. 
2. The suspension was mixed gently with 180111 of lysis solution until clear. 
3. The lysate was mixed gently with 180111 of neutralisation buffer to precipitate cellular 
debris. 
4. Following centifugation the supernatant or 'cleared lysate' was removed for further 
purification. 
5. Cleared lysate was mixed with 1ml of plasmid miniprep purification resin (Promega). 
The resin bearing the plasmid DNA was collected on a support column (Promega) and 
washed with 2ml of plasmid wash solution then dried by centifugation. 
6. Plasmid DNA was eluted from the resin with SOIlI of 6S-70oC TE by centifugation. 
7. Plasmids were stored at -20 or 4°C. 
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2.20 Isolation of cos mid DNA 
2.20.1 Small-scale; 
1. The first four steps of the plasmid isolation method described above were followed 
for small-scale cosmid DNA isolation. 
2. Cleared lysates were twice extracted with an equal volume of phenol/chloroform to 
remove protein, followed by extraction with an equal volume of chloroform to remove 
traces of phenol. 
3. One tenth volume of 3M Sodium acetate (pH5.2) and two volumes of ethanol were 
added and left at -20°C for 30 minutes to precipitate cosmid DNA. 
4. DNA pellet was washed twice in cold 70% ethanol, air dried for 5 minutes and 
resuspended in 50,...1 ofTE buffer. 
5. Cosmids were stored at 4°C or -20°C. 
2.20.2 Large-scale; 
1. Cells from 500ml overnight cultures grown in LB+antibiotic were pelleted by 
centifugation and resuspended in 15ml of plasmid prep resuspension solution. 
2. Resuspended cells were mixed gently with 15ml of plasmid prep lysis solution until 
clear 
3. The lysate was mixed gently with 15ml of plasmid prep neutralisation solution to 
precipitate cellular debris. 
4. Following centrifugation the cleared lysate supernatant was removed for further 
purification. 
5. Cosmid DNA was precipitated with 0.6 volumes of isopropanol. 
6. Following centrifugation pellets were resuspended in 2ml ofTE buffer. 
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7. Exactly 2g of Caesium Chloride was mixed with 2ml of Cosmid DNA solution. 
8. 200J-l1 of Ethidium Bromide (lOmg/ml) was added to exactly 2.5ml of the Caesium 
ChloridelDNA mix. 
9. The mix was loaded into 3ml polycarbonate tubes (Beckman) and centrifuged at 
80000 rpm for 18 hours at 20°C in a TLI00J fixed angle rotor (Beckman). 
10. The cosmid DNA band was removed from the tube using a needle and syringe in a 
volume of approximately 100J-l1. The volume was increased to 300J-l1 with TE buffer. 
11. An equal volume of butanol was added, vortexed and centrifuged to extract 
Ethidium Bromide. The extraction was repeated (at least four times) until red colour 
could not be seen in either the aqueous or the butanol phase. The volume was increased 
to 1ml with TE buffer. 
12. Caesium Chloride was removed with three rounds of centrifugation through 
Centricon-30 filters. Volume was readjusted to 1ml with TE buffer before each round. 
13. Cosmid DNA concentration was determined at 00260 assuming one absorbance unit 
at 00260 contains 50 J-lg/ml of double stranded DNA. 
14. Cosmid DNA was stored at 4°C or -20°C. 
2.21 Sequencing 
All sequencing was carried out on plasmid DNA templates containing inserts of interest, 
using suitable vector primers flanking the insert on both sides ego T7 or SP6 in vector 
pCRII (Invitrogen). 
1. 3J-lg of plasmid DNA in 50J-l1 of dH20 was denatured by incubation at 37°C for 30 
minutes in O.2M NaOHI 0.2mM EDTA. 
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2. The mixture was neutralised by addition of 0.1 volumes of 3M Sodium acetate 
(pH5.2) and the DNA precipitated at -70°C for 15 minutes with 3 volumes of Ethanol. 
3. Following centrifugation, the pelleted DNA was washed with cold 70% Ethanol, aIr 
dried for 5 minutes and resuspended in 7J..lI of dH20. 
4. 2J..lI of sequenase reaction buffer and 1 J..lI of primer (XX) were added, the mixture was 
then heated to 6SoC for 2 minutes and allowed to cool slowly (30 minutes) to room 
temperature to anneal primer to template. 
S. The following were then added to the mixture in order; 
Dithiothreitol (O.IM) IJ..lI 
Diluted labelling mix (Ix) 2J..lI 
esS] dA TP O,SJ..lI 
Diluted sequenase (1.63U/J..lI) 2J..lI 
6. After a 2 minute incubation at room temperature 3.5J..lI of this mixture was transferred 
to four tubes each containing 2.5J..lI of a termination mix. 
7. After a further 2 minute incubation 4J..lI of stop solution was added to allfour tubes. 
8. The tubes were heated to 9SoC for 2 minutes and 4J..lI of each mix was then loaded 
onto a 6% polyacrylamide gel in four adjacent lanes. 
9. Electrophoresis was carried out in TBE buffer at 800Volts for 3-6 hours. 
10. Gels were fixed in 10% acetic acid! 10% methanol for IS minutes, dried and 
autoradiographed overnight. 
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2.22 Whole cell protein extract preparation 
(Adapted from a method by Andrews and Faller 1988, Nucleic Acids Research, Vol. 19, 
p2499.) 
1. Whole cell extracts, prepared from between 5x105 and 107 cells, were washed in 
10ml of ice cold PBS and either scrapped or pelleted into eppendorf tubes. 
2. Cell pellets were resuspended in 400J.ll of ice cold hypotonic buffer (IOmM HEPES-
KOH pH7.9, 1.5mM MgC12, 10mM KCl, 0.5mM DTT, 0.2mM PMSF) and incubated 
on ice for 10 minutes. 
3. Cells were centrifuged for 10 seconds at 13000rpm then resuspended in 100J.lI ice 
cold hypertonic buffer (20mM HEPES-KOH pH7.9, 25% glycerol, 420mM NaC1, 
l.5mM MgCI2, 0.2mM EDTA, 0.5mM DTT, O.2mM PM SF) and incubated for a further 
20 minutes. 
4. Cellular debris was removed by centrifugation for 2 minutes at 4°C, the supernatant 
was aliquoted and stored at -70°C. 
5. A 10~1 sample was taken to measure protein concentration. 
2.23 Protein concentration assay (Sigma P5656) 
1. lOJ.lI of extract was diluted into 400J.lI of dH20, then mixed with 400~1 of Lowry 
reagent and left at room temperature for 20 minutes. 
2. Protein standard solutions (Bovine serum albumin) ranging in concentration from 25 
to 300~g/ml in a volume of 400~1 were also mixed with Lowry reagent and left at room 
temperature for 20 minutes. 
3. 200~1 of Folin & Ciocalteu's phenol reagent was added to each mix and left to allow 
colour to develop for 30 minutes. 
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4. Absorbance at 750nm wavelength was measured. 
S. Extract protein concentrations were calculated by extrapolation from a calibration 
curve which was based on the absorbance of the protein standard solutions. 
2.24 End-labelling of oligonucleotides 
1 .. 2S0ng of oligonucleotide was end-labelled with T4-polynucleotide kinase and [y-
32p]ATP in buffer (SOmM Tris-HCI pH7.6, 10mM MgCI2, SmM Dithiothreitol, O.1mM 
Spermidine, O.lmM EDTA), as follows; xJ.l.IOligonucleotide 
IJ.l.I [y-32p]ATP 
5J.1.1 Buffer 
1 J.l.1 T4 polynucleotide kinase (3U/J.l.I) 
to 50J.l.l with dH20. 
2. Reactions were incubated at 37°C for 30 minutes and tenninated at 65°C for 5 
minutes. 
3. SJ.l.1 of Sodium acetate and 100J.l.l of Ethanol were added, mixed and left at -20°C for 
30 minutes 
4. Precipitated oligonucleotides were pelleted by centrifugation at 13000rpm for S 
minutes, washed twice with cold 70% ethanol and air-dried. 
S. Pellets were resuspended in 2S0J.l.l of TE. 
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2.25 Electrophoretic mobility shift assay (EMSA) 
1. 7~g of whole cell extract was mixed with 41lg of poly(dI.dC)(dI.dC) in binding 
buffer (lOmM Tris-HCI (pH7.5), 50mM NaCl, ImM EDTA, ImM DTT, 5% glycerol) 
and preincubated at room temperature for 15 minutes to adsorb non specific DNA-
binding proteins which are present in protein extracts. 
2. lOng of labelled oligonucleotide (I OOOcpmlng) was then added to make the final 
reaction mixture volume 20~ . .Ll, as follows; 7~g Protein extract 
2~110X binding buffer 
4~1 Poly(dl.dC)(dl.dC) 
I JlI 10ng/JlI Labelled oligonucleotide 
3. Reactions were incubated at room temperature for 20 minutes. 
4. 4~1 of loading buffer was added and DNA-protein complexes were separated on 5% 
non-denaturing polyacrylamide gels in TBE at 100 volts for 2 hours. 
5. Gels were fixed in 10% acetic acid, 10% methanol prior to drying and 
autoradiography. 
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CHAPTER 3. MUTATION ANALYSIS IN THE P AX3 GENE IN EMBRYONAL 
AND ALVEOLAR RHABDOMYOSARCOMA 
The introductory chapter above, describes the evidence which implicates the P AX3 
gene in the genesis of alveolar rhabdomyosarcoma. It is the DNA binding elements of 
this gene, rather than those of the FKHR gene, which remain intact following the 
creation of the fusion gene product by chromosome translocation. Therefore, it would 
not be surprising if an aberration in P AX3 gene function also played a role in the 
genesis of embryonal rhabdomyosarcoma. The most common cytogenetic feature of 
embryonal rhabdomyosarcoma, which supports this hypothesis, is the presence of 
trisomic chromosome 2, the chromosome on which the P AX3 gene resides (Beigel et 
aI, 1995). 
Point mutation m an oncogene as a possible cause of transformation has been 
demonstrated previously in studies of the receptor tyrosine kinase gene, RET. RET 
gene mutations have been found in both familial and sporadic forms of medullary 
thyroid carcinoma (MTC), papillary thyroid carinoma (PTC) and multiple endocrine 
neoplasia types 2A and 2B(MEN 2A or MEN 2B) (Mulligan et al, 1993; Donis-keller et 
al, 1993; Hofstra et al, 1994). The RET gene, like the PAX3 gene, was first defined as 
a dominant oncogene by DNA transformation assay (Grieco et al, 1990). Oncogenic 
activation, in patients with PTC, was shown to be due to chromosomal rearrangement 
in which the extracellular domain of RET is replaced by protein fragments from various 
other genes. Patients with MTC or MEN 2A carry point mutations which involve four 
conserved cysteine residues in a cysteine-rich domain of the RET gene. These 
mutations are thought to interfere with ligand binding (Mulligan et al, 1993; Donis-
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Keller et al,1993). In patients with sporadic forms of MTC and MEN 2B, point 
mutation causes a methionine-to-threonine change in the tyrosine kinase domain of RET 
which may cause altered target specificity (Hofstra et al, 1994). 
To test the hypothesis that alterations in the PAX3 gene locus are involved in embryonal 
as well as alveolar rhabdomyosarcoma, tumour samples and cell lines were analysed for 
intragenic mutations. 
3.1 Mutation detection methods. 
Several methods are available for analysing gene sequences for possible mutations. 
The most thorough but also most inefficient method would be to clone and sequence the 
whole gene in each tumour sample. Other more rapid methods rely on the ability to 
differentiate between wild type and mutant alleles to identify samples bearing 
mutations, followed by cloning and sequencing of the mutant allele (see below). 
Because of their structure in eukaryotes, genes have to be analysed exon by exon. 
The chemical cleavage of mismatch (CCM) method results in the base-specific chemical 
modification and cleavage of mismatched basepairs following the cross-hybridisation of 
patient to wildtype DNA (Cotton et al, 1988). The chemicals, hydroxamine and 
osmium tetroxide are used to modify specifically mismatched cytosine and thymine 
nucleotides respectively. The chemically altered mismatch sites are then cleaved with 
piperidine to produce two DNA fragments. The sizes of the fragments will depend on 
the location of the mismatch. 
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In the enzyme cleavage of mismatch (ECM) method, mutations are detected by a 
method which is similar to CCM. Rather than requiring multiple incubation steps 
which involve toxic chemicals, mismatch sites in patient-wildtype heteroduplex DNA 
are recognised and cleaved by the bacteriophage T4 endonuclease VII enzyme (Youil et 
al, 1993). However, this enzyme has residual double-stranded DNA activity which 
results in high background cleavage, so the ECM method is not as efficient as other 
methods. 
The heteroduplex analysis technique is based on differences in the migration rates of 
homoduplex and heteroduplex DNA molecules through polyacrylamide gels (White et 
aI, 1992). Under appropriate conditions, an extra band will appear in samples 
containing both wildtype and mutant alleles. Heteroduplexes can be created by 
denaturing double-stranded DNA at 95°C and reforming the double-strands by slow 
cooling prior to loading on a gel. 
The denaturing gradient gel electrophoresis (DGGE) method exploits the differences in 
DNA melting temperatures which are caused by altered base composition (Sheffield et 
aI, 1989). DNA samples are PCR amplified using a primer with a GC-rich 5' end. 
Samples are electrophoresed through a gradient of denaturant. Depending on the base 
composition, samples will melt but the two DNA strands will be held together by the 5' 
'GC-clamp'. The denatured and clamped sample molecules have much lower mobility. 
Mutant and wildtype alleles will melt at different positions in the gel and thus can be 
resolved. 
Finally, the single strand conformation polymorphism (SSCP) method exploits the fact 
that single-stranded DNA fragments will adopt a particular conformation, which is 
dependent on their base composition, when run under appropriate conditions on a non-
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denaturing polyacrylamide gel (Grita et aI, 1989). The SSCP method was developed to 
look for subtle mutations such as point mutations or small deletions/insertions in 
sequences up to 400bp in length. The technique can be used to detect such changes 
whether they are present in both alleles of a gene or within one allele. The method 
involves radio labelling PCR products, denaturing the double-stranded helix and then 
slowly separating the two single stranded DNA molecules by electrophoresis on a non-
denaturing polyacrylamide gel. Slow electrophoresis allows the single-stranded DNA 
molecules to form secondary structures which will affect gel mobility. Even a single 
point mutation within an allele can alter this secondary structure conformation and thus 
alter mobility. 
For this study, genomic DNA from both embryonal and alveolar rhabdomyosarcoma 
tumours were analysed for intragenic mutation using the Single-Strand Conformation 
Polymorphism (SSCP) method (Grita et al, 1989). The same method has been used 
previously to look for mutations in the PAX3 gene in patients with Waardenburg 
syndrome in which inactivating mutations in the P AX3 gene have been detected 
(Tassabehji et ai, 1992). It is feasible that activating/enhancing mutations alter the 
DNA binding kinetics or the messenger RNA/protein stabilty of P AX3 in Embryonal 
Rhabdomyosarcoma, thus contributing to neoplasia. However, if disease associated 
mutations are not present within the P AX3 gene, this finding would not necessarily 
exclude its involvement. Promoter element or position effect mutations might be 
involved, and such mutations are more difficult to detect. 
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The PAX3 gene is comprised of eight exons. Exons 2-6, which code for the DNA-
binding elements within the gene, have been studied previously using the SSCP method 
in patients with Waardenburg syndrome (Tassabehji et aI, 1992). Primer sequences and 
expected PCR product sizes are indicated in table 3.1 below; 
Table 3.1 Primers used in SSCP analysis of the PAX3 gene. 
EXON PRIMER PRIMER PAIRS PRODUCT SIZE 
1 ElF 5' -GATATAA TTTCCGAGCGAAGTGC 
EIR 5' -GTCCCAGGCCCTGGGATCCAGG 160bp 
2 E2F 5' -GAAGACTGCGAAATTACGTGCTGC 
E2R 5' -GACCACAGTCTGGGAGCCAGGAGG 368bp 
3 E3F 5' -AGGGTACCGGGTACCAACGCCTGC 
E3R 5' -GT AATAGCGACTGACTGTCGCGCC 185bp 
4 E4F 5' -AGCCCTGCTTGTCTCAACCATGTG 
E4R 5' -TGCCCTCCAAGTCACCCAGCAAGT 243bp 
5 E5F 5' -ACTGTAA TGGTGTCTTGCAGTCGG 
E5R 5' -CTGTCTGGACTGAAGTAGGACACG 350bp 
6 E6F 5' -AACTATTATTTCATCAGTGAAA TC 
E6R 5' -ATTCACTTGTAT AAAATATCCACC 291bp 
7 E7F 5' -GCTGCAA TCTGGATCTCTCTG 
E7R 5' -GAGTTGAGTTT ATCTCCCTTC 361bp 
8 E8F 5' -GT AAGCCTTGGACTTTTT AG 
E8R 5' -GACAAGTTTGACACACAACTTTG 363bp 
Unlabelled PCR amplification products for each exon were analysed by electrophoresis 
through 2% agarose gels to ensure that clean single products of the expected size could 
be obtained from each DNA sample. 
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Despite using a range of primer annealing temperatures (55-65°C) and a range of 
concentrations of Magnesium chloride (l-4mM) during PCR amplification it was not 
possible to amplify a single clean product from exon 1 of the P AX3 gene. Similar 
difficulties had been encountered previously in amplifying this product from genomic 
DNA samples of patients with Waardenburg syndrome (Tassebehji et al, 1994). 
Therefore, it was not possible to screen exon I for mutations by SSCP analysis. 
The remaining seven exons could be amplified cleanly from genomic DNA samples, so 
they were analysed by SSCP. The seven exons were each analysed in of total of twenty 
genomic DNA samples. The samples consisted of nine embryonal rhabdomyosarcoma 
samples (one cell line and eight primary tumour samples), seven alveolar 
rhabdomyosarcoma samples (three cell lines and four primary tumour samples), and 
four control samples. The karyotypes of the eight primary embryonal 
rhabdomyosarcoma samples and four primary alveolar rhabdomyosarcoma samples are 
not known. The four control samples comprised of a human placental DNA, DNA 
from the cell line A673 which was derived from a neuroepithelioma tumour, and two 
fibroblast derived cell lines (GM10401 and GM03576, see materials and methods) 
which had been cytogenetically characterised and shown to be trisomic for chromosome 
2. If there was an indication of mutation in any of the test samples in any of the exons, 
a similar analysis was performed on a further twenty human control genomic DNA 
samples to determine whether these mutations were specifically associated with 
rhabdomyosarcoma. 
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Table 3.2 summarises the SSCP analysis; 
DNA source Exon2 Exon3 Exon4 Exon5 Exon6 Exon7 Exon8 
Embryonal RMS (9) 1/9 0/9 0/9 0/9 0/9 0/9 119 
Alveolar RMS (7) 217 017 017 017 017 017 017 
Control (24) 2/24 0/24 0/24 0/24 0/24 0/24 2/24 
The SSCP banding pattern in three out of sixteen rhabdomyosarcoma samples indicated 
that there could be a polymorphism in exon2 of the P AX3 gene. However~3 of 
twenty-four control samples also had a polymorphism which migrated at the same rate 
as the rhabdomyosarcoma samples (see figure 3.1). Similarly, one of sixteen 
rhabdomyosarcoma samples had a polymorphism in exon8 of the P AX3 gene, but two 
out of twenty four control samples also had the same polymorphism (see figure 3.2). 
Since the observed polymorphisms are present in both test and control samples it is 
unlikely that they contribute towards the malignant phenotype. 
In an attempt to confirm that the abnormalities detected were merely polymorphic 
variants, PCR amplification products from exons two and eight were cloned and 
sequenced. The polymorphism in exon2 is a point mutation at base 44 which does not 
alter the subsequent amino acid structure of the PAX3 protein (see figure 3.3). The 
polymorphism in exon8 is a point mutation in the 15bp 'Pyrimidine-rich region' of the 
3' splice site (see figure 3.4). The Pyrimidine-rich region is commonly, but not 
universally, found at the 3' splice site so it is unlikely that this polymorphism will 
affect splicing of the P AX3 gene (padgett et aI, 1986). The effect of the splice site 
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Figure 3.1 Analysis of the PAX3 exon2 polymorphism by single strand conformation 
polymorphism (SSCP). Labelled PCR amplification products using primers E2F and 
E2R (table 3.1) from rhabdomyosarcoma cell lines and patient samples were denatured 
and the two single stranded DNA molecules (bands A and B) separated by 
electrophoresis on a non-denaturing polyacrylamide gel. Bands from samples bearing a 
sequence polymorphism are slightly shifted (band C). Similar shifted bands from 
normal DNA samples are also present indicating that the polymorphisms are not disease 
associated. Band D is non-denatured sample. Gaps between sample lanes are due to 
poor well formation. 
Patient Control 
Figure 3.2 Analysis of polymorph isms in PAX3 exon8 observed by SSCP. Labelled 
PCR amplification products using primers E8F and E8R (table 6.1) from 
rhabdomyosarcoma cell lines and patient samples were denatured ~d the two single 
stranded DNA molecules (bands A and B) separated by electrophoresis on a non-
denaturing polyacrylamide gel. A band from a patient sample bearing a sequence 
polymorphism is slightly shifted (band C). A similar shifted band is also present in 
control samples indicating that there is no disease association. 
control 
rms 
control 
GAAGACTGCGAAATTACGTGCTGCTGTTCTTTGCTTTTTATTTTCCTCCAGTGACTTTTCCCTTGCTTCTCTnnI 
GAAGACTGCGAAATTACGTGCTGCTGTTCTTTGCTTTTTATTTTCCTCCAGTGACTTTTCCCTTGCTTCTCTnnI 
INTRON 1 EXON 2 
8T PLGOGRV NOLGGV F I NGR 
CACCTTCCCACAGTGTCCACTCCCCTCGGCCAGGGCCGCGTCAACCAGCTCGGCGGCGTnnTATCAACGGCAGG 
* 
rms CACCTTCCCACAGTGTCCACTCCCCTCGGCCAGGGCCGCGTCAACCAGCTCGGCGGGGTnnTATCAACGGCAGG 
Figure 3.3 The PAX3 exon2 sequence. The sequence of four control samples of the 
3'-end ofintronl and the 5'-end ofexon2 of the PAX3 gene is identical to published 
sequences. Sequencing of four normal and rms polymorphic sample clones indicates 
that a single base substitution has occurred at the 44th base in exon2 (*). The 
substituted base is the third in a codon and, due to the degeneracy of the code, does not 
alter the resulting encoded amino acid structure (glycine). The E2F primer is 
underlined. 
control 
intron 7 Exon 8 
v M G L L T 
I GCTGCAATCTGGATCTCTCTGCATTTTAACCTCTTCCCAATCTGGCTCI II I IIIAGGTAA TGGGACTCCTGAC 
* 
erms GCTGCAATCTGGATCTCTCTGCATTTTAACCTCTTCCCAATCTGGCTGIIIIIIIAGGTAATGGGACTCCTGAC 
Figure 3.4 The PAX3 exon8 sequence. The sequence of four control samples of the 
3' -end of intron7 and the 5' -end of exon8 of the P AX3 gene is identical to published 
sequences. Sequencing of the three polymorphic samples indicate that a point mutation 
has occurred in the pyrimidine-rich region of the 3' splice site of intron7. 
polymorphism on the splicing of the P AX3 gene could be analysed by reverse 
transcriptase-PCR (RT-PCR) ofPAX3 mRNA. However, the tumour samples used in 
this study were too small to allow the isolation of RNA. 
Although disease associated mutations within the coding region of the P AX3 gene could 
not be found in embryonal or alveolar rhabdomyosarcoma in this study, this finding 
does not preclude the involvement of the P AX3 gene in the embryonal form of the 
disease. Since the P AX3 gene is only normally expressed during foetal development, 
any mutation which allows deregulation of expression in the adult could contribute to 
embryonal rhabdomyosarcoma. Promotor element or position effect mutations which 
could cause such deregulation of P AX3 gene expression are discussed in the final 
section of this thesis. 
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CHAPTER 4 CLONING OF CHROMOSOME TRANSLOCATION 
BREAKPOINTS USING COSMIDS 
The experimental data presented in this chapter was gathered before the sequencing of 
the P AX3 gene intron in which chromosome translocation breakpoints are grouped and 
before the FKHR gene structure had been investigated (Macina et aI, 1994; Davis et al, 
1995). A method was developed to isolate cosmid derived clones which span the 
translocation breakpoint in the cell line RH28. A cosmid library had previously been 
constructed from genomic DNA of the somatic cell hybrid RHFI4. The RHF14 hybrid 
contains the derivative chromosome 13 of the RH28 cell line but not the derivative 
chromosome 2 or the two corresponding normal chromosomes (Mitchell et al, 1991). 
The method involved isolating cosmids from the RHF 14 library and from a normal 
human genomic cosmid library which hybridised with probes based on P AX3 and 
FKHR exons. It was assumed that cosmids isolated using these probes would also 
contain portions of the relevant intron in which the chromosome translocation 
breakpoint lay. By probing RHF 14 cosmids, digested with various restriction 
enzymes, with appropriate cosmids from both normal chromosomes it ought to be 
possible to isolate a single restriction fragment which hybridises with both probes. A 
band which has sequences derived from both normal chromosomes presumably 
contained the translocation breakpoint (see figure 4.1). Two technical problems had to 
be overcome; 
1. Using a whole cosmid as a probe to search for common genomic sequences in 
another cosmid would cause hybridisation between common vector sequences. There 
are two ways of overcoming this problem. First, cosmids to be used as probe are 
69 
Figure 4.1 Cosmidi cosmid hybridisation method to isolate breakpoint spanning 
sequences. 
Cosmids were isolated from the RHF14 library and from a normal human genomic 
cosmid library which hybridised with probes based on P AX3 and FKHR exons. By 
probing RHF 14 cosmids, digested with various restriction enzymes, with cosmids from 
both normal chromosomes it should have been possible to isolate a single restriction 
fragment which hybridises with both probes. A band which has sequences derived 
from both normal chromosomes was presumed to contained the translocation 
breakpoint. 
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initially digested with restriction enzyme and gel purified on agarose to separate vector 
from insert. The insert, in one or more restriction digest fragments, could then be used 
as probe. Second, filters can be probed with vector sequence to identify which bands 
contain vector so that they can be discounted when filters are probed with whole 
cosmid. 
2. Cosmid inserts will contain human repetitive elements such as ALU or LINE repeats 
(Singer, 1982). Repetitive elements in the cosmid probes will non-specifically 
hybridise with repetitive elements in the target cosmids on the filters. To prevent non-
specific hybridisation repetitive elements within the cosmid probe can be preassociated 
or blocked with cot-I DNA (Weiner et al, 1986). Cot-l DNA has been processed to be 
enriched with repetitive element DNA. 
4.1 ISOLATION OF RHF14 COSMIDS 
When the library screening was carried out the derivative chromosome 13 was known to 
contain the first seven exons of the P AX3 gene and the 3' part of the FKHR gene. 
Because the chromosome translocation breakpoint region in the RH28 cell line had 
previously been mapped to a region approximately 2 kilo bases from exon eight of the 
P AX3 gene on chromosome 2 and approximately 14 kilobases from exon seven (Barr et 
ai, 1993). Only probes homologous to PAX3 exon seven and the 3' part of the FK.HR 
gene could be used, because the RHF 14 cosmid library does not contain P AX3 exon 
eight sequence. The size of the intron within the FKHR gene on chromosome 13 was 
unknown. It was assumed that cosmids isolated from the RHF14 library with the 
P AX3 exon seven probe would not contain the breakpoint region. Therefore cosmids 
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were also isolated using a 3' FKHR exon probe assuming that the breakpoint region on 
chromosome 13 would be less than 14 kilobases from 3' FKHR exonic sequences. 
Primary screening with the FKHR probe produced nine possible positive colonies. 
Secondary screening confirmed that four of the nine primary positive colonies 
hybridised specifically with the probe. Individual colonies containing each of the 
positive cosmids were picked and grown overnight in L-broth containing antibiotic. 
Small scale preparations of cosmids were digested and the resulting fragments separated 
by electrophoresis on 0.8% agarose gels (see figure 4.2). 
Since the cosmids were isolated from a cosmid library from a somatic cell hybrid 
(human DNA in a mouse background) it was feasible that they originated from the 
murine homologue of the FKHR gene locus. To test if the cosmids isolated were 
human or murine, peR products were amplified from murine 3T3 cell line genomic 
DNA and from RH28 genomic DNA. The primers chosen for peR were designed to 
allow amplification of sequences from the 3' FKHR exon which had been used as probe 
in the cosmid library screening. The peR products were cloned and sequenced. The 
sequence of the RH28 derived peR product clones exactly matched the published 
human FKHR gene sequence (Galili et aI, 1993). Ten conservative base changes were 
apparent in the sequence of the 3T3 cell line derived peR product clones (see figure 
4.3). Thus the absence of base changes in the cosmid clones strongly suggests that they 
are of human origin. 
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1kb RHF14 cosmid 
ladder A H C 
Figure 4.2 RHF 14 cosmid restriction digest patterns. Restriction digestion of RHF 14 
cosmid with ApaI (A), HindII (H), ClaI (C) indicating a size of 30-35kb. 
Published 
sequence 
Rh28 
3T3 
5' -A ATI CGT CAT AAT CTG TCC CTA CAC AGC AAG TIC A TI CGT GTG CAG 
5' -A AU CGT CAT AA T CTG TCC CT A CAC AGC AAG TIC A TT CGT GTG CAO 
5'-A ATT CGT CAT AAT CTG TeC CIT CAC AGC AAG TIT ATT CGA GTG CAG 
* * * 
amino acids I RHN L S LH S K FIR V 0 
AAT GAA GGA ACT GGA AAA AGT TCT TGG TGG A TG CTC AAT CCA GAG GGT GGC AAG 
AA T GAA GGA ACT GGA AAA AGT TCT TGG TOG ATG CTC AAT CCA GAG GGT GGC AAG 
AA T GAA GGA ACT GGA AAG AGT TCT TGG TGG A TG CTC AAT CCA GAG GGA GGC AAG 
* * 
NEGT GK SSWWMLNPE GGK 
AGC GGG AAA TCT CCT AGG AGA AGA GCT GCA TCC ATG GAC AAC AAC AGT AAA TIT 
AGC GGG AAA TCT CCT AGG AGA AGA GCT GCA TCC ATG GAC AAC AAC AGT AAA TIT 
AGC GGA AAA TCA CCC CGG AGA AGA GCT GCG TCC ATG GAC AAC AAC AGT AAA TIT 
* * * * * 
S G K S P R R R A AS M DN N S K F 
GCT AAG AGC CGA AGC-3' 
GCT AAG AGC CGA AGC-3' 
GCT AAG AGC CGA AGC-3' 
Figure 4.3 Sequence differences between mouse and man in the FKHR gene. peR 
products (primers underlined), of the 3' FKHR exon which had been used as probe in 
the cosmid library screening, were amplified from murine 3T3 cell line genomic DNA 
and from RH28 genomic DNA. The peR products were cloned and sequenced. The 
sequence of the RH28 derived peR product clones exactly matched the published 
human FKHR gene sequence (Galili et aI, 1993). Ten conservative base changes 
(*)were apparent in the sequence of the 3T3 cell line derived peR product clones. 
Thus the absence of base changes in the cosmid clones strongly suggests that they are of 
human origin. 
4.2 ISOLATION OF NORMAL CHROMOSOME 2 AND 13 COSMIDS 
To screen for chromosome 13 cosmid clones from a normal cosmid library, the same 3' 
FKHR exonic sequence probe was used. Chromosome 2 cosmid clones were sought by 
screening with a probe based on the published PAX3 exon 8 sequence (Barr et aI, 1993). 
Two cosmid clones were isolated with each probe, which when digested contained 
similar restriction fragments, again suggesting that they originated from the same 
overlapping genomic region. 
4.3 COSMID TO COSMID HYBRIDISATION 
The two RHF 14 cosmid clones which had been isolated as described above were 
digested with a number of different restriction enzymes to find out which would 
produce an appropriate series of fragments on an agarose gel. Restriction with TaqI 
resulted in 10 fragments ranging in size from 5kb to 500bp. DNA was transferred to 
Hybond-N+ filters by Southern blotting. Filters were then probed with vector sequence 
to determine which bands contained vector. The same filters were then stripped to 
remove the vector probe and probed with each normal cosmid probe which had been 
preassociated with Cot-l DNA. Both cosmid probes hybridised to a 2kb band (see 
figure 4.4). The band was isolated from an agarose gel and used to probe filters 
containing digests of the normal P AX3 and FKHR cosmids (see figure 4.5). The 2kb 
probe was preassociated with Cot-l DNA as it might have contained repetitive 
elements. It hybridised to specific bands from both sets of normal cosmids from 
chromosomes 2 and 13, suggesting that it contained sequences derived from both 
chromosomes. The 2kb band was cloned and sequenced. It contains a sequence of 
approximately 200bp with homology to a long interspersed repeat (LINE). 
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Figure 4.4 Cosmidl cosmid hybridisation reveals a possible 2kb cross-hybridising 
restriction fragment. The two RHF14 cosmid clones were digested with TaqI or HindI! 
and the DNA transferred to Hybond-N+ filters by Southern blotting. Filters were then 
probed with vector sequence to determine which bands contained vector (bands *). The 
same filters were then stripped to remove the vector probe and probed with each normal 
cosmid probe which had been preassociated with Cot-l DNA. A 2kb band hybridised 
to both cosmid probes(#). 
PAX3 cosmid 
HindU ApaI 
FKHRcosmid 
HindU ApaI 
Figure 4.5 Hybridisation of the 2kb restriction fragment to PAX3 and FKHR cosmids. 
The 2kb band was isolated from an agarose gel and used to probe filters containing 
HindU or ApaI digests of the normal PAX3 and FKHR cosmids. The 2kb probe was 
preassociated with Cot-l DNA as it might have contained repetitive elements. It 
hybridised to specific bands from both normal cosmids, suggesting that it contained 
sequences derived from both chromosomes. The 2kb band was cloned and sequenced. 
It contains a sequence of approximately 200bp with homology to a long interspersed 
repeat (LINE). 
At this point the sequence of the P AX3 intron 7 was published and submitted to the 
Genbank database. Comparison of the 2kb clone and intron 7 sequences indicated that 
the 2kb clone did not contain sequences derived from intron 7. Following this 
disappointing discovery the structure of the FKHR gene locus was described (Davis et 
aI, 1995). The FKHR gene is composed of three exons and the t(2;13) translocations 
occur within a 130kb intron 1. Since cosmid inserts are on average 40kb in size it 
became apparent that the normal chromosome 13 cosmids that had been isolated 
previously were unlikely to contain sequences spanning the translocation breakpoint. 
Furthermore, since the RHF 14 cosmids were selected using an FKHR gene based 
probe, they would not contain the translocation breakpoint either. 
The likely explanation for the hybridisation of the 2kb probe to both the normal 
chromosome 2 and 13 cosmids is that the LINE repeat present within the 2kb sequence 
was not sufficiently blocked with Cot-l DNA and could therefore hybridise to repetitive 
elements in the normal P AX3 and FKHR cosmids. This problem would have been 
highlighted if the 2kb clone had been hybridised to filters containing genomic DNA 
from normal tissue and from the parent RMS cell line which contains the chromosome 
translocation, Rh28. 
On reflection, a better way of cloning the Rh28 translocation breakpoint would have 
been to sequence the P AX3 intron 7 starting from exon 8 through the breakpoint region 
of Rh28. It would be necessary to sequence approximately 2-3kb of the intron to cover 
the breakpoint region. The 2-3kb region of the intron immediately 5' of P AX3 exon 
eight also contains the breakpoint regions for two other t(2;13) bearing cell lines 
(personal communication, FG Barr). The sequence data could then be used to design a 
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probe to screen the RHF14 genomic cosmid library. By sequencing the relevant part of 
the P AX3 intron a probe could be designed which did not contain any repetitive 
elements. Cosmids which had previously been isolated could then be screened using 
the same probe for fragments containing breakpoint sequences. 
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CHAPTER 5 CLONING TRANSLOCATION BREAKPOINTS BY 
VECTORETTEPCR 
A vectorette PCR based approach was used to clone novel unknown chromosome 13 
sequences that had been juxtaposed to known, chromosome 2, P AX3 intronic 
sequences as a result of the t(2;13) chromosome translocation. The method involves 
digestion of genomic DNA with an appropriate restriction enzyme, followed by ligation 
of compatible vectorette 'adaptors' to these ends to produce a vectorette 'library' (see 
figure 5.1; Riley et al,1990). Using an appropriately sited PAX3 intron primer together 
with a vectorette adaptor primer it should be possible to amplify a product spanning the 
translocation breakpoint by PCR. Non-specific amplification is reduced because of the 
design of the vectorette adaptors which allows only templates generated from the 
specific PAX3 primer to bind vectorette primer (see figure5.1). To confirm that any 
novel sequence cloned in this way is derived from chromosome 13, primers based on 
this sequence may be used to amplify a PCR product from a somatic cell hybrid which 
contains human chromosome 13 as its only human component (PGMEI or 289; 
Mitchell and Cowell, 1989; Zhong et al, 1992). 
5.1 Cloning of the derivative chromosome 13 translocation breakpoint in Rh28. 
The cell line, Rh28, contains the t(2;13)(q35;qI4) chromosome translocation 
associated with alveolar rhabdomyosarcoma. Cytogenetic analysis indicates that Rh28 
bears both the derivative and the normal chromosome 2, the derivative chromosome 13, 
but not the normal chromosome 13 (Douglass et al, 1987). A somatic cell hybrid, 
RHF 14, has been generated, based on the RH28 cell line, which bears the derivative 
chromosome 13, but not the derivative or normal chromosome 2 (Mitchell et al, 1991). 
All the PCR-based experiments described in this section have been carried out on both 
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Figure 5.1 Vectorette peR method. Genomic DNA from the translocation bearing 
cell line is digested with a restriction enzyme. Vectorette adaptors with compatible 
ends are ligated to the digested fragments to produce a vectorette 'library'. In the first 
round of peR the primer based on the known sequence will bind to its template 
allowing synthesis of a DNA strand which spans the adjacent unknown sequence and 
the vectorette adaptor. The vectorette adaptor primer will not have a template to bind 
to, thus preventing synthesis of the second strand. 
In the second round of peR the known sequence primer will bind and allow strand 
synthesis as in the first round of peR. The vectorette adaptor primer will bind to the 
strand that was synthesised in the first round of peR, thus allowing synthesis of a 
second DNA strand which will span the adjacent unknown sequence and the known 
sequence. Exponential amplification can then proceed in further rounds of peR. 
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Rh28 and RHF14 genomic DNA to ensure that amplification products come from the 
derivative chromosome 13 and not the normal chromosomes 2. 
The genomic translocation breakpoint of the Rh28 cell line has been mapped previously 
to a O.6kb region between a SacI and a Apal site in the 16kb intron 7 of the PAX3 gene 
(Barr et at, 1993). The presence of these two restriction sites was confirmed in the 
complete sequence of the intron in the Genbank database (Mac ina et aI, 1995; accession 
no. UI2259). To verify that intron sequences 5' of the SacI site were still present in the 
derivative chromosome 13, genomic DNA from Rh28 and the associated RHF14 
somatic cell hybrid were used as template to amplify a predicted 484 base-pair 
fragment from positions 12794 to 13278 in the intron, which should include a Pst! site 
at position 12845 (see figure 5.2b). The predicted amplification product was identified 
and digestion with Pst! restriction enzyme resulted in two bands of the predicted size, 
51 and 433 base-pairs, confirming the presence in both RH28 and RHF14 of the 
relevant intron sequences. 
Four vectorette libraries in total were then constructed from genomic DNA from Rh28 
or RHF 14 cell lines, one pair using HaeIII restriction enzyme and the other pair using 
Sau3A restriction enzyme. Nested primers, based on sequences immediately 5' of the 
SacI site, were designed to be used in conjunction with vectorette adaptor primers. 
The HaeIII and Sau3A restriction enzymes were chosen because their recognition sites 
are not present within the breakpoint region nor between the primer binding and SacI 
sites. Primers 12800F and UVP were used in a first round of amplification, and nested 
primers 13300F and USP were used in a second round of amplification. A 200bp band 
was amplified from the Rh28/HaeIlI and the RHF 14/HaeIlI vectorette libraries and a 
400bp band was amplified from the Rh28/Sau3A and the RHFI4/Sau3A vectorette 
libraries (see figure 5.2c). 
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Figure 5.2 Schematic representation of the two normal and two derivative chromosome 
breakpoint regions in the Rh28 cell line. 
a, Derivative chromosome 2. The vectorette peR product extends from primer 13500R 
to a 8au3A restriction site (8). The derivative 2 breakpoint is at position 13302, 101 bp 
from the derivative 13 breakpoint at position 13402. 
b, Normal chromosome 2. The breakpoint region in Rh28 has been mapped to a 0.6kb 
region between a Sael and a Apal site within the 17. 5kb P AX3 intron 7. 
c, Derivative chromosome 13. peR was used to verify the presence of sequences 
immediately 5'of the Sael site, including a PstI site at position 12845, in the derivative 
chromosome 13. Vectorette peR products span the breakpoint from primer 13300F to 
either the HaeIII (H) or the 8au3A(S) site. The breakpoint is at position 13402 in the 
P AX3 intron. 
d, Normal chromosome 13. The vectorette peR product from primer 30R to a HaeIII 
site (H) spans the breakpoint region on normal chromosome 13. 
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All four products were cloned and sequenced and in all four cases the sequence obtained 
indicates that the genomic breakpoint on the derivative chromosome 13 occurs at 
position 13402/3 of the P AX3 intron. Novel sequence, presumed to represent intron 
sequence within the FKHR gene on chromosome 13, was identified lying 3' of the 
breakpoint in both Sau3A and HaeIII library clones. Two hundred and sixty nine base-
pairs of novel sequence were identified in the Sau3A clones, of which the first 66 base-
pairs exactly matched those present in the HaeIII clones (see figure 5.3). 
5.2 Cloning of chromosome 13 sequences which span the translocation breakpoint 
in Rh28. 
As the cytogenetic analysis of Rh28 indicates that there is no normal chromosome 13 
present, the vectorette libraries used to clone derivative chromosome 13 breakpoints 
described above would not be appropriate for cloning normal chromosome 13 products. 
However, reverse transcriptase PCR (RT-PCR) indicates that the normal FKHR gene 
product is expressed in Rh28 (Galili et al, 1993). This finding suggests that either a 
complete or a partial chromosome 13 is present in the cell line. Therefore, the same 
vectorette libraries were used to attempt to clone normal chromosome 13 sequences 
spanning the breakpoint in Rh28. The novel sequences found 3' of the derivative 13 
translocation breakpoint were used to design a second pair of nested primers. Primers 
50R and UVP were used in a first round of amplification as above. Nested primers 30R 
and USP were used in second round amplification. A 150bp and a 800bp product were 
amplified from the Rh281HaeIII vectorette library and a similar 800bp product was 
amplified from the RHF14IHaeIII vectorette library (see figure 5.2d). 
The 800bp products are of the size predicted if amplification was from the derivative 
chromosome 13 template. The 150bp product, present in Rh28 only, ought to represent 
normal chromosome 13 sequence. No PCR product could be identified from the 
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Figure 5.3 Rh28 derivative chromosome 13 breakpoint sequence from P AX3 intron 
primer 13300F to Sau3A restriction site (both underlined). The breakpoint occurs at 
position 13402 of the P AX3 intron (u). 269bp of novel chromosome 13 sequence 
follows the breakpoint. Putative Translin recognition sequences occur immediately 5' 
and 3' of the breakpoint (double underlined). 
TACATATAGCTCATGGGAAAGTGTGCATGTTTTGAATAAAATTCTGCTCTGAGCTCATCA 
---------+---------+---------+---------+---------+--------~+ 
ATGTATATCGAGTACCCTTTCACACGTACAAAACTTATTTTAAGACGAGACTCGAGTAGT 
AGTATAACTGTACATACAGCATTCCATTTCTCCCTTAAAGTGACATACCATTGACTGAAT 
---------+---------+---------+---------+---------+---------+ 
TCATATTGACATGTATGTCGTAAGGTAAAGAGGGAATTTCACTGTATGGTAACTGACTTA 
u 
TTCAAGTAAGTATCTTCATGAAGGACAATATTACATTTTAAGACCTGCTCTAGGGGTTGT 
---------+---------+---------+---------+---------+---------+ 
AAGTTCATTCATAGAAGTACTTCCTGTTATAATGTAAAATTCTGGACGAGATCCCCAACA 
AAAATAGTACTGCTGTTATTGGGAGGCGTTGGGTAGG~ACAGCAGCAGGGAGAGAGA 
_________ +---------+---------+---------+---------+---- _____ + 
TTTTATCATGACGACAATAACCCTCCGCAACCCATCCCCGGTGTCGTCGTCCCTCTCTCT 
GGCTCCCATCGTACAAACTTGCAGACTTTTATTAAAACGTATTTATTGATTGCAAATTAT 
---------+---------+---------+---------+---------+---------+ 
CCGAGGGTAGCATGTTTGAACGTCTGAAAATAATTTTGCATAAATAACTAACGTTTAATA 
GTCAACAGAGTGAGGCTTTGGTAACTCTTCAAGTTACTAGTGTTTCCTTCTTTGCATAGT 
---------+---------+---------+---------+---------+---------+ 
CAGTTGTCTCACTCCGAAACCATTGAGAAGTTCAATGATCACAAAGGAAGAAACGTATCA 
TGTTTCCCATCACCCTTTAAACATCTGCTGCTTCTGGTCTTGTCCAGTCATGCTTGAGTG 
---------+---------+---------+---------+---------+---------+ 
ACAAAGGGTAGTGGGAAATTTGTAGACGACGAAGACCAGAACAGGTCAGTACGAACTCAC 
TAG 
experiments using the Rh28/Sau3A or the RHFI4/Sau3A vectorette libraries, possibly 
because the nearest Sau3A site is too far from the breakpoint to allow efficient 
amplification. The 150bp amplification product was then cloned and sequenced. The 3' 
sequence immediately adjacent to the 30R primer matches that of the derivative 13 
clones up to the breakpoint. The clone also contained 111 bp of unique sequence 5' of 
the breakpoint (see figure 5.4). Together with the sequences 3' of the breakpoint on the 
derivative chromosome 13, a total of 380bp of novel sequence have been cloned. To 
confirm that this represents a contiguous sequence on chromosome 13, a primer pair 
close to the two ends of this unique sequence were designed. The expected 313bp 
product could be amplified, cloned and sequenced from Rh28, Placenta, PGMEI and 
289 genomic DNA. Figure 5.4 includes the entire sequence obtained from chromosome 
13. 
5.3 Cloning of the derivative chromosome 2 translocation breakpoint in Rh28. 
To determine whether there have been any insertions and/or deletions associated with 
the chromosome translocation a similar approach to that above was used to clone the 
reciprocal translocation breakpoint on derivative chromosome 2. Nested primers, 
13600R and 13500R, were designed, based on sequences in the PAX3 intron 
immediately 3' of position 13402/3, now established as the translocation breakpoint 
position on the derivative chromosome 13. It is possible that these sequences are 
deleted from derivative chromosome 2 but there was no straightforward way of testing 
this hypothesis as a somatic cell hybrid cell line containing only derivative chromosome 
2 material was not available. 
Amplification of the Rh28lHaelIl and Rh28/Sau3A vectorette libraries was carried out 
with primers 13600R and UVP, followed by nested 13500R and USP primers. A 
300bp product was amplified from the Rh28/Sau3A vectorette library and a 900bp 
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Figure 5.4 Normal chromosome 13 sequence which spans the Rh28 derivative 
chromsome 13 breakpoint. Chromosome 13 based primer 30R and HaeIII restriction site 
are underlined. III bp of novel sequence 5' of the derivative 13 breakpoint have been 
cloned. This together with the novel sequence cloned above represents a contiguous 
380bp of chromosome 13. 
z 
QGCCTTGTTCTTGGAGAATAGGTTTCTTGTTTATCTGAATGGCTTTTCTTTGCGTCACTA 
---------+---------+---------+---------+---------+---------+ 
CCGGAACAAGAACCTCTTATCCAAAGAACAAATAGACTTACCGAAAAGAAACGCAGTGAT 
TGCCAGATAGTCACTCTTGGAGCAGAAATGATGGTTTTAAAATCTCTCTTACATTTTAAG 
_________ + _________ + _________ + _________ + _________ + _________ + 
ACGGTCTATCAGTGAGAACCTCGTCTTTACTACCAAAATTTTAGAGAGAATGTAAAATTC 
ACCTGCTCTAGGGGTTGTAAAATAGTACTGCTGTTATTGGGAGGCGTTGGGTAGGGGCCA 
---------+---------+---------+---------+---------+---------+ 
TGGACGAGATCCCCAACATTTTATCATGACGACAATAACCCTCCGCAACCCATCCCCGGT 
CAGCAGCAGGGAGAGAGAGGCTCCCATCGTACAAACTTGCAGACTTTTATTAAAACGTAT 
---------+---------+---------+---------+---------+---------+ 
GTCGTCGTCCCTCTCTCTCCGAGGGTAGCATGTTTGAACGTCTGAAAATAATTTTGCATA 
TTATTGATTGCAAATTATGTCAACAGAGTGAGGCTTTGGTAACTCTTCAAGTTACTAGTG 
---------+---------+---------+---------+---------+---------+ 
AATAACTAACGTTTAATACAGTTGTCTCACTCCGAAACCATTGAGAAGTTCAATGATCAC 
TTTCCTTCTTTGCATAGTTGTTTCCCATCACCCTTTAAACATCTGCTGCTTCTGGTCTTG 
---------+---------+---------+---------+---------+---------+ 
AAAGGAAGAAACGTATCAACAAAGGGTAGTGGGAAATTTGTAGACGACGAAGACCAGAAC 
TCCAGTCATGCTTGAGT~ 
---------+---------+-
AGGTCAGTACGAACTCACTAG 
product amplified from the Rh281HaeIII vectorette library (see figure 5.2a). The 900bp 
product was of the size predicted for normal chromosome 2. The 300bp product, 
presumed to represent derivative chromosome 2, was cloned and sequenced (see figure 
5.5). The first 164bp of sequence extending from the 13500R primer matched the 
original chromosome 2 sequence, indicating that the translocation breakpoint in the 
derivative 2 chromosome is at position 1330112 of the P AX3 intron, which therefore 
differs from the breakpoint in the derivative 13 chromosome at position 13402/3. As 
101bp of chromosome 2 sequence is present in both derivative chromosomes, there 
appears to have been a duplication in this region. The final 82bp sequence of this clone 
was again novel and did not match the newly-derived chromosome 13 sequence 
described above. The 82bp sequence could be amplified from Rh28 and placental 
genomic DNA, but not from chromosome 2 or chromosome 13 monochromosomal 
somatic cell hybrids (GM10826B, 289 and PGME1). That the 82bp sequence is not 
derived from either chromosome 2 or chromosome 13 suggests that an insertion of 
material from another chromosome may have occurred. 
5.4 Cloning the derivative 13 breakpoints in other t(2;13) bearing cell lines 
The breakpoint regions from five other t(2;13) bearing cell lines have been mapped to 
distinct regions within intron 7 of the PAX3 gene (see figure 5.6, personal 
communication from Dr Fred Barr). The breakpoint regions for the cell lines CW12 
and TTC487 have been mapped to overlapping regions ofintron 7 approximately 9kb 5' 
of the Rh28 breakpoint. The Rh5 breakpoint maps to a region 2kb 5' of the Rh28 
breakpoint. The Rh30 and Rh18 breakpoints have been mapped to regions 
approximately lkb and 2kb 3' respectively of the Rh28 breakpoint (see figure 5.6). 
Vectorette libraries were constructed from genomic DNA of each of these cell lines 
using appropriate restriction enzymes and vectorette adaptors (see table 5.1). Somatic 
cell hybrids containing the derivative 13 chromosomes of these cell lines are not 
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~CTCAGAGAGTTGTGGCGATAGTTACTAGAACATAGCAAAACTAATTGGGCAAAAGG 
---------+---------+---------+---------+---------+---------+ 
CTAGGAGTCTCTCAACACCGCTATCAATGATCTTGTATCGTTTTGATTAACCCGTTTTCC 
\) 
GTTCTGCTCGCTGTGCTCTGTGGCTCATCAAGTATAACTGTACATACAGCATTCCATTTC 
---------+---------+---------+---------+---------+---------+ 
CAAGACGAGCGACACGAGACACCGAGTAGTTCATATTGACATGTATGTCGTAAGGTAAAG 
TCCCTTAAAGTGACATACCATTGACTGAATTTCAAGTAAGTATCTTCATGAAGGACAATA 
---------+---------+---------+---------+---------+---------+ 
AGGGAATTTCACTGTATGGTAACTGACTTAAAGTTCATTCATAGAAGTACTTCCTGTTAT 
TTAATTTAGAGTTTATTTTCCTTTTATTTAGTGCCACTGGATATCTTTCCTCTCTGGACT 
---------+---------+---------+---------+---------+---------+ 
AATTAAATCTCAAATAAAAGGAAAATAAATCACGGTGACCTATAGAAAGGAGAGACCTGA 
GATATAG 
CTATATC 
Figure 5.5 Rh28 derivative chromosome 2 breakpoint sequence from PAX3 intron 
primer 13500R to Sau3A restriction site (both underlined). This breakpoint occurs at 
position 13301 of the PAX3 intron (u) indicating that 101bp ofPAX3 intron sequence 
has been duplicated. Somatic cell hybrid peR suggests the remaining 82bp of sequence 
(bold) is not derived from either chromosome 2 or chromosome 13. 
nC487 RHS RH28 RH18 
EXON8 
CW12 RH30 
51 iE. (3frR 
Figure 5.6 The breakpoint regions for the six t(2;13) cell lines used in this study have been mapped to the positions indicated within the PAX3 
intron seven. The breakpoint regions for cell lines CW12, Rh28 and Rh18 were described in Barr et al, 1993. The TTC487, Rh5 and Rh30 
breakpoint regions were determined by Dr. F.G.Barr (personal communication). 
available. It was therefore likely that amplification products would be produced from 
the normal chromosome 2 in each case. These amplification products should be of 
known size and will thus be easy to identify. Amplification products of different sizes 
could originate from the derivative chromosome 13 in each case. 
Nested primers were synthesised based on sequences immediately 5' of breakpoint 
regions in each cell line. Vectorette libraries were constructed using the appropriate 
restriction enzyme for digestion of genomic DNA followed by ligation of vectorette 
adaptors with compatible ends. Sequential PCR reactions were performed with pairs of 
intron specific and vectorette primers. Amplification products from all five vectorette 
libraries were cloned and sequenced. Only products from the TTC487 and RHS cell 
lines contained sequences corresponding to the possible derivative chromosome 13. 
Products from other libraries were derived from the normal chromosome 2 or were non-
specific. The product from the TTC487 cell line library matched the sequence of the 
PAX3 intron up to position 4557 followed by 56bp of novel sequence (see figure 5.7). 
The product from the RH5 cell line library matched the P AX3 intron sequence up to 
position 11099 followed by 316bp of novel sequence (see figure 5.8). The 56bp of 
novel sequence found in the TTC487 cell line amplification product is not a large 
enough template to allow PCR-based verification that it is derived from chromosome 
13. Primers were designed based on the novel sequence found in the clone amplified 
from the RH5 vectorette library. The expected product could be amplified from PGME 
and 289 genomic DNA templates indicating that it is from chromosome 13. 
The novel chromosome 13 sequences cloned from the RH28, RHS and TTC487 cell 
lines do not match each other and have no significant similarity to any sequences in the 
Genbank or EMBL databases. 
An explanation for there not being derivative chromosome 13 based amplification 
products from the CWI2, RH30 and RH18 vectorette libraries may be that the gap 
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CTGGGTCTCTCTCCACAGGACTTGTTTGCTTCCTCTCTGATTGTTTTGTCAAAGCTTTAG 
---------+---------+---------+---------+---------+---------+ 
GACCCAGAGAGAGGTGTCC~GAACAAACGAAGGAGAGACTAACAAAACAGTTTCGAAATC 
TGTTTTCTTATGAGGTGCTTTTGATTGAAACCTCATCAATTTAAAACCTTATCAG 
---------+---------+---------+---------+---------+-----
ACAAAAGAATACTCCACGAAAACTAACTTTGGAGTAGTTAAATTTTGGAATAGTC 
Figure 5.7 TTC487 derivative chromosome 13 sequence. The breakpoint occurs at 
position 4557 of the PAX3 intron (u). Putative Translin recognition sequences are 
double underlined. 
Figure 5.8 Rh5 derivative chromosome 13 sequence. The breakpoint occurs at position 
11099 of the P AX3 intron (u). Putative Translin recognition sequences are double 
underlined. 
u 
GTTATGCAACTCATTTCTGCGCTAATTCTCTGTCTAGATTTATATTTTAGTCATCTT~ 
---------+---------+---------+---------+---------+---------+ 
CAATACGTTGAGTAAAGACGCGATTAAGAGACAGATCTAAATATAAAATCAGTAGAATCC 
GTAGTCTCCTTGATTACTTTTTTTTTTTTTTCTTGAGAATGGGTCAGGTTTTTCCATTTC 
---------+---------+---------+---------+---------+---------+ 
CATCAGAGGAACTAATGAAAAAAAAAAAAAAGAACTCTTACCCAGTCCAAAAAGGTAAAG 
TTCTTATAGGGAGGTAATTTTGGATTATATTCTGGATATTACAAATGATAAATGATAATT 
---------+---------+---------+-----~---+---------+---------+ 
AAGAATATCCCTCCATTAAAACCTAATATAAGACCTATAATGTTTACTATTTACTATTAA 
TATATATATAAATTTTCGTTATGCCCGTCTTAAAAGCATTGATTTTCTTTTCTAAAGCAG 
---------+---------+---------+---------+---------+---------+ 
ATATATATATTTAAAAGCAATACGGGCAGAATTTTCGTAACTAAAAGAAAAGATTTCGTC 
GCAATTGATTAACTTACCTGAATTCAAGCTGCAAAACTATCCCCCCATAGTAGGTGGCAG 
---------+---------+---------+---------+---------+---------+ 
CGTTAACT~TTGAATGGACTTAAGTTCGACGTTTTGATAGGGGGGTATCATCCACCGTC 
TGTACATTTCAGTTCAGTTCTCTTAGCTGGCCTACTTGGAGCCTGCTCTGTGCATGTGTG 
---------+---------+---------+---------+---------+---------+ 
ACATGTAAAGTCAAGTCAAGAGAATCGACCGGATGAACCTCGGACGAGACACGTACACAC 
TTTCACGQATC 
---------+-
AAAGTGCCTAG 
between intron specific- and vectorette primers is too large to allow efficient 
amplification. In anticipation of this problem the vectorette libraries were constructed 
using frequent cutting restriction enzymes, for example Sau3AI or TaqI, which have 
four base recognition sites. However, technical problems such as inefficient primer 
binding or vectorette library construction may have been the cause. Because it is 
necessary to clone PCR products and sequence clones following amplification it was not 
feasible to test a number of vectorette PCR conditions. 
Table 5.1 Restriction enzymes used in vectorette library construction for t(2;13) 
bearing cell lines. 
CELL LINE Restriction 
enzyme 
CW12 Sau3AI 
TTC487 TaqI 
RH5 Sau3AI 
RH30 TaqI 
RH18 TaqI 
breakpoint 
region 
4552-4741 
4221-4741 
11 078-11947 
13935-14478 
14478-15444 
region size 
189bp 
520bp 
869bp 
543bp 
966bp 
5.5 Cloning of normal chromosome 13 sequences spanning the breakpoints in cell 
lines RHS and TTC487 
RT-PCR analysis indicates that the normal FKHR transcipt is expressed in RH5, 
suggesting that the normal intact locus is present (Galili et al, 1993). RT-PCR analysis 
has not been carried out on TTC487. The same RH5 and TTC487 vectorette libraries 
have been used to clone sequences from normal chromosome 13 which span the 
translocation breakpoint. Since it is not known whether the TTC487 cell line has an 
intact FKHR gene locus, another vectorette library was constructed from human 
placental genomic DNA using the same restriction enzyme, TaqI, as in the TTC487 
vectorette library. Several amplification products were cloned and sequenced from 
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each of these vectorette libraries but in every case were either from the derivative 13 
chromosome or were non-specific. 
5.6 Analysis of sequences around the translocation breakpoints 
The whole 16.6kb intron7 of the PAX3 gene on chromosome 2 has been sequenced 
(Macina et ai, 1995). Three microsatellite and two Alu repeat sequences are present 
within the intron. These common sequences are not close to any of the breakpoints in 
the cell lines TTC487, RH5 or RH28 which suggests that they are unlikely to be 
involved in the mechanism by which the t(2;13) chromosome translocations have 
occurred. Recombinase protein signal sequences and oligopurine/oligopyrimidine 
motifs have been implicated in chromosome translocation mechanisms in lymphoid 
malignancies; these motifs could not be found in a search of the sequences around the 
t(2; 13) translocation breakpoints. 
Recently a novel protein, now called Translin, has been identified which specifically 
binds to sequences found adjacent to breakpoint junctions of chromosome translocations 
in many cases of lymphoid malignancy (Aoki et al, 1995). The authors compared 
nucleotide sequences at the 5' flanking site of chromosome breakpoint junctions in 91 
cases of human lymphoid neoplasms. These included translocations involving 
immunoglobulin gene loci, T-cell receptor gene loci and others not involving loci 
which normally undergo gene rearrangement. The consensus sequence derived from 
the 91 cases is; 
A(65%), T(88%), 0(85%), C(75%), A(96%), 0(78%), and 
0(86%), C(76%), C(63%), Aff(40%156%), C(68%), C(64%), T(45%). 
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The consensus is in two parts which maybe separated by up to four bases. The same 
Translin protein can also bind to a dimer of the second part of the consensus sequence. 
The sequences flanking breakpoint junctions usually match the consensus sequence at 7 
to 10 of the 13 bases ( 54-77% homology). 
Analysis of the sequences in the derivative 13 chromosomes in the three cell lines above 
indicate the presence of potential Translin binding sites both 5' and 3' of the breakpoints 
(see table 5.2) 
Table 5.2 Translin binding sites which flank t(2;13) breakpoints in alveolar 
rhabdomyosarcoma with published translin sites which flank other breakpoints showing 
similar homology to the consensus translin binding site. 
breakpoint translin site % homology reference 
position 
consensus ATGCAGGCC (A/T)CCT Aokietal 1995 
bcr/ab1 TTGCAGTGA G CCG 62 Chenetal 1989 
TCR/TTG2 GTGAAGGCT C CGC 62 Boehmetal 1988 
IgH/bcl6 CTGCACGTG C GAT 43 Baronetal 1993 
Rh28 13402 ATGAAGGAC A ATA 62 
TTTAAGACC T GCT 62 
Rh5 11099 ATGCAACTC A TTT 62 
AGGGTAGTC T CCT 62 
TTC487 4557 TTGTTTGCT T CCT 62 
AT GCATATA T GTA 43 
Analysis of sequences around breakpoints in both derivative chromosomes of the Rh28 
cell line suggests that inter-chromosomal translocations are more complex at the 
sequence level than might have been expected. There has been both duplication of 
101bp ofPAX3 intron 7 and insertion of DNA of undetermined size into the derivative 
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chromosome 2. The inserted DNA does not appear to originate from chromosomes 2 or 
13. 
The striking feature of the sequences flanking the derivative chromosome 13 in the 
RH28 cell line and also in the two other cell lines analysed is the presence of potential 
Translin protein DNA-binding sites. Similar sites have been found adjacent to 
chromosome translocation breakpoints in a wide range of lymphoid neoplasms. To 
determine whether these newly identified sequences can act as Translin binding sites, a 
series of studies based on in vitro gel shift analysis were then carried out (see next 
chapter). 
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CHAPTER 6 PROTEIN BINDING STUDIES 
A number of techniques are available to characterise DNA-Protein interactions which 
can also serve as a basis for isolating DNA-binding proteins. The preparation of cell 
extracts from the cytoplasm or nucleus is usually the first step in any of these 
techniques. In DNaseI protection mapping (footprinting) the region or regions to which 
a protein binds, either in co-operation with other proteins or on its own, can be 
elucidated (Galas and Schmitz, 1978). For example, footprinting can be used to find 
the binding region of a regulatory protein in several hundred base pairs of a gene 
promoter sequence. However, a more rapid and simple method for studying DNA-
protein interactions is the electrophoretic mobility shift assay (EMSA). The basic 
protocol involves allowing binding of protein to radiolabelled DNA oligonucleotide and 
separating the DNA-Protein complex from unbound DNA by electrophoresis through a 
non-denaturing, low ionic strength polyacrylamide gel. Under these conditions, 
covalent bonding between DNA and protein remains intact and the mobility of a DNA-
Protein complex is significantly retarded, relative to unbound oligonucleotide, because 
of the size and charge of the protein. By addition of a large mass of alternating 
copolymer DNA (poly[dl.dC].poly[dI.dC]), specific binding of protein from a crude 
extract can be detected. The copolymer provides a large number of non-specific sites 
for protein to bind to, thus leaving labelled DNA sequences open to the specific binding 
of proteins of interest (Carthew et ai, 1985; Singh et ai, 1986). 
In the previous chapter t(2;13) chromosome translocation breakpoints were cloned and 
sequenced. The sequences immediately adjacent to these breakpoints appear to be 
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significantly homologous to the consensus binding sequence for Translin protein (Aoki 
et al, 1995). To test whether these breakpoint flanking sites will indeed bind Translin 
protein the EMSA method was employed. 
The ability for Translin protein to bind to DNA oligonucleotides by EMSA has been 
studied previously by Aoki et al (1995). They were able to demonstrate a number of 
features of Translin protein binding; 
1. Translin will bind to both double-stranded and single-stranded DNA 
oligonucleotides, but with higher affinity to single-stranded oligonucleotides. 
2. Translin will bind specifically to oligonucleotides based on sequences found adjacent 
to chromosome breakpoints in a range of lymphoid neoplasms. 
3. A consensus translin binding sequence can be deduced from these sequences. 
Translin will have little or no binding activity to oligonucleotides with sequences 
unrelated to this consensus. 
4. An antibody (raised by Aoki, et al) against Translin protein will interfere with 
oligonucleotide-protein complex formation. 
S. Translin protein is found in the cytoplasm and nucleus of lymphoid cel1lines such as 
RPMI8226, but only the cytoplasm of non-lymphoid cell lines such as HeLa, A431 and 
K562. 
Translin protein has been purified to homogeneity using the gel mobility shift assay as a 
basis for fractionation and the gene coding for Translin was cloned and sequenced. It 
codes for a 228 amino acid protein which does not share homology to any other known 
protein. A 'leucine zipper' motif, five potential protein kinase C phosphorylation sites, 
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three tyrosine kinase phosphorylation sites and one N-glycosylation site are present in 
the Translin amino acid sequence (Aoki et al, 1995). 
These data were used to design experiments to determine if Translin protein was present 
in RMS cell lines and, if so, whether it would bind to the sequences found flanking 
chromosome translocation breakpoints in the cell lines RH28, RH5 and TTC487. 
6.1 Binding of protein from Rhabdomyosarcoma cell lines to oligonucleotides 
Whole cell protein extracts were prepared from RD, an embryonal rhabdomyosarcoma 
cellline, Rh30, a t(2; 13) bearing alveolar rhabdomyosarcoma cell line, and several other 
cell lines, HeLa, A431, K562, which previously have been shown to contain Translin 
protein (Aoki et al, 1995). EMSA assays are generally carried out with extracts of 
nuclear proteins as most transcription factors are located in the nucleus. To ensure that 
any Translin protein in these cell lines was present in the extract, regardless of its initial 
intracellular location (see point 5 above), whole cell extracts rather than nuclear extracts 
were prepared. 
Extracts from cell lines RD, RH30 and HeLa were used in EMSA to look for binding of 
protein to four different oligonucleotides. Single-stranded oligonucleotides were used 
for this and all the following experiments. The oligonucleotides were; 
1. 'consensus' 5'-ATITCATGCAGGCCTCCTAGTCA-3'. The middle 13 bases of 
this oligonucleotide constitute the consensus sequence for Translin protein DNA-
binding. 
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2. ' 5'RH28' 5'-AlTICAIGMGGACMTMGICA-3'. The middle 13 bases of 
this oligonucleotide constitutes a putative Translin binding site which is immediately 5' 
of the derivative chromosome 13 breakpoint in the t(2;13) chromosome translocation in 
the cell line Rh28. 
3. '3'RH28' 5'-AlTICIIIMGACCTGCTAGTCA-3'. The middle 13 bases of 
this oligonucleotide constitutes a putative Translin binding site which is immediately 3' 
of the derivative chromosome 13 breakpoint in the t(2;13) chromosome translocation in 
the cell line Rh28. 
4. 'nonspecific' 5'-AlTICCACIATCQACIACAGTCA-3'. The middle 13 bases of 
this oligonucleotide are unrelated to any Iranslin binding site. 
In EMSA, free labelled oligonucleotide probe will migrate rapidly to the bottom of the 
polyacrylamide gel. Any labelled oligonucleotide which has protein bound to it will 
migrate more slowly through the gel. In the initial experiment two slowly migrating 
bands are present (figure 6.1, bands A&B). The faster migrating band B is present in 
incubations with all four oligonucleotides and with all three extracts tested. The 
intensity of band B in the HeLa cell line extract is much less than that seen with the RD 
and RH30 cell line extracts. For all three cell lines tested, the slower migrating band A 
is present in the lanes containing the 'consensus' oligonucleotide and the lanes 
containing the '5'RH28' and '3'RH28' oligonucleotides. However this band is not 
present in the lane containing the 'nonspecific' oligonucleotide which is unrelated to a 
translin binding site. 
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Figure 6.1 Binding of protein in the electrophoretic mobility shift assay (EMSA). 
Extracts from cell lines RD, RH30 and HeLa were used in EMSA to look for binding of 
protein to four different oligonucleotides; one based on the consensus trans lin 
recognition sequence, two based on putative translin recognition sequences found 
flanking t(2;13) breakpoints, and one unrelated sequence. Unbound, 32P-labelled 
oligonucleotide probe will migrate rapidly to the bottom of the polyacrylamide gel 
(band C). Any labelled oligonucleotide which has protein bound to it will migrate 
more slowly through the gel. In this experiment two slowly migrating bands are 
present (figure4.1, bands A and B). The faster migrating band B is present in 
incubations with all four oligonucleotides and with all three extracts tested. The 
intensity of band B in the HeLa cell line extract is much less than that seen with the RD 
and RH30 cell line extracts. For all three cell lines tested, the slower migrating band A 
is present in the lanes containing the 'consensus' oligonucleotide and the lanes 
containing the '5'RH28' and '3'RH28' oligonucleotides. However this band is not 
present in the lane containing the 'nonspecific' oligonucleotide which is unrelated to a 
translin binding site. 
RD Rh30 Hela 
A __ 
B--
c 
Bela cells are known to contain Translin protein which will bind to specific sequences 
in gel mobility shift studies (Aoki et al, 1995). Protein derived from rms cell lines RD 
and Rh30 will bind to the same sequence resulting in the appearance of bands which 
migrate at the same rate. Bands which migrate at the same rate also appear when all 
three extracts are exposed to oligonucleotides based on sequences found adjacent to the 
derivative chromosome l3 breakpoint in the cell line RH28. 
6.1 Specificity of oligonucleotide-protein binding 
Is the binding of protein to oligonucleotide in the previous experiment dependent on the 
sequence of bases? To answer this question competition experiments were carried out. 
EMSA reactions were set up as described above, but included in the incubations were 
increasing quantities of unlabelled oligonucleotide which will compete with the labelled 
oligonucleotide for protein. If the competing oligonucleotide has the same sequence as 
the labelled oligonucleotide the intensity of the gel shift band should be reduced. When 
the competing oligonucleotide has an unrelated sequence the intensity of the gel shift 
baud may be reduced, indicating binding is not sequence specific. Alternatively, the 
intensity of the gel shift band will not be reduced indicating binding is sequence 
specific. 
Two experiments were performed with either the 'consensus' oligonucleotide or the 
6S'RH28' oligonucleotide. The RD, RH30 and HeLa extracts plus the two other 
Translin bearing extracts A431 and K562 were tested. In each experiment, for each 
extract, a set of four EMSA reactions were performed. The first in each set of four 
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contained no competing unlabelled oligonucleotide. In the remaining three tubes of 
each set of four, a 40, 80 and 160 fold molar excess of competing unlabelled 
oligonucleotide was included. Figure 6.2 shows an experiment in which labelled 
'consensus' oligonucleotide IS competing with increasing quantities of unlabelled 
'consensus' oligonucleotide. The band intensity is gradually reduced with increasing 
unlabelled oligonucleotide for all of the extracts tested. When the labelled 'consensus' 
oligonucleotide is competing with equivalent increasing quantities of unlabelled 
'nonspecific' oligonucleotide band intensity is not reduced (see figure 6.3). 
The competition experiments described here indicate that the binding of protein to 
oligonucleotide requires sequence specificity 
6.3 Sizing of protein that binds to oligonucleotides 
The above EMSA experiments were performed on non-denaturing polyacrylamide gels, 
which are not suitable for determining the molecular mass of the protein which is 
binding to oligonucleotide. The molecular mass of the particular protein in a whole cell 
extract that is binding to labelled oligonucleotide can be measured by irreversibly 
crosslinking the protein to the oligonucleotide using UV -light, and separating the 
complex on a denaturing polyacrylamide gel together with a set of molecular weight 
markers. 
A series of incubations with RD protein extract and 'consensus' labelled oligonucleotide 
were exposed to UV light for varying lengths of time. The samples were separated by 
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A431 K562 Hela Rh30 RD 
Figure 6.2 Specificity of protein/oligonucleotide interaction in EMSA - specific 
competitor In the first of each set of four lanes labelled oligonucleotide has been 
incubated with 7)lg of whole cell extract from the cell lines A431 , K562, Hela, Rh30 
and RD respectively. Lanes 2, 3 and 4 of each set include a 40, 80 and 160 molar 
excess of the same unlabelled oligonucleotide showing competition for protein. The 
final lane contains free labelled oligonucleotide only. 
A431 K562 Hela Rh30 RD 
Figure 6.3 Specificity of protein/oligonucleotide interaction in EMSA - non-specific 
competitor. Addition of non-specific unlabelled oligonucleotide in the same molar 
excess as in figure 4.2 does not result in competition for protein. 
electrophoresis through a denaturing polyacrylamide gel. The gel was fixed with 10% 
acetic acid! 10% methanol, dried and autoradiographed. Rather than the expected 
single band, a range of bands of differing molecular mass appeared on the 
autoradiograph. Four repetitions of the same experiment resulted in the appearance of a 
number of bands of varying intensity. 
A possible explanation for these observations is that because a high concentration of 
crude protein extract is present in close proximity to the labelled oligonucleotide, the 
UV light has caused crosslinking between nonspecifically binding proteins and labelled 
oligonucleotide. The molecular mass of the protein which binds to the test 
oligonucleotides specifically could be estimated if it was purified from cell extract. 
However, although a purification protocol had been developed for Translin protein this 
is a lengthy and difficult procedure. Therefore, other methods besides molecular mass 
estimation were used to try to identify the DNA-binding protein 
6.4 Effect of oligonucleotide mutation on oligonucleotide-protein complex 
formation 
In a further experiment to determine whether the sequences adjacent to the t(2;13) 
chromosome translocation breakpoint are Translin binding sites, a series of 
oligonucleotides were designed, based on the '5'RH28' oligonucleotide, which have an 
increasing number of base substitutions (underlined) so that they have a decreasing 
similarity to the Translin consensus binding site sequence; 
1. 5'RH28 5' -A TTTCATGAAGGACAA T AAGTCA-3' 
91 
2. 
3. 
4. 
5. 
6. 
5'-ATTTCITGAAGGACAATAAGTCA-3' 
5'-ATTTCIAGAAGGACAATAAGTCA-3' 
5' -A TTTCIACAAGGACAAT AAGTCA-3' 
5' -A TTTCIACACGGACAA T AAGTCA-3' 
5' -A TTTCIACACAGACAA T AAGTCA-3' 
The oligonucleotide series (starting with the '5'RH28' sequence) has homology to the 
consensus sequence ranging from 62% to below 25%. 
Figure 6.4 below shows a gel mobility shift autoradiogram involving incubations of the 
above six oligonucleotides with whole cell extracts from , the RD cell line. The first two 
lanes include the '5'RH28' oligonucleotide with and without cell extract. A strong 
protein-oligonucleotide complex band is present as in the above experiments. The 
remaining pairs of lanes involving the other oligonucleotides in the series show a 
significant reduction in protein-oligonucleotide complex formation. 
6.5 Effect of anti-trans lin antibody on oligonucleotide-protein complex formation 
The above experiments suggest that a protein or protein complex is present in the rms 
cell lines tested which can bind to oligonucleotides based on the sequences found next 
to t(2;13) chromosome translocation breakpoints. To obtain direct evidence that this 
protein is Translin, an antibody raised against recombinant Translin protein was 
obtained (a gift from Dr M Kasai). Aoki et a1 had previously demonstrated that the 
epitope of the anti-translin antibody is close to the DNA-binding element of translin, 
92 
5bc 4bc 3bc 2bc lbc 5'Rh28 
+ + + + + + 
Figure 6.4 Effect of oligonucleotide base changes on protein/oligonucleotide 
interaction in EMSA. Binding of protein from RD cell line extract to six different 
labelled oligonucleotides. Pairs of lanes either do contain extract (+) or do not contain 
extract (-). The oligonucleotide series, based on the '5 'RH28' oligonucleotide, have 
an increasing number of base substitutions (1 bc,2bc,3bc ... ) which reduce their 
similarities to the translin consensus recognition sequence. 
and therefore will block the binding of recombinant Translin protein to oligonucleotides 
in gel mobility shift assays. 
The anti-Translin antibody was included in experiments involving incubation of the 
RH30 and K562 protein extracts with '5'RH28' and '3'RH28' labelled oligonucleotides 
(Figure 6.5). A reduction in band intensity was apparent when the antibody was 
present. The reduction was greater when the amount of antibody was increased. As a 
control, a non-specific antibody fraction from the same animal as the translin antibody 
was used to show that the reduction in band intensity was specifically due to the 
presence of the translin antibody. 
In conclusion, the experiments described in this chapter indicate that there is DNA-
binding protein in nns cell lines which can bind specifically to oligonucleotides. The 
oligonucleotide sequences are based on those found adjacent to several t(2;13) 
chromosome translocation breakpoints found in alveolar rhabdomyosarcoma. 
Oligonucleotide mutagenesis and antibody interference studies suggest that this protein 
is Translin. 
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K562 Hela Rh30 RD 
Figure 6.5 Effect of anti-trans lin antibody on protein/oligonucleotide inter ti n in 
MA. 
In the first of each set of four lanes labelled oligonucleotide has been incubat d with 
7f.1g ofwbole cell extract from the cell lines K562, HeJa, Rh30 and 
Lanes 2 and 3 of each set include 0.] and O.51lg of anti-translin antib dy r 
(rabbit IgG gift from M.Kasai). The epitope of the anti dy 0 erlap th 
binding element of translin and thus preven the interacti n tv een tran lin and 
labelled oligonucleotide in the gel shift assay. Reducti n in band int 'n it 
apparent in incubations containing translin antibody for alJ \ h Ie cell e tr 
The fourth lane of each set includes O.51lg of oon- pe ifi rabbit IS anti dy which 
has no effect on binding. 
CHAPTER 7 DISCUSSION 
7.1 AIMS OF THIS THESIS 
1. Cytogenetic analysis of rhabdomyosarcoma tumours has shown that a translocation 
t(2;13)(q14;q35) is observed in tumours with alveolar histology. The locus involved on 
chromosome 2 is the transcription factor PAX3. The translocation t(2;13) is not seen in 
tumours with embryonal histology, but trisomy of chromosome 2 is a frequent finding. 
These data suggest that mutations of the P AX3 gene could also have a role in the 
genesis of the embryonal variant. 
The first aim of this thesis was to test this hypothesis by screening tumour DNA from 
patients with embryonal rhabdomyosarcoma for intragenic mutations within the P AX3 
gene. No disease associated mutations could be found in exons 2-8. The findings are 
discussed in section 7.2. 
2. Despite the progress made in understanding the mechanisms which cause 
chromosome translocations involving juxtaposition of proto-oncogenes next to genes of 
the immune system, little is known about whether similar mechanisms cause other 
chromosome translocations involving gene fusion such as that seen in alveolar 
rhabdomyosarcoma. Thirty out of fifty-six different translocations or inversions 
described in a review (Rabbitts, 1994) do not involve immunoglobulin or T-cell receptor 
gene rearrangement. 
The second aim of this project was to clone chromosome translocation breakpoints from 
alveolar rhabdomyosarcoma cell lines which bear the t{2; 13) translocation in an attempt 
to elucidate the mechanism by which they occur. 
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Chapter 4 describes unsuccessful experiments designed to isolate breakpoint spanning 
restriction fragments from a cell line by cosmid-cosmid hybridisation. Chapter 5 
describes vectorette PCR based experiments which led to the cloning of derivative 
chromosome 13 breakpoints in three cell lines, and the complete molecular description 
of a t(2; 13) translocation. These findings are discussed in section 7.3 below. 
7.2 MUTATION ANALYSIS IN THE PAX3 GENE IN EMBRYONAL AND 
ALVEOLAR RHABDOMYOSARCOMA 
Chapter 3 includes a description of experiments in which the exons of the P AX3 gene 
were screened for mutations such as point mutations or small deletions in embryonal 
and alveolar rhabdomyosarcoma tumour samples. Mutation studies of the receptor 
tyrosine kinase gene RET in patients with medullary thyroid carcinoma (MTC) and 
multiple endocrine neoplasia type 2A (MEN 2A) have demonstrated point mutations 
within this gene as a possible cause of transformation (Hofstra et al, 1994;). The RET 
gene, like the P AX3 gene, is associated with tumour-specific chromosomal 
rearrangements in papillary thyroid carcinoma and a developmental anomaly, 
Hirschsprung's disease (Romeo et al, 1994; Edery et al, 1994; Donis-Keller et al, 1993). 
The SSCP method was used because it allows the quick and efficient screening of a 
large number of samples, and because the same method had been used previously to 
successfully screen the PAX3 gene for mutations in patients with Waardenburg 
syndrome. Possible mutations were found in exons 2 and 8, but the same alterations 
were seen in a range of control samples, indicating that these sequence variations are 
polymorphisms rather than disease associated mutations. 
The negative findings in chapter 3 do not exclude a possible role for the P AX3 gene in 
the aetiology of embryonal rhabdomyosarcoma. Position effect mutations or promoter 
element mutations may be responsible for the activation of the gene but are more 
difficult to analyse. 
7.3 CLONING OF CHROMOSOME TRANSLOCATION BREAKPOINTS 
The molecular cloning of the t(2;13) translocation breakpoints that lie in the PAX3 and 
FKHR genes, occurring on chromosomes 2 and 13 respectively, in three cell lines Rh28, 
Rh5 and TTC487, has shown that the breakpoints occur within the 16kb intron seven of 
the P AX3 gene and within the 130kb intron one of the FKHR gene. Although both 
introns represent large targets for chromosome translocation, the uniform structure of 
expressed chimeric P AX3IFKHR gene products suggests that there is an absolute 
requirement for translocations to occur between these two introns (Galili et al, 1993). 
The breakpoint regions within the P AX3 intron in several other translocation bearing 
cell lines have been mapped, and there is no indication of clustering of breakpoints 
within the intron (Barr et al, 1993; personal communication, FG Barr). Following the 
sequencing of the complete intron, no association between these breakpoint regions and 
the two ALU repeats and three micro satellite sequences, located within the intron, 
could be found (Mac ina et aI, 1995). 
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The vectorette PCR technique was used to clone the translocation breakpoints as this 
technique permits the cloning of unknown sequences which are adjacent to known 
sequences. Within the t(2;13) translocation, unknown FKHR intron sequence is 
adjacent to known P AX3 intron sequence. In the technique, adaptors are ligated to the 
ends of restriction enzyme digested DNA. The sequence of the cloned region is then 
determined by PCR using an adaptor primer in combination with primer from the 
known sequence. The specificity of the PCR is, theoretically, dependent on the 
known sequence primer only. 
There are some disadvantages to usmg the vectorette PCR method when cloning 
translocation breakpoints: 
1. It is not possible to know if the required PCR product has been amplified until it has 
been cloned, sequenced and identified. Because the length of the expected PCR 
product is unknown, amplification products which are to be cloned and sequenced 
cannot be preselected by size on an agarose gel. Cloning and sequencing can be a 
lengthy procedure, particularly if the PCR reaction results in a number of amplification 
products. 
2. If the normal chromosome 2 is present as well as the derivative chromosome 13, 
PCR primer sequences complementary to P AX3 intron sequence will hybridise both to 
the normal and derivative chromosomes. Amplification products from normal 
chromosome 2 were cloned and sequenced in several cell lines in this study. 
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3. During the process of ligating adaptors to the digested genomic DNA, it is possible 
to generate chimeric clones by ligation of multiple DNA fragments. Therefore, when 
analysing the sequence of cloned amplification products, it is important to ensure that 
no restriction sites at which genomic DNA had been originally digested are present. 
For example, if a vectorette library is constructed with Sau3A restriction enzyme and 
subsequently clones are isolated and sequenced from the library which contain the 
Sau3A restriction site, they are likely to be chimeric. 
By using a vectorette PCR approach, the derivative chromosome 13 translocation 
breakpoints from three cell lines were cloned. The derivative chromosome 2 
breakpoint and breakpoint spanning sequences on normal chromosome 13 were also 
cloned in one of the three cell lines. The complete description of the effects of the 
chromosome translocation in the cell line indicates that it is a complex process at the 
molecular level. A duplication of 101 bp of sequence has occurred, since it is present in 
both derivative chromosomes. An insertion of material of undetermined size and 
unknown origin has occurred in derivative chromosome 2. 
The derivative chromosome 13 breakpoint sequences have also been described in two 
other cell lines. In all three cell lines, binding sites for the protein translin were found 
flanking the breakpoints. Translin binding sites have also been found flanking 
translocation breakpoints in a range of lymphomas (Aoki et al, 1995). Chapter 6 
describes further studies which suggest that RMS cell lines contain translin protein, and 
that translin will bind to the newly described breakpoint flanking sequences. The 
protein binding studies are discussed in section 7.4 below. 
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7.4 INTERACTION OF PROTEINS WITH TRANSLOCATION BREAKPOINT 
SEQUENCES 
Translin protein was purified to homogeneity using the gel mobility shift assay as a 
basis for fractionation and the gene coding for Translin was cloned and sequenced (Aoki 
et aI, 1995). It codes for a 228 amino acid protein. A 'leucine zipper' motif, five 
potential protein kinase C phosphorylation sites, three tyrosine kinase phosphorylation 
sites and one N-glycosylation site are present in the Translin amino acid sequence (Aoki 
et al, 1995). 
Using gel mobility shift assays they were also able to demonstrate that: 
I. Translin will bind to both double-stranded and single-stranded DNA 
oligonucleotides, but with higher affinity to single-stranded oligonucleotides. 
2. Translin will bind specifically to oligonucleotides based on sequences found adjacent 
to chromosome breakpoints in a range of lymphoid neoplasm's. 
3. A consensus translin binding sequence can be deduced from these sequences. 
Translin will have little or no binding activity to oligonucleotides with sequences 
unrelated to this consensus. 
4. An antibody (raised by Aoki, et al) against Translin protein will interfere with 
oligonucleotide-protein complex formation. 
5. Translin protein is found in both the cytoplasm and nucleus of lymphoid cell lines 
such as RPMI8226, but only the cytoplasm of non-lymphoid cell lines such as HeLa, 
A431 and K562. 
99 
The experimental data described in chapter 6 demonstrates that translin is present in 
rhabdomyosarcoma cell lines, and is capable of binding to the sequences which have 
been found flanking the t(2;13) translocation breakpoints. The electrophoretic 
mobility shift assay (EMSA) method used as a basis for the experiments has proven 
simple and versatile, generating several lines of evidence suggesting that it is translin 
protein rather than another protein which is binding to the flanking sequences: 
1. A protein, from cell lines known to contain translin, binds to t(2;13) breakpoint 
flanking sequences and the consensus translin binding site. 
2. A protein from RMS cell lines binds to the same sequences and with the same 
mobility on non-denaturing polyacrylamide gels. 
3. Mutation of conserved bases in the translin binding site abrogates protein binding 
4. The crucial evidence involved including an antibody in the EMSA reactions that had 
been raised against translin protein. ProteinlDNA binding was almost completely 
blocked in the presence of 0.5J.1.g of antibody despite the presence of a large quantity of 
whole cell extract in the reactions (7J.1.g) which could have interfered with 
protein/antibody binding. 
Since translin is present in RMS cells, and DNA sequences which bind translin are 
adjacent to chromosome breakpoints, it is likely that translin has a central role in the 
generation of the chimeric chromosomes. This suggestion raises several questions 
about translin: 
1. What phenomenon initiates the activation of translin? 
2. What is the normal function of trans lin? 
3. How is the normal function of trans lin controlled? 
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Aoki et aI, have recently isolated and cloned a further protein, TRAX, which interacts 
with and has extensive homology to, translin. TRAX has a potential leucine zipper 
DNA-binding motif like translin, but also contains nuclear targeting sequences which 
suggests a possible role in the active transport of translin into the nucleus. 
It is unlikely that evolution has provided cells with a mechanism for producing 
mutations that ultimately will prove disadvantageous. It is much more likely that 
translin has a normal role in repair of DNA breakage, hence the chromosome 
translocations seen in RMS cells most probably represent inappropriate repair of DNA 
breaks. 
Little is yet known about how translin mediates its normal function or about how it 
binds to its target sequences. One possibility would be that a DNA break is recognised 
and causes a signal to be passed to the cytoplasm which allows the transport of translin 
into the nucleus and to the DNA break site. A single molecule binds to the recognition 
sequence, and a translin multimer then develops with further binding along the DNA 
sequence with lower sequence specificity. Translin might function as 'scaffolding' 
around broken DNA ends, so bringing the ends into synapsis and facilitating the 
activity of other DNA repair enzymes. How might translin be integrated into the 
overall scheme of DNA break repair? 
7.S DOUBLE STRAND BREAK (DSB) REP AIR AND A MODEL FOR THE 
GENERATION OF CHROMOSOME TRANSLOCATIONS 
There are three categories of DNA damage repair: 
1. Excision repair of damaged bases and nucleotides which uses the information on the 
undamaged strand to repair the damaged one. 
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2. Mismatch repair which occurs after DNA replication in S phase, which relies on the 
parental strand to correct a misincorporation in the newly synthesised strand. 
3. Double-strand break (dsb) repair, which occurs in two ways. Firstly, homologous 
recombination, in which the double-strand break (dsb) in one chromosome is repaired 
using the sequence information on the sister chromosome, and secondly, DNA end 
joining. In the yeast Saccharomyces cerevisiae homologous recombination is the 
prevalent mode of dsb repair whereas DNA end joining is prevalent in multicellular 
eukaryotes (Friedberg et al, 1995). A specialised form of DNA rejoining occurs in B-
and T -lymphocytes called V(D)J recombination which is a process that normally brings 
together the 'variable', 'diversity' and 'joining' regions of immunoglobulin genes. 
The relationship between V(D)J recombination and the generation of chromosome 
translocations is well established (see chapter 1.9). 
The importance of DNA end joining in the rearrangement of immunoglobulin genes is 
illustrated by mice that are spontaneous severe combined immunodeficiency (scid) 
mutants. These mice lack the ability to rejoin DNA in V(D)J recombination, but also 
are sensitive to ionizing radiation, indicating a general failure of DNA end joining 
(Fulop et al, 1990; Hendrikson et al, 1991). 
7.5.1 Proteins involved in dsb repair 
The first protein thought to be involved in dsb repair is termed Ku and was initially 
identified as an autoantigen from the sera of patients with scleroderma-polymyositis 
overlap syndrome (Mimori et ai, 1981). Further studies have shown that Ku interacts 
with free ends of double-stranded DNA without any sequence specificity, and serves as 
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the DNA binding component of a protein named DNA-dependant protein kinase (DNA-
PK) which phosphorylates a number of DNA binding proteins in the nucleus (Dvir et al, 
1992; Gottlieb and Jackson, 1993). Further details of mechanisms for the repair of dsbs 
have been provided by the isolation of dsb repair defective mutants from bacteria, yeast 
and mammalian cells. Dsb repair mutants were selected on the basis of their extreme 
sensitivity to ionising radiation, such as X-rays, which are known to cause DNA dsbs 
(Jeggo, 1990). Eleven complementation groups of ionizing-radiation-sensitive 
mammalian cell mutants have been described, exhibiting a range of sensitivities to X-
rays and other DNA-damaging agents (Collins, 1993). Members of four of these 
complementation groups (IR4-7) are specifically and exquisitely sensitive to dsbs 
suggesting that their mutant gene products interact in a single pathway of dsb repair. 
Mapping of the gene for DNA-PK has shown that it corresponds to the position for the 
murine scid defect and for the human gene that complements it (Sipley et aI, 1995; 
Miller et al, 1995; Blunt et al, 1995). Both DNA-PK and Ku have now been implicated 
in V(D)J recombination and dsb repair, DNA-PK and the two subunits of Ku, Ku80 
and Ku70, also correspond to three of the ionizing-radiation-sensitive mammalian cell 
mutants indicated above (Lieber et al, 1997). Little is known about what brings the 
DNA ends into synapsis in preparation for rejoining following the ionizing radiation 
induced cleavage of DNA to create a double-strand gap. 
An interesting parallel could be drawn from the similarities between V(D)J 
recombination and dsb repair, and the involvement of DNA binding sites for translin 
protein in two types of chromosome translocation (Those which appear to involve the 
V(D)J recombination mechanism and those which do not). Assuming that chromosome 
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translocations and inversions are most likely to occur because of incorrect repair of 
double-strand breaks, translin may playa role in the mechanisms that involve DNA-PK 
and Ku. Because it binds to DNA with sequence specificity and is able to multimerise, 
trans lin may perform a structural stabilization role near DNA ends around which the 
repair process can take place. By including an element of sequence specificity into the 
repair process it would be necessary to have a very large number of translin binding 
sites spread throughout the genome to prevent significant loss of genetic material. The 
translin binding sites described in this thesis found flanking the t(2; 13) translocation and 
those flanking other translocations are only 40-70% homologous to the consensus 
sequence, suggesting that binding sites could be common. The hypothesis that translin 
plays an important role in dsb repair and the genesis of chromosome translocations 
could be tested by inactivating the translin gene in a transgenic mouse model using 
embryonic stem cell technology. 
7.5.2 A modelfor the/ormation of chromosome translocations 
It has been estimated that 15% of DNA double strand breaks are converted into 
chromosome breaks (Cornforth and Bedford, 1983). It is likely that a small subset of 
these chromosome breaks occur in the same cell, at the same time, and in close 
proximity to each other. A model for the generation of chromosome trans locations or 
inversions maybe as follows: 
Two double-strand breaks occur on different chromosomes at the same time and in close 
proximity to each other. The breaks may be complex including, for example, stretches 
of single-stranded DNA and base damage which cause the breaks to persist for longer 
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than usual. The four ends may diffuse apart and when they have been prepared for 
rejoining by the repair mechanisms outlined above the wrong ends are brought together. 
Consequently, chromosome trans locations or inversions occur which mayor may not 
affect gene loci on the misrepaired chromosomes. There is unlikely to be an adverse 
effect as a result of such an event in the majority of cases. However, if a chromosome 
translocation affects an important gene locus in a particular cell type, it may result in 
the development of neoplasia. 
7.6 THE t(2;13) CHROMOSOME TRANSLOCATION AND POSITION 
EFFECT MUTATIONS 
7.6.1 The role of the PAX3IFKHR gene product 
The creation of the chimeric P AX3IFKHR gene product is important in the aetiology of 
rhabdomyosarcoma. Experiments demonstrate that the fusion protein is capable of 
binding to and transcriptionally activating model P AX3 binding sites and transient 
cotransfection assays using e5-CAT reporter plasmids indicate that the PAX3-FKHR 
fusion protein is a more potent transcription activator than PAX3 (see chapter 1.8; 
Fredericks et aI,1995; Sublett et ai, 1995). The principal difference between PAX3 and 
PAX3-FKHR is the substitution of the carboxyl terminal domain of PAX3 for the 
putative transcriptional activation domain of FKHR. Experiments have been performed 
to demonstrate that it is this substitution that alters the transcriptional activation 
potential of the fusion protein (Bennicelli et ai, 1995; Sublett et ai, 1995). In similar 
experiments, evidence suggests that there are elements in the N-terminal region of 
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PAX3 which can inhibit transactivation of PAX3 but not PAX3-FKHR (Bennicelli et 
al,1996). 
7.6.2 Expression of the PAX3IFKHR gene 
Another possible consequence of the t(2;13) chromosome translocation in alveolar 
rhabdomyosarcoma is the deregulation of expression from the P AX3 promoter because 
of position effect mutations. These mutations alter gene expression through long-range 
effects on chromatin structure. Position effect mutations were first described in 
Drosophila as a consequence of chromosome rearrangements in which a gene, normally 
found in euchromatin, is placed in close proximity to heterochromatin. The expression 
of genes up to as much as a megabase from the heterochromatin can be affected by such 
a rearrangement (Henikoff, 1990). A number of germline and somatic position effect 
mutations have since been described in mouse and man (Bedell et al, 1996). For 
example, two cases of aniridia, which is caused by mutation of the P AX6 gene, have 
been described in which the gene has been silenced by a position effect. In one case, a 
chromosome inversion breakpoint is located 85 to 95kb 3' of the PAX6 gene, and in the 
other case a chromosome translocation is located upto 185kb 3' of the gene (Fantes et 
al, 1995). Other examples involve somatic position effect mutations which result in the 
activation or deregulation of cellular proto-oncogenes and are associated with tumour 
induction. A t(2;8) variant chromosome translocation in Burkitt's lymphoma results in 
the juxtaposition of immunoglobulin enhancer elements 140 to 300kb from the mycl 
gene causing deregulated expression (Graham and Adams, 1986). Structural alterations 
of chromosome 3 up to 300kb 3' or 5' of the EVI I proto-oncogene cause its aberrant 
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activation in 2% of patients with acute myelogenous leukaemia (Suzukawa et al, 1994; 
Levy et aI, 1994). 
Although the PAX3 and FKHR genes are structurally affected by the t(2;13) 
chromosome translocation in alveolar rhabdomyosarcoma, position effects maybe 
responsible for the activation of expression of the chimeric gene product. The 
translocation breakpoints are 80 to 90kb from the 5' end of the P AX3 gene. The 
FKHR gene on chromosome 13 is normally expressed in adult tissues whereas the 
P AX3 gene on chromosome 2 is normally only expressed during development. 
Chromosome 13 structural elements which allow expression of FKHR may be 
overriding the silencing of expression of P AX3 in adult tissue through position effects. 
7.7 FURTHER STUDIES 
To substantiate the suggestion that translin sites are found flanking translocation 
breakpoints it would be interesting to analyse further examples of alveolar RMS and 
other non-lymphoid tumour specific translocation breakpoints to see if the junction 
fragments in these tumours also display translin sequence homology. Further examples 
would indicate whether translin is involved in the generation of translocations in 
general. 
Since translin protein is located in the cytoplasm of non-lymphoid cell types, it may be 
that its transport into the nucleus is caused by some physiological process. Because 
translin appears to bind to sequences adjacent to chromosome translocation breakpoints 
it may also be reasonable to assume that transport of translin into the nucleus is induced 
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when nuclear DNA has been damaged, and that translin is involved in the repair of such 
damage. It may be possible to exploit the cytoplasmic location of translin in 
experiments in which cells are exposed to DNA damaging agents. Measurement of the 
levels of translin protein in the cytoplasm and the nucleus could demonstrate transport 
of translin into the nucleus following such exposure. A DNA double strand break is 
the most likely cause of chromosome translocation so that studies using DNA damaging 
agents such as X-rays which cause this kind of damage should be infonnative. 
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Jeremy G Chalk l , Frederic G Barr2 and Christopher D MitchelP 
iUnil'ersity o/Ox/ord. Department 0/ Paediatrics. John Radcliffe Hospital. Oxford OX3 9DU, UK; lDil'isions 0/ Pathology and 
Laboratory Medicine, University of Pennsylvallia, Phi/adelphia, PA 19104·6082. USA 
Alveolar rhabdomyosarcoma is characterized by a 
t(2;13)(q35;q14) chromosome translocation, which leads 
to the fusion of the PAX3 and the FKHR genes. The 
resulting fusion gene encodes a chimeric protein which 
has abetrant transcriptional acthity. We report the 
molecular definition 'Of the genomic breakpoints on both 
. . . 
u...;,i.\ ..... Li,L ........... ' .. 
chromosome 13 breakpoints in two other cases. The 
DNA sequences adjacent to the breakpoints on the 
derivative chromosome 13 are remarkable for their 
resemblance to recognition sequences for the protein 
translin. Gel shift analyses confirm that these sequences 
bind translin. These findings suggest that transtin may 
not only be important in the genesis of chromosomal 
translocations in lymphoid malignancy, but also in 
translocations found in solid tumours. 
Keywords: 
Introduction 
Numerous cytogenetic studies have demonstrated that 
most human neoplasms carry cnromosomal aberra-
tions. Leukemias, lymphomas and solid tumours have 
been shown to carry specific chromosomal abnormal-
ities. A variety of studies have shown that these 
chromosome. translocations result in the altered 
expression and/or structure of cellular gene products, 
leading to functional activation which contributes to 
the initiation or progression of the neoplastic state 
(Rabbitts, 1994). 
Rhabdomyosarcoma, a malignant tumour ansmg 
from skeletal muscle precursors, is the commonest 
form of soft-tissue sarcoma in childhood. The majority 
of alveolar rhabdomyosarcomas are characterized by a 
specific chromosome translocation - t(2;13)(q35;qI4) 
(Douglass et al., 1987). This translocation has been 
shown to cause the fusion of 5' DNA-binding domains 
of the P AX3 gene to 3' regions of the FKHR gene, 
resulting in the expression of a chimeric protein 
product (Barr et al., 1993; Galili et al., 1993). The 
genomic breakpoints appear to occur consistently in 
the 17.5 kb iIl,tron 7 of the PAX3 gene on chromosome 
2 and a large 130 kb intron I of the FKHR gene on 
chromosome 13 (Davis et al., 1995). 
Two consequences of the t(2;13) translocation have 
been described. Fi~stly, although the DNA binding of 
Correspondence: CD Mitchell 
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PAX3/FKHR protein is impaired relative to that of. 
PAX3 protein, the fusion protein is a much more 
potent transcriptional activator and will transfo~ 
under conditions in which wild-type PAX3 is not 
(Fredericks et al., 1995; Scheidler et al., (996). 
Secondly, both PAX3 and the PAX3/FKHR fusion 
blasts, with the latter demonstratIng cnJ:iancea mhlbl-
tory ability. This ability is dependent on both the 
paired box and the homeodomain being intact (Epstein 
eJ ai., 1995). 
Chromosome translocations in malignant tumours 
may arise by a variety of mechanisms. The transloca-
tions seen in some lymphomas and leukemias involve 
the immunoglobulin or T cell receptor genes (Rabbitts, 
1994). The presence of the Ig/TCR recombinase signal 
sequence on both affected chromosomes indicates that 
errors in normal gene rearrangement are responsible 
for translocations in these' cases. The breakpoint 
junctions of chromosome translocations in some other 
lymphoid malignancies are characterized by another 
consensus sequence. A protein, purified from the 
Lymphoid cell line DND-4I, binds to oligonucleotides 
based on sequences from a number of different 
breakpoint junctions of this kind (Aoki et al., 1995). 
The gene, named Translin, which codes for this protein 
has been identified and cloned. and is characterized by 
a leucine. zipper DNA-binding motif. eight potential 
phosphorylation sites and one N-glycosylation site. 
Translin protein is located in the nucleus and 
cytoplasm in lymphoid cell lines, but in the cytoplasm 
only· of non-lymphoid and non-haematopoetic cell lines 
(Aoki et al., 1995). 
Similar motifs have not yet been reported at 
translocation breakpoints in solid tumours, and the 
mechanisms by which translocations in these tumours 
occur remain obscure. We wished to know if there were 
sequence motifs flanking the breakpoints in the t(2; 13) 
translocation which might predispose to rearrange-
ments occurring in these particular regions. 
Results 
Cloning of the derivative chromosome 13 translocation 
breakpoint in Rh28 
Vectorette PCR (Riley et al .• 1990) was used to clone 
novel unknown chromosome 13 sequences that have 
been juxtaposed to known, chromosome 2, PAX3 
intronic sequences as a result of the t(2;13) chromo-
some translocation in rhabdomyosarcoma cell lines 
Rh28, Rh5 and TTC487. Genomic DNA was digested 
with an appropriate restriction enzyme. and the 
1200 
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resulting fragments then ligated to compatible vector-
ette 'adapters' to produce a vectorette 'library'. DNA 
fragments spanning the translocation breakpoint were 
then identified by using an appropriately sited PAX3 
intron primer together with a vectorette adapter primer 
in peR. To confirm that any novel sequence cloned in 
this way is derived from chromosome 13, primers 
based on this sequence could be used to amplify a PCR 
product from a somatic cell hybrid which contains 
human chromosome 13 as its only human component 
(PGMEI or 289) (Cowell and Mitchell, 1989; Zhong et 
al., 1992). 
The genomic translocation breakpoint of the Rh28 
cell line has been mapped previously to a 0.6 kb region 
between a Sacl and a ApaI site in the 17.5 kb intron 7 
of the PAX3 gene (see Figure 1 b). The presence of 
these two restriction sites was confirmed in the 
-~-»-, •• ~~ "I" 11-,,, i",trr)n in thf> Gf'nh,mk rlatabase 
taccession no. U1LLJ::i) ~fYi<ll,;llld ti w., 1':1;)::;). lU 
verify that intron sequences 5' of the SacI site were 
still present in the derivative 13 chromosome, genomic 
DNA from Rh28 and the associated derivative 
chromosome 13 bearing RHF14 somatic cell hybrid 
(see Materials and methods) were' used as template to 
amplify a 484 base-pair fragment from positions 12794 
to 13278 in the intron. This product includes a PstI site 
at position 12845 (see Figure Ic). The expected 
products were amplified and subsequent digestion of 
these products with Pst! restriction enzyme resulted in 
two fragments of the predicted size, 51 and 433 base-
pairs. 
Four vectorette libraries were constructed in total 
from genomic DNA from Rh28 or RHF14 cell lines, 
on~ pai.r using HaeIII restriction enzyme and another 
palr USlI~g Sau3A restriction enzyme. Nested primers-
were d.eslgned based on sequences immediately 5' of the 
Sac! SIte a~d were used in .conjunction with vectorette 
adapter pnmers. Primers 12800F and UVP were used 
S 13302 13402 EXC:»tI 
--. _l • -- ,-' --Y,,! =...-.... :; __ -,#-Q-a- _________ ,. ...... 
., 
EXCJ)I7 '" _ _ E)«)NS 
2 ~~{-------~I--~I __ ~--~[I--~~ 
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Figure 1 Schematic representat,ion of. the ~wo nonnal and two 
derivative chromosome breakpomt regIons In the Rh28 ceO line. 
(a) Derivative chromosome 2. The vectorette peR product 
extends from primer 13500R to a Sau3A restriction site (S). 
The derivative 2 breakpoint is at position 13302, 101 bp from the 
derivative 13 breakpoint at position 13402. (b) Normal 
chromosome 2. The breakpoint region in Rh28 has been mapped 
to a 0.6 kb region between a Sael and a ApaI site within the 
17.5 kb PAX3 iotron 7. (c) Derivative chromosome 13. peR was 
used to verify the presence of sequences immedia~ely 5' of t~e S~eI 
site includinl? a PstI site at position 12845, m the denvauve 
chr~mosome -13. Vectorette PCR products span tbe breakpoint 
from primer 13300F to either the HaeII~ (H) or lbe ~au3A (5) 
site. The breakpoint is at position 13402 In the PAX3 IOtron. (d) 
Normal chromosome 13. The vectoretle PCR product from 
primer 30R to a Haelll site (H) spans the breakpoint region on 
normal chromosome 13 
in a first round of amplification, and nested prim( 
13300F' and USP were used in a second round 
amplification. A 200 bp product was amplified frc 
the Rh28/HaeIII and the RHFI4/HaeIII vectore 
libraries. A 400 bp product was amplified from I 
RhZ8{Sau3A and the RHF14/Sau3A vectorette 
braries (see Figure le). All four products were cion 
and sequenced. All four sequencing experime 
indicate that the genomic breakpoint occurred 
positon 13402/3 of the PAX3 intron. Novel sequen 
presumed to represent FKHR intron on chromoso 
13, was present 3' of the breakpoint in both Sau3A ~ 
HaeIII library clones. Two hundred and sixty n 
base-pairs of novel sequence were identified in 
Sau3A clones, of which the first 66 base-pairs exal 
matched those present in the HaeIII clones (see Fig 
2a). 
Cloning of chromosome 1.) seljuence.:i \vIliL/i ;,jJUfI IItt 
translocation breakpoint in Rh28 
The novel sequences found 3' of the derivative 
translocation breakpoint were used to design a secr 
pair of nested primers. Primers 50R and UVP v. 
used in a first round of amplification using the s~ 
vectorette libraries as above. Nested primers 30R 
USP were used in second round ampliciation. A IS( 
and a 800 bp product was amplified from the RI 
HaeIII vectorette library and a similar 800 bp prol 
was amplified from the RHF14/HaeIII VectOl 
library (see Figure Id). The 800 bp products wer' 
the size predicted if amplific~tion. was from 
derivative 13 chromosome template. Uie ISf 
product, present in Rh28 only, ought to repre 
normal chromosome 13 sequence. No product coul 
identified from the Rh28/Sau3A or the RHF14/Sa 
vectorette libra~es. The 150 bp amplification pro 
was then cloned and sequenced. The. sequ 
immediately adjacent to the 30R primer. matches 
of the clones from the derivative chromosome 13 t 
the breakpoint. The clone also contained 111 b 
unique sequence 5' of the breakpoint. Together 
the sequences 3' of the breakpoint on the deriv 
chromosome 13, a total of 380 bp of novel seq\ 
have been cloned. To confinn that this novel seq\ 
represents a contiguous region of chromosome 
primer pair spannning the breakpoint in this U1 
sequence were designed. The expected 313 bp pn 
could be amplified from Rh28, Placenta, PGME: 
289 genomic DNA. Sequence of the pro 
confirmed the fidelity of the amplification rea' 
Figure 2b includes the entire sequence obtained 
chromosome 13. 
Cloning of the derivative chromosome 2 transloeal 
breakpoint in Rh28 
To determine whether there have been any inse 
and/or deletions associated with the chron 
translocation we used a similar approach as abc 
clone the reciprocal translocation breakpoir 
derivative chromosome 2. Nested primers, 1: 
and 1 3500R, were designed, based' on sequco 
the PAX3 intron immediately 3' of position 13 
now established as the translocation brea 
position on _ the derivative chromosom~ 13. 
a 
TACATATAGC7CAlr~NA&AGTGTGC~TGTTTTGAAT~TTCTGCTCTCACCTCATCA 
-_. -- ----... -- - -- ----... --......... --... _ ... - .. _ .. -..... -- - .. -...... - ... - .. --.... --.. .,. 
ATGT~T~TCC~GTACCCTTTCACACGTACAAAACTT~TT!TAAGACGAGACTCC~AGI 
AGTATAACTGTACATACAGCATTCCATTTCTCCCTTilAAGTGACHACCATTGACTGAAT 
-_ ....... - - -+ ..... -. -- --+- -.- -_ ...... -- -..... -- .. -.-_ .... -_ .. -- +_ .. - ... -. --. 
TCATATTGACATGTATGTCGTAACGTAAACAGGGAATTTCACTGTATCGTAACTGACTTA 
u 
TTCAAG'l'MGTil.TCTTCAWMr.GbCMIATTACA1";T1MGhCCIGCICTAGGGGTTGT 
---------.---- .... -.-.------- ... ,.--._-----<10---------.--------_ .. 
AAGTTCATTCATAGAAGTACTTCCTGTTATAATGTAAAATTCTGGACGAGATCCCCAACA 
AAAATAGTACTGCTGTTATTGGGAGGCGTTGGGTA~CAGCAGCAGGGAGAGAGA 
.. _ .. __ - - __ ..... - _ .... _ .. _+ ____ .. ____ ._ ...... _. __ ... ___ - _ .... - -T- - - - 0. _ - - + 
TTTTATCATGACGACAATAACCCTC~CCCATCCCCGGrGTCGTCGTCCCTCTCTCT 
GGCTCCCATCGTACAAACTTGCAGACTTTTATTAAAACGTATTTATTGATTGCAAATTAT 
- ... - _ .. - - -+ - - - - - - __ - + _____ - - - _+_ .. - - _.0 _ .• __ .... _____ +_ ... _ .. _____ .. 
CCGAGGGTAGCATGTTTGAACGTCTGAAAATAATTTTGCATAAATAACTAACGTTTAATA 
GTCAACAGAGTGAGGCTTTGGTAACTCTTCAAGTTACTAGTGTTTCCTTCTTTGCATAGT 
- -- ---- --.- - - - - .. -- .... --- -- --- .. - --- -- --- ... ------ .. - -+- - - .--.-- .... 
TGTT7CCCATCACCCTTTAAACATCTGCTGCTTCTGG7C7TGTCCAGTCATGCTTGAGTQ 
- _ ... - .. _ .. --. - - _ .. -- --- +- -- --- - - - +- - ..... _ ............... _ .. -_ .. +_ .. - - - - .. --. 
ACAAAGGGTAGTGGGAAATTTGTAGACGACGAAGACCAGAACAGGTCAGTACGAACTCAC 
TAG 
.. - .... - ----+- '"'- ....... _ .. - .. --- -_ ........ -... - _ .. ---_ .. + ...... _ .... _. -.- ... - --- .--+ 
TGCCAGATAGTCACTC'l'TGGAGCAGAAATGATGGTTTTAAAATCTCTCTTACATTTTAAG 
.... - - .. - - ... -+_ .... - -- - ... -+-- _ .. _.- -.. +_ ....... - .. - .. "'+_ .. - _ ...... - ... +- .... -...... _ .. + 
ACCTGCTCTAGGGGTTGTAAAATAGTACTGCTGTTATTGGGAGGCGTTGGGTAGGGGCCA 
.. _ .. - --- .... +_ ........ _ .... -+ .. _ ....... - - .... + .. - - _ ... - - - ... +- - .... - ..... - -+- - .. - - .... --+ 
CAGCAGCAGGGAGAGAGAGGCTCCCATCGTACAAACTTGCAGACTTTTATTAAAACGTAT 
. _ ....... --- -+-- ........ ---+----- .. -- -... ----- _ .. -- ... ---_ .... ---+- - - ... - -- - .. + 
GTCG'l'CGTCCCTCTCTCTCCGAGGGTAGCATGTTTGAACGTCTGAAAATAATTTTGCATA 
TTATTGATTGCAAATTATGTCAACAGAGTGAGGC'M'TGGTAACTCTTCAAGTTACTAGTG 
............ - - -+- - - - _ .. ---+-- -- _ .. -. -+- - - _ .. - -_ ...... -- ...... - .. '"'+_ .. - '"' --- --+ 
AATAACTAACGTrTAATACAGTTGTCTCACTCCGAAACCATTGAGMGTTCAATGATCAC 
TTTCCTTCTTTGCATAGTTGTTTCCCATCACCCTTTAAACATCTGCTGCTTCTGGTCTTG 
-- ... ---~- .. -- .. ------+----- .. --- .. ------ ... --+-- .. ------+ .. --------+ 
AAAGGAAGAAACGTATCAACAAAGGG!AGTOGGAAATTTGTACACGACGAAGACCAGAAC 
TCCAGTCATGCTTGA~ 
.. _ .. - .. -- - -+- _ .. - _ .. -- -+-
AGGTCAGTACGAACTCACTAG 
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C 
·~CTCAQAGAGTTGTGGCGATAGTTACTAGAACATAGCAAAACTAATTGGGCAAAAGG 
_ .... - -- -- -,--" - -- - - --.- .. - - - -- - -~ -_ .. - -- .. _ .... - --- .... -- -11-- - .... - _ .... - .. 
CTAGGAGTCTCTCAACACCGCTATCAATGATCTTGTATCGTTTTGATTAACCCGTTTTCC 
u 
GTTCTGCTCGCTGTGCTCTGTGGCTCATCAAGTATAACTGTACATACAGCATTCCATTTC 
CAAGACGAGCGACACGAGACACCGAGTAGTTCATATTCACATGTATGTCGTAAGGTAAAG 
TCCCTTAAAGTGACATACCATTGACTGAATTTCAAGTAAGTATCTTCATGAAGGACAATA 
AGGGAATTTCACTGTATGGTAACTGACTTAAAGTTCATTCATAGAAGTACTTCCTGTTAT 
TTAATTTAGAGTTTATTTTCCTTTTATTTAGTGCCACTGGATATCTTTCCTCTCTGGACT 
AATTAAATCTCAAATAAAAGGAAAATAAATCACGGTGACCTATAGAAA'4AGAQ'CCTGA 
GATATAG 
d 
GTTATfjC ... c;rC/lTTTCTGCGCTAATTCTCTGTCTAGATTTATATTTTAGTCATCTTA'iW 
-----~---+'"'--------+--.------+-------- .. +-----'"'---+---------+ 
CAATACGTTGAGTAAAGACGCGATTAAGAGACAGATCTAAATATAAAATCAGTAGAATCC 
GIAGICTCCTTQATTACIILllirillLlllCTTGAGAATGGGTCAGGTTTTTCCATTTC 
-.. -- .. ----+~- .. -.- .. --+ ... --------+-------- .. +---------+---------+ 
CATCAGAGGAACTAATQA).AJ\"),hhl.,,l.,,"l.GAAcrcTTACCCAGTCc.AAAAAGC7AAAG 
TTCTTATAGGGAGGTAATTTTGGATTATATT=t<TATTACAAATGATAAATGATAATT 
AAGAATATCCCTCCATTAAAACCTAATATAAGACCTATAATGTTTACTATTTACTATTAA 
TATATATATAAATTTTCG'l"l'ATGCCCGTCTTAAAAGCATTGATTTTCTTTTCTAAAGCAG 
ATATATATATTTAAAAGCAATACGOGCAGAATTTTCGTAACTA'I.AGA"'AGATrTCGTC 
---------+---------+ .. _-------+---------+---------+--------- .. 
CGTTAACTAATTGAATGGAC'ITAAGTTCGACGTTTTGATAGGGGGGTATCATCCACCGTC 
e 
CTGGGTCTCTCTCCACAGGi\CTl'G'Q'I!jc;rrcC"'CTCTGATTCTTTTGTCAAAGCT':1'AG 
GACCCAGAGAGAGGTGTCCTGAACAAACGAAGGAt!AGACTAACAAAACAGTTTCG:v..ATC 
TGTTTTCTTATfjllpGIGClTl'IGATTGAAACCTCATCAATTTAAAACCTTAn:AG 
ACAAAAGAATACTCCACGAAAACTAACTTTGGAGTAGTTAAATTTTGGAATAGTC 
figure 2 Sequences of vectorelte PCR clones which spa~ the t(2; (3) chromosome t~anslocation breakpoints in the cell line~ Rh28. RhS and 
lTC487. (a) Rh28 derivative chromosome 13 breakpomt sequence from PAX3 mtron pnmer 13300F to Sau3A restnc!lon site (both 
underlined). The breakpoint occurs at position 13402 of the PAX3 intron (0). 269 bp of novel chromosome 13 sequence follows the 
breakpoint. Putative TransJin recognition sequences occur immediately 5' and 3' of the breakpoint (double underlined). (b) Nonnal 
chromosome 13 sequence which spans the Rh28 derivative chromosome 13 breakpoint. Chromosome 13 based primer 30R and Haelll 
restriction site are underlined. III bp of novel sequence 5' of the derivative 13 breakpoint have been cloned. This together with the novel 
sequence cloned above represents a contiguous 380 bp of chromosome 13. (c) Rh28 derivative chromosome 2 breakpoint sequence from 
PAX3 intron primer I3S00R to Sau3A restriction site (both underlined). This breakpoint occurs at position 13301 of the PAX3 intron (v) 
indicating that 101 bp of PAX3 intron sequence has been duplicated. Somatic cell hybrid PCR suggests the remaining 82 bp of sequence 
(bold) is not derived rrom either chromosome 2 or chromosome 13. (d) RhS derivative chromosome 13 sequence. The breakpoint occurs at 
position 11099 or the PAX) intron (0). Putative Translin recognition sequences are double underlined. (e) TTC487 derivative chromoso~e 13 
sequence. The breakpoint occurs at position 4557 of the PAX) intron (0). Putative Translin recognition sequences are double underhncd 
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possible that these sequences are deleted from 
derivative chromosome 2 but there is no straightfor-
ward way of testing this hypothesis as a somatic cell 
hybrid cell line containing derivative chromosome 2 
material only is not available. 
Amplification of the Rh28jHaeIIl and Rh28jSau3A 
vectorette libraries was carried out with primers 
13600R and UVP, followed by nested 13500R and 
USP primers. A 300 bp product was amplified from 
the Rh28jSau3A vectorette library and a 900 bp 
product amplified from the Rh28jHaelIl vectorette 
library (see Figure la). The 900 bp product was of the 
size predicted for normal chromosome 2. The 300 bp 
product, presumed to be derived from the derivative 
chromosome 2, was cloned and sequenced (see Figure 
2c). The first 164 bp of sequence extending from the 
13500R primer matched the original chromosome 2 
en"'","nr" innir'lt;nCT th~t tht" translocation breakpoint 
III lne denvallve 1. ciuumosome 1::> at PO::>ll".hl u:"v 1/":' 
of the PAX3 intron. The breakpoint in the derivative 
13 chromosome is at position 13402/3. As 101 bp of 
chromosome 2 sequence is present in both derivative 
chromosomes, there appears to have been a duplica-
tion of this region. The final 82 bp sequence of this 
clone is again novel and does not match the newly-
derived chromosome 13 sequence described above. 
The 82 bp sequence could be amplified from Rh28 
and placental genomic DNA, but not from somatic 
cell hybrids containing chromosome 2 or 13 as their 
only human components (GMI0826B, 289 and 
PGME1). Since the 82 bp sequence is not derived 
from either chromosome 2 or chromosome 13 an 
insertion of material from some other chromosome 
may have occurred. 
Cloning the derivative 13 breakpoints 'in two other 
t(2;13) bearing eel/lines Rh5 lznd TTC487 
The breakpoints in the PAX3 gene for the cell lines 
Rh5 and TTC487 have been mapped and lie in 
different regions of intron 7 to that of Rh28. The 
Rh5 breakpoint region lies in a 869 bp region between 
a XbaI site at position 11078 and a EcoRI site at 
position 11947, approximately 2 kb 5' of the Rh28 
breakpoint within intron 7. The TIC487 breakpoint 
lies between a BgU site at position 4221 and a AvaIl 
site at position 4741. This 520 bp region is 7 kb 5' of 
the Rh5 breakpoint region and 9 kb 5' of the Rh28 
breakpoin~. Vectorette libraries were constructed from 
Rh5 genomic DNA using Sau3A restriction enzyme 
and from TTC487 genomic DNA using TaqI restric: 
tion enzyme. Nested primers were designed from 
sequences immediately 5' of each breakpoint region 
and used in conjunction with vectorette primers in a 
nested PCR protocol as above. A 300 bp product from 
the Rh5 reaction and a 400 bp product from the 
TTC487 reaction were cloned and sequenced. 
The sequence of the 300 bp clone from the Rh5 
library matches the published PAX3 intron 7 sequence 
up to position 11099 followed by 316 bp of novel 
sequence. PCR with primers based on this sequence on 
somatic cell hybrids, PGME and 289, confirmed that 
the 316 bp of novel sequence derives from chromsome 
13. The sequence of the 400 bp clone from the TTC487 
library matches the published PAX3 intron 7 sequence 
up to position 4557 followed by 51 bp of novel 
,:"....;y,u;."u""'v. J.J. ... " j.L L'~ I..;~ ..... \.1 L'~.~ ~<._",l".:.,_"~ .! t L '~'.' 
is not large enough to analyse by PCR to confirm 
whether it is derived from chromosome 13 or not. 
Analysis of sequences around the translocation 
breakpoints 
Figure 2a includes the entire 423 base pairs sequencec 
from the derivative chromosome 1'3 junction fragmen 
in Rh28 and Figure 2c the derivative chromosome : 
junction fragment in Rh28. Figures 2d and 2e includt 
the derivative 13 sequences from cell lines Rh5 ane 
TTC487 respectively. A search of the sequences aroune 
the translocation breakpoints did' not reveal th( 
presence of dyad symmetries, short direct repeats 
interspersed repetitive sequences, oligopurine/oligopyr 
,.- imidine sites or recombinase signal sequences. W. 
noted possible homology with the recently describe< 
consensus fecagni.tion sequence for Translin proteir 
adjacent"to the derivative chromosome 13 junction 
.. (Table 1): For example, the sequence in the PAX 
intron from position 13387 to. 13399 is ATGAAGGA 
CAATA which has a 62% homology to the transli 
consensus sequence. This sequence is just 3 nucleotidf 
from the derivative 13 breakpoint in Rh28. Thn 
nucleotides on the 3' side of the Rh28 derivative 1 
breakpoint is the sequence TI'T AAGACCTGCT whic 
again displays 62% homology to the translin consenSI 
sequence. This finding implies that Translin could ha' 
a role in the genesis of the translocatic 
Table 1 Homology between the translin consensus sequence binding site and sites found flanking 
chromosome translocation breakpoints. The consensus sequence was derived by Aoki tt al from the 
chromosome breakpoint junctions in 91 cases of human lymphoid neoplasm including the three sequences 
indicated below. These three sequences were also shown to bind translin protein in gel shift assays (Aoki et 
ai, 1995) 
Breakpoint 
position Translin :rile % homology Reference 
Consensus ATGCAGGCC (A/T) CCT Aoki el al., 1995 
bcrfabl TTGCAGTCiiA G CCG 62 Chen el al., 1989 
TCR(ITG2 GTGAAGGCT C CGC 62 Boehm tl al., 1988 
IgHfbc16 CTGCACGTG C GAT 43 Baron et al., 1993 
Rh28 13402 ATGAAGGAC A ATA 62 
TTTAAGACC T GCT 62 
Rh5 11099 ATGCAACTC A TTT 62 
AGGGTAGTC T CCT 62 
TIC487 4557 TTGTTTGCT T CCT 62 
ATGCATATA T GTA 43 
.. ' , 
t(2;13)(q35;qI4). Thus, we sought to determine if these 
DNA sequences could bind Translin protein. 
Protein binding studies 
Whole cell protein extracts were prepared from RD, an 
embryonal rhabdomyosarcoma cell line, Rh30, a 
t(2; 13) bearing alveolar rhabdomyosarcoma cell line, 
and several other cell lines which previously have been 
shown to contain Translin protein (Aoki et ai., 1995). 
Gel mobility shift assays have shown that translin 
protein will bind to oligonucleotides which are based 
01"1 sequences immediately adjacent to chromosome 
translocation breakpoints in a range of lymphoid 
tumours (Aoki et al., 1995). An oligonucleotide, based 
on the sequence found 5' of the (2;13) translocation 
breakpoint in Rh28, was used in gel mobility shift 
assays. Protein from all the cell lines tested, including 
+h,p .. t" ..... h.A ............... ,: .. ~ ... ,,~. __ ~"' __ "': ~~~·,.-..~1 ~!('I'.:,-! + ........ ('t·" -:-":,..' -, 
tide. When unlabelled oligonucleotide was included as 
specific competitor at 40-160-fold molar excess over 
labelled probe, it was evident that formation of stable 
labelled complex with protein was considerably 
reduced (Figure 3a). When a non-specific unlabelled 
oligonucleotide was included as a competitor, no 
reduction in complex formation was observed. 
Specificity of complex formation was further character-
ized by preincubation with either preimtnune IgM or 
anti-translin antibody (a gift of Dr M Kasai). The 
epitope of the translin antibody is at or near the DNA-
binding element of trans lin protein and thus prevents 
its binding to labelled oligonucleotide in this assay. A 
sm~ll red~cti~n is apparent when 0.1 J.Lg of translin 
antIbo?y 1~ Included in the reaction and a large 
~eductlOn IS aPl?arent when 0.5 J.Lg of antibody is 
Included .. There. IS no. r~duction in binding when the 
n~n-speclfic ~ntlbody IS mcluded. Binding of protein to 
o!lgonucleottde was blocked with the anti-translin 
antibody but w~s unaffected by preimmune antibody. 
further supporting the notion that translin binds 
sequences found next to the t(2; 13) breakpoint in 
Rh28 (Figure 3b). 
Discussion 
We report the molecular cloning of the t(2;13) 
translocation breakpoints that lie in the PAX3 and 
FKHR genes, occurring on chromosomes 2. and 13 
respectively, in the cell lines Rh28, Rh5 and TTC487. 
Breakpoints within both genes are intronic. At the 
molecular level. the rearrangement in Rh28 is complex. 
and involves both a duplication of 101 bp of PAX3 
intron sequence adjacent to the breakpoint and a 
possible insertion of undetermined size. The functional 
consequences of this translocation mandate that the 
breakpoint in PAX3 lies in intron 7 and in FKHR in ' 
intron I, as the resulting chimeric gene .on the 
derivative chromosome 13 requires PAX3 exons 1-7 
and FKHR exons 2 and 3 for activity. Is there any 
evidence that DNA sequence flanking the breakpoints 
predisposes to translocations involving these two 
genes? The presence ·of putative binding sites for the 
protein trans lin was noted. Translin has been 
previously identified by its ability to bind to conserved 
sequences adjacent to chromosome translocation 
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Figure 3 Bindin~ of protein in a gel mobility shift assay to a 
single stranded, l P-labelled oligonucleotide which is based on the 
sequence 5' of the Rh28 derivative 13 chromosome. (8) In the first 
of each set of four lanes labelled oligonucleotide' has been 
incubated with 7 pg of whole cell extract from the cell lines A431, 
KS62, Hela, Rh30 and RD respectively. Lanes 2, 3 and 4 of each 
set include 8 40, 80 and 160 molar excess of the same unlabelled 
oligonucleotide showing competition for protein, The final lane 
contains free labelled oligonucleotide only. Addition of non-
specific unlabelled oligonucleotide does not result in competition 
for protein (not shown), (b) Specific inhibition of DNA binding 
activity. In the first of' each set of four lanes labelled 
oligonucleotide has been incubated with 7 pg of whole cell 
extract from the cell lines K562, Hela, Rh30 and RD respectively. 
Lanes 2 and 3 of each set include 0.1 and O.S pg of anti-translin 
antibody respectively (rabbit IgG, gift from M Kasai), The 
epitope of the antibody overlaps the DNA-binding element of 
translin and thus prevents the interaction between translin and 
labelled oligonucleotide in the gel shift assay, Reductions in band 
intensity are apparent in incubations containing translin antibody 
for all whole cell extracts tested. The fourth lane of each set 
includes 0.5 pg of non-specific rabbit JgG antibody which has no 
effect on binding 
breakpoints in a variety of lymphoid malignancies. 
Homology is seen in both component~ of t.he derivative 
chromosome 13. unlike the situatIOn 10 lymphoid 
tumours where the recognition sequence is only 
normally present on the 5' side of the ~ranslocation, 
Typically. the DNA sequences seen 10 lymphoid 
tumours have a 50-70% homology to the consensus 
recognition sequence. We have s~own that Translin 
protein is present in rhabdiod cell hnes and that it will 
bind to oligonucleotides that are base,d on the putative 
translin binding sites found fiankmg chromosome 
translocation breakpoints. , ., 
These findings raise the posstbilIty that the 
chromosomal rearrangement seen in alveolar rhabdo-
It of' ' 
myosarcoma arises in part as a resu ,an mteractJOn 
of damaged DNA with activity of Transhn or a related 
04 
Translin sites flank chromosome translocation breakpoints 
JG Chalk et a/ 
protein. Translin protein is located specifically in the 
cytoplasm of non-lymphoid cell lines (Aoki ~t ?I., 
1995). The data presented here raise the intng~m.g 
possibility that active transport of Translin protem IS 
associated with a nuclear mechanism which may result 
in the formation of a chromosome translocation. 
It is the first time such an observation has been 
made in a solid tumour. Clearly, it is now essential to 
analyse further examples of alveolar RMS. and other 
non-lymphoid tumour specific translocatlOr: break-
points to see if the junction fragments 10 these 
tumours also display Translin sequence homology. 
Materials and methods 
Rh28, RhS and TTC487 are alveolar rhabdomyosarcoma 
cell lines which contain the translocation t(2; 13)(q35;q 14) 
(Douglas et al., 1987; Galili et al., 1993; Sorensen et ai., 
1995). RHFl4 is a somatic cell hybrid which contains the 
derivative 13 chromosome from Rh28 but not the 
derivative chromosome 2 or normal chromosome 2 
(Mitchell et al., 1991). PGMEI and 289 are somatic cell 
hybrids with human chromosome 13 as their only human 
component (Cowell and Mitchell, 1989; Zhong et al., 
1992). GM 10826B is a somatic cell hybrid with human 
chromosome 2 as its only human component. 289 and 
GM10826B genomic DNA were supplied by the UK 
HGMP Resource Centre. Rh28, RHF14 and PGMEI 
genomic DNA was extracted and purified using a Nucleon 
genomic DNA extration kit (Scotlab). 
Construction of vectorette libraries 
Five Ilg of each DNA was digested in buffer containing 5 
units of restriction enzyme (Boeb.ringer Mannehim) in a 
final volume of SO Ill. Digests were then heat denatured at 
70°C for 10 min. One III of each digest was ligated together 
with 3 pmol of appropriate vectorette adaptor (Genosys) in 
the presence of 1 mM ATP and 10 units of T4 DNA ligase 
(Amersham). After 4 h at room temperature, 60 III of water 
was added. Vectorette libraries were stored in aliquots at 
- 20°C (Riley et aI., 1990). 
Primer design 
Primers that are specific to chromosome 2 have been based 
on the intron 7 sequence of the PAX3 gene deposited in 
Genbank (accession number U12259) (Macina et al., 1995). 
The universal vectorette primer (UVP) and the universal 
sequencing primer (USP) were .both supplied by Gen~s~s. 
Other primers were synth~slzed by phos~horamldlte 
chemistry on an Applied Blosystems 380B Instrument: 
12800F 5'-GCTGTGCTGAGTGCTGTGG-3'; 13300F 5'-
TAGCTCATGGGAAAGTGTGC-3'; 50R 5'-GGTTGC-
GGAGGGTTATTGTCG-3'; 30R 5'-AAATGTTGGGG-
ATCTCGTCC-3" 13600R 5'-CATGAATAAGTTGTGT-
TAAGC-3'; 13500R 5'-CTATATCAGTCCAGAGAGG-3'; 
Rh5F 5'-GTIAAATTAGAAGAACATCTGCC-3'; RhSFN 
S' -GGTT A TGCAACTCA TTTCTGC-3'; TIC F 5' -GCTG;-
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Amplification of vectorette libraries 
A 5 III aliquot of each vectorette library was amplified in a 
total volume of SO Jll containing 10 mM Tris-CL pH 8.3, 
50 mM KCL, 1.5 mM MgClz, 0.1 % gelatin, 100 JIM dNTP 
and 1 pmole of each primer. Reaction mixtures were 
denatured at 94°C for 5 min before adding 1 unit of Taq 
DNA polymerase (Perkin-Elmer Cetus) and 1 unit of 
Perfectmatch enhancer (Stratagene). Subsequent cycles 
consisted of I min at 94°C, 1 min at S8°e and 2 min at 
noc for a total of 40 cycles. One III of a 1 : 100 dilution of 
each reaction mixture was used in a further round of 
amplification under the same reaction conditions (but 
excluding Perfectmatch enhancer) using nested primers. 
Aliquots of the reactions were analysed on 1.5% agarose 
AmphiicallOh P10UU':L'> ""'\; \..,vh" .. "l._':~J u.~~, i-'~''''~ 
plasmid vector (Invitrogen). Plasmid DNA from clones was 
isolated using Wizard Miniprep (promega), and then alkali 
denatured prior to sequencing. For each sequencing reaction 
2 Ilg of double stranded plasmid DNA and 6 ng of primer 
were used in the Sequenase system ver 2.0 (USB! Amersham). 
In all sequencing experiments four independent clones were 
sequenced with vector primers from both strands. 
Gel mobility shift assays 
Whole cell extracts were prepared from between 5 x 10' and 
10' cells which were washed in ice cold PBS and either 
scrapped or pelleted into eppendorf tubes and resuspended 
in 400 "I of ice cold hypotonic buffer. (10 mM HEPES-
KOH pH 7.9, 1.5 mM MgCI2 • 10 mM KCI, 0.5 mM OTT, 
0.2 mM PMSF) and incubated on ice for 10 min. Cells were 
then resuspended in 100 III ice cold hypertonic buffer 
"(20 mM HEPES-KOH pH 7.9, 25% glycerol, 420 mM 
NaCl, 1.5 mM MgCh, 0.2 mM EDTA, 0.5 mM OTT, 
0.2 mM PM SF) and incubated for a fUrther ·20 min. 
Cellular debris was removed by centrifugation for 2 min 
at 4°C thesupematant was aliquoted and' stored at 
- 70°C: Protein concentration was determined by the 
Lowry method (Sigma). . . 
Oligonucleotides were end-labelled With T4-polynucleotlde 
kinase and [y-J2)ATP (both Amersham). Seven Ilg of who!e 
cell extracts were incubated at room temperature for 20 mID 
with 10000 c.p.m. of 32P-labelled oligonucleotides (10 pg), in 
20 III of binding buffer containing 10 mM Tris-HCl (PH 7.5), 
50 mM NaCl 1 mM EOTA. 1 mM DTT, 5% glycerol and 
4 Ilg of polY(dI-dC)(dI-dC). DNA-protein complexes were 
separated on 5% non-denaturing polyacrylamide gels. Geh 
were fixed, dried and autoradiographed .. 
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